

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)


PCT

(10) International Publication Number
WO 2004/075713 A2

- (51) International Patent Classification⁷: **A61B**
- (21) International Application Number:
PCT/CA2004/000281
- (22) International Filing Date: 26 February 2004 (26.02.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/450,406 26 February 2003 (26.02.2003) US
- (71) Applicant (for all designated States except US): **MOUNT SINAI HOSPITAL** [CA/CA]; 600 University Avenue, Room 970, Toronto, Ontario M5G 1X5 (CA).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **DIAMANDIS, Eleftherios, P.** [CA/CA]; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA).
- (74) Agent: **KURDYDYK, Linda**; McCarthy Tetrault, 66 Wellington Street West, Suite 4700, P.O. Box 48, Toronto Dominion Bank Tower (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: MULTIPLE MARKER ASSAY FOR DETECTION OF OVARIAN CANCER



(57) Abstract: Methods for diagnosing and monitoring ovarian cancer in a subject comprising measuring a plurality of kallikrein polypeptides, and optionally CA125, or nucleic acids encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE: Multiple Marker Assay for Detection of Ovarian Cancer**FIELD OF THE INVENTION**

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating ovarian cancer.

5 BACKGROUND OF THE INVENTION

Epithelial ovarian carcinoma is the most common and most lethal of all gynecologic malignancies. Only 30% of ovarian tumors are diagnosed at an early stage (Stage I/II), when survival rates reach 90%. The rest are diagnosed at an advanced stage, with survival rates of less than 20% (Greenlee RT, Hill-Harmon MB, Murray T, et al., 2001. *CA Cancer J Clin* .2001;51:15-36). Currently, the only well-accepted
 10 serological marker is CA125, a large glycoprotein of unknown function (Meyer T, Rustin GJ., *Br J Cancer* .2000;82:1535-1538). However, CA125 has limitations as a diagnostic, prognostic and screening tool (Holschneider CH, Berek JS, *Semin Surg Oncol* .2000;19:3-10). Consequently, there is a need to enhance the overall diagnostic/prognostic capability of CA125.

Kallikreins are a subgroup of secreted serine proteases, encoded by highly conserved and tightly
 15 clustered multigene families in humans, rats and mice. The human kallikrein gene family resides on chromosome 19q13.4 and is comprised of 15 members, whose genes are designated as *KLK1* to *KLK15* and the corresponding proteins as hK1 to hK15 (Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204; Yousef GM, Chang A, Scorilas A, et al., *Biochem Biophys Res Commun*. 2000;276:125-133; Diamandis EP, Yousef GM, Clements J, et al. *Clin Chem* .2000;46:1855-1858). Kallikreins are expressed in a wide variety
 20 of tissues and are found in many biological fluids (e.g. cerebrospinal fluid, serum, seminal plasma, milk, etc.) where they are predicted to process specific substrates. Kallikreins may participate in cascade reactions similar to those involved in digestion, fibrinolysis, coagulation, wound healing and apoptosis ((Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204). Many kallikreins have been found to be differentially expressed in endocrine-related malignancies (Diamandis EP, Yousef GM, *Expert Rev. Mol. Diagn*
 25 .2001;1:182-190), including prostate (Barry MJ. Clinical practice, *N Engl J Med* .2001;344:1373-1377; Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al., *Crit Rev Clin Lab Sci* .1998;35:275-368; and Yousef GM, Scorilas A, Jung K, et al., *J Biol Chem* .2001;276:53-61), ovarian (Kim H, Scorilas A, Katsaros D, et al., *Br J Cancer*, 2001;84:643-650; Anisowicz A, Sotiropoulou G, Stenman, et al., *Mol Med* .1996;2:624-636; Tanimoto H, Underwood LJ, Shigemasa K, et al., *Cancer* .1999;86:2074-2082; Magklara A, Scorilas A, Katsaros D, et al., *Clin Cancer Res* .2001;7:806-811; Yousef GM, Kyriakopoulou LG, Scorilas A, et al.,
 30 *Cancer Res* .2001;61:7811-7818; Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118), breast (Yousef GM, Magklara A, Chang A, et al., *Cancer Res* .2001;61:3425-3431; Yousef GM, Chang A, Diamandis EP; *J Biol Chem* .2000;275:11891-11898; and Yousef GM, Magklara A, Diamandis EP, *Genomics* .2000;69:331-341), and testicular cancer (Luo LY, Rajpert-De Meyts ER, Jung K, et al.,2001;85:220-224). In addition, many kallikrein genes examined thus far are under steroid hormone regulation, implicating a role for kallikreins in endocrine-related tissues (Yousef GM, Diamandis EP., *Endocr Rev.*, 2001;22:184-204). Furthermore, hK6, hK10 and hK11 have been recently identified as novel serological ovarian cancer biomarkers (Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118 Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P., *Clin Biochem*. 2000;33:579-

- 2 -

583, and Diamandis EP, Okui A, Mitsui S, et al., *Cancer Res.* 2002;62:295-300).

SUMMARY OF THE INVENTION

The present invention seeks to overcome the drawbacks inherent in the prior art and seeks to provide sensitive and accurate multimarker methods for the detection of ovarian cancer. A plurality of kallikrein polypeptides and polynucleotides encoding the polypeptides, optionally in combination with CA125 and polynucleotides encoding CA125 can have particular application in the detection of ovarian cancer. A plurality of kallikrein markers (i.e. two or more of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11) and polynucleotides encoding the polypeptides, optionally in combination with CA125 and polynucleotides encoding CA125, constitute biomarkers for the diagnosis, monitoring, progression, treatment, and prognosis of ovarian cancer, and they may be used as biomarkers before surgery or after relapse.

In accordance with the methods of the invention, the presence of levels of markers in a sample can be assessed, for example by detecting the presence in the sample of (a) polypeptides or polypeptide fragments corresponding to the markers; (b) metabolites which are produced directly or indirectly by polypeptides corresponding to the markers; (c) transcribed nucleic acids or fragments thereof having at least a portion with which the markers are substantially identical; and/or (c) transcribed nucleic acids or fragments thereof, wherein the nucleic acids hybridize with the markers.

In an aspect of the invention, a method is provided for detecting ovarian cancer in a patient comprising detecting a plurality of kallikrein polypeptides, optionally in combination with CA125, in a sample from the patient wherein the method provides substantially increased sensitivity compared to methods using CA125 alone. In an embodiment, sensitivity is increased by at least 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, and 35% compared to using CA125 alone.

In an embodiment, the invention provides a method for detecting a plurality of kallikrein markers, and optionally CA125, associated with ovarian cancer in a patient comprising:

- (a) obtaining a sample from a patient;
- (b) detecting or identifying in the sample kallikrein markers, optionally in combination with CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
- (c) comparing the detected amounts with amounts detected for a standard.

The term "detect" or "detecting" includes assaying, assessing, imaging or otherwise establishing the presence or absence of the target kallikrein and CA125 polypeptides or polynucleotides encoding the polypeptides, subunits thereof, or combinations of reagent bound targets, and the like, or assaying for, imaging, ascertaining, establishing, or otherwise determining one or more factual characteristics of ovarian cancer, metastasis, stage, or similar conditions. The term encompasses diagnostic, prognostic, and monitoring applications. The kallikrein polypeptides and CA125 can be detected individually, sequentially, or simultaneously.

According to a method involving kallikrein markers optionally in combination with CA125, the levels in the sample of the kallikrein markers (2, 3, 4, 5, or 6) and optionally CA125, wherein the markers comprise or are selected from kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein

- 3 -

11, are compared with the normal levels of the kallikrein markers, and optionally CA125, in samples of the same type obtained from controls (e.g. samples from individuals not afflicted with ovarian cancer). Significantly different levels in the sample of the kallikrein markers (and optionally CA125) relative to the normal levels in a control is indicative of ovarian cancer.

5 In an embodiment, the invention provides a method for diagnosing and monitoring ovarian carcinoma in a subject comprising detecting in a sample from the subject kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. The kallikrein markers and CA125 can be detected using antibodies that bind to the kallikrein markers and CA125 or parts thereof.

10 Thus, the invention provides a method of assessing whether a patient is afflicted with or has a predisposition for ovarian cancer, the method comprising comparing:

- (a) levels of kallikrein markers, and optionally CA125, in a sample from the patient, wherein the kallikrein markers comprise kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
- 15 (b) normal levels of kallikrein markers, and optionally CA125, in samples of the same type obtained from control patients not afflicted with ovarian cancer, wherein significantly different levels of the kallikrein markers and optionally CA125, relative to the corresponding normal levels of the kallikrein markers, and optionally CA125, is an indication that the patient is afflicted with ovarian cancer.

20 In an embodiment of a method of assessing whether a patient is afflicted with ovarian cancer (e.g. screening, detection of a recurrence, reflex testing), the method comprises comparing:

- (a) levels of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
- 25 (b) normal levels of the kallikrein markers, and optionally CA125, in a control non-ovarian cancer sample.

A significant difference between the levels of the kallikrein markers, and optionally CA125, in the patient sample and the normal levels is an indication that the patient is afflicted with ovarian cancer.

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting
30 ovarian cancer in a patient. This method comprises comparing:

- (a) levels of kallikrein markers, and optionally CA125, in a first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11 ; and
- 35 (b) levels of the kallikrein markers, and optionally CA125, in a second sample obtained from the patient following therapy.

A significant difference between the levels of the kallikrein markers, and optionally CA125, in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer.

- 4 -

The "therapy" may be any therapy for treating ovarian cancer including but not limited to chemotherapy, immunotherapy, gene therapy, radiation therapy, and surgical removal of tissue. Therefore, the method can be used to evaluate a patient before, during, and after therapy, for example, to evaluate the reduction in tumor burden.

5 In an aspect, the invention provides a method for monitoring the progression of ovarian cancer in a patient, the method comprising:

- (a) detecting in a patient sample at a first time point, kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
- 10 (b) repeating step (a) at a subsequent point in time; and
- (c) comparing the levels detected in (a) and (b), and therefrom monitoring the progression of ovarian cancer in the patient.

In another aspect, the invention provides a method for assessing the aggressiveness or indolence of ovarian cancer (e.g. staging), the method comprising comparing:

- 15 (a) levels of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
- (b) normal levels of the kallikrein markers, and optionally CA125 in a control sample.

20 A significant difference between the levels in the sample and the normal levels is an indication that the cancer is aggressive or indolent.

The invention provides a method for determining whether ovarian cancer has metastasized or is likely to metastasize in the future, the method comprising comparing:

- 25 (a) levels of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
- (b) normal levels (or non-metastatic levels) of the kallikrein markers, and optionally CA125, in a control sample.

A significant difference between the levels in the patient sample and the normal levels is an indication that the cancer has metastasized or is likely to metastasize in the future.

30 The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, and a method of selecting an agent for inhibiting ovarian cancer in a patient.

The invention further provides a method of inhibiting ovarian cancer in a patient comprising:

- 35 (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing levels of kallikrein markers, and optionally CA125, in each of the aliquots, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11;
- (d) administering to the patient at least one of the test agents which alters the levels of the

- 5 -

kallikrein markers, and optionally CA125, in the aliquot containing that test agent, relative to other test agents.

The invention also contemplates a method of assessing the ovarian carcinogenic potential of a test compound comprising:

- 5 (a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and
- (b) comparing levels of kallikrein markers, and optionally CA125, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

10 A significant difference between the levels of the kallikrein markers, and optionally CA125, in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses ovarian carcinogenic potential.

In preferred embodiments of the methods of the invention, the kallikrein markers comprise a plurality of kallikrein markers, for example, at least three, four, five, or six of the markers. In particular, a
15 plurality of kallikrein markers may be selected from the group consisting of kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10, from the group consisting of kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, or from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.

Other methods of the invention employ one or more polynucleotides capable of hybridizing to
20 polynucleotides encoding kallikrein markers, and optionally CA125. Methods for detecting polynucleotides encoding a kallikrein markers, and optionally CA125, can be used to monitor ovarian cancer by detecting the nucleic acids.

Thus, the present invention relates to a method for diagnosing and monitoring ovarian cancer in a sample from a subject comprising isolating nucleic acids, preferably mRNA, from the sample; and detecting
25 polynucleotides encoding kallikrein markers, and optionally CA125, in the sample. The presence of different levels of polynucleotides encoding kallikrein markers, and optionally CA125, in the sample compared to a standard or control is indicative of disease, disease stage, and/or prognosis, e.g. longer progression-free and overall survival.

In an embodiment, the invention provides methods for determining the presence or absence of
30 ovarian cancer in a subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of ovarian cancer in the subject. Within certain embodiments, mRNA is detected via polymerase chain reaction using, for example
35 oligonucleotide primers that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, or complements of such polynucleotides. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing oligonucleotide probes that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, or complements of such polynucleotides.

When using mRNA detection, the method may be carried out by combining isolated mRNA with

- 6 -

reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of polynucleotides encoding kallikrein markers, and optionally CA125, in the sample. For mRNA the analyzing step may be accomplished using Northern Blot analysis to detect the presence of polynucleotides encoding kallikrein markers, and optionally CA125. The analysis step may be further accomplished by quantitatively detecting the presence of polynucleotides encoding kallikrein markers, and optionally CA125, in the amplification product, and comparing the quantity of markers detected against a panel of expected values for the known presence or absence of the kallikrein markers in normal and malignant tissue derived using similar primers.

In embodiments of the methods of the invention, a plurality (eg. three, four, five or six) polynucleotides encoding kallikrein polypeptides are employed. In particular, a plurality of polynucleotides encoding kallikrein markers may be selected from the group consisting of polynucleotides encoding (i) kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10; (ii) polynucleotides encoding kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (iii) polynucleotides encoding kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.

The invention also provides a diagnostic composition comprising a plurality of kallikrein polypeptides and optionally CA125 polypeptide, or polynucleotides encoding the polypeptides, or agents that bind to the polypeptides or polynucleotides.

In an embodiment, the composition comprises probes that specifically hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, or fragments thereof. In another embodiment a composition is provided comprising specific primer pairs capable of amplifying polynucleotides encoding kallikrein markers, and optionally CA125, using polymerase chain reaction methodologies. In a still further embodiment, the composition comprises agents that bind to kallikrein markers, and optionally CA125, (e.g. antibodies) or fragments thereof. Probes, primers, and agents can be labeled with detectable substances.

In an aspect the invention provides an *in vivo* method comprising administering to a subject agents that have been constructed to target kallikrein markers, and optionally CA125.

The invention therefore contemplates an *in vivo* method comprising administering to a mammal imaging agents that carry labels for imaging and that bind to kallikrein markers, and optionally CA125, and then imaging the mammal.

Still further the invention relates to therapeutic applications for ovarian cancer employing kallikrein markers, and optionally CA125, nucleic acids encoding the polypeptides, and/or agents identified using methods of the invention.

The invention also includes kits for carrying out methods of the invention. In an embodiment, the kit is for assessing whether a patient is afflicted with ovarian cancer and it comprises reagents for assessing kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

In another aspect the invention relates to a kit for assessing the suitability of each of a plurality of test compounds for inhibiting ovarian cancer in a patient. The kit comprises reagents for assessing kallikrein

- 7 -

markers, and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. The kit may also comprise a plurality of test agents or compounds.

5 The invention contemplates a kit for assessing the presence of ovarian cancer cells, wherein the kit comprises antibodies specific for selected kallikrein markers, and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

10 Additionally the invention provides a kit for assessing the ovarian carcinogenic potential of a test compound. The kit comprises ovarian cells and reagents for assessing kallikrein markers, and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

15 In an aspect the invention provides a method of treating a patient afflicted with ovarian cancer comprising providing to cells of a patient antisense oligonucleotides complementary to polynucleotides encoding kallikrein markers, and optionally CA125, which are overexpressed in ovarian cancer. In an alternative method, expression of genes corresponding to kallikrein markers, and optionally CA125, which are underexpressed in ovarian cancer are increased.

20 The invention relates to a method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer comprising inhibiting or increasing expression (or overexpression) of genes encoding kallikrein markers and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, that are either overexpressed or underexpressed, in ovarian cancer.

25 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

The invention will now be described in relation to the drawings in which

30 Figure 1 is a graph showing hk5 concentration in serum from non-cancer and cancer patients.
Figure 2 is a graph showing hk6 concentration in serum from non-cancer and cancer patients.
Figure 3 is a graph showing hk7 concentration in serum from non-cancer and cancer patients.
Figure 4 is a graph showing hk8 concentration in serum from non-cancer and cancer patients.
Figure 5 is a graph showing hk10 concentration in serum from non-cancer and cancer patients.
Figure 6 is a graph showing hk11 concentration in serum from non-cancer and cancer patients.
35 Figure 7 is a graph showing CA125 concentration in serum from non-cancer and cancer patients.
Figure 8 is a ROC curve illustrating the added value of using kallikreins and CA125 together in a multivariate function.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to newly discovered correlations between expression of certain markers and

ovarian cancer. The combinations of markers described herein may provide sensitive methods for detecting ovarian cancer. The levels of expression of a combination of markers described herein may correlate with the presence of ovarian cancer or a pre-malignant condition in a patient. Methods are provided for detecting the presence of ovarian cancer in a sample, the absence of ovarian cancer in a sample, the stage of an ovarian cancer, the grade of an ovarian cancer, the benign or malignant nature of an ovarian cancer, the metastatic potential of an ovarian cancer, assessing the histological type of neoplasm associated with the ovarian cancer, the indolence or aggressiveness of the cancer, and other characteristics of ovarian cancer that are relevant to prevention, diagnosis, characterization, and therapy of ovarian cancer in a patient. Methods are also provided for assessing the efficacy of one or more test agents for inhibiting ovarian cancer, assessing the efficacy of a therapy for ovarian cancer, monitoring the progression of ovarian cancer, selecting an agent or therapy for inhibiting ovarian cancer, treating a patient afflicted with ovarian cancer, inhibiting ovarian cancer in a patient, and assessing the carcinogenic potential of a test compound.

Glossary

The terms "sample", "biological sample", and the like, mean a material known or suspected of expressing or containing a plurality of kallikrein markers or polypeptides (2, 3, 4, 5, or 6 polypeptides), and optionally CA125 polypeptide, or polynucleotides encoding the polypeptides. The test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The sample can be derived from any biological source, such as tissues, extracts, or cell cultures, including cells (e.g. tumor cells), cell lysates, and physiological fluids, such as, for example, whole blood, plasma, serum, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid and the like. The sample can be obtained from animals, preferably mammals, most preferably humans. The sample can be treated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, the addition of reagents, and the like. Nucleic acids and polypeptides may be isolated from the samples and utilized in the methods of the invention. In a preferred embodiment, the sample is a serum sample.

The term "subject" or "patient" refers to a warm-blooded animal such as a mammal, which is suspected of having ovarian cancer, or a condition, disease, or syndrome associated with ovarian cancer. Preferably, "subject" refers to a human.

"CA125", "CA125 polypeptide", or "carbohydrate antigen 125" refers to a high-molecular weight mucin, which can be defined by its ability to bind to monoclonal antibody OC125. The CA125 protein core comprises a short cytoplasmic core tail, a transmembrane domain, and a large and heavily glycosylated extracellular domain dominated by a repeat domain of 156 amino acids rich in serine, threonine, and proline (Yin BW and Lloyd KO, J Biol Chem. 2001, 276:27371-27375; O'Brian TJ et al, Tumor Biol., 2001 22:348-366; and Hovig E. et al, Tumor Biol. 2001, 22:345-347). The sequence of CA125 is shown in GenBank Accession No. NP_078966, AAL65133 and AF414442 (SEQ ID NO. 1). The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The term also includes the native sequence polypeptide, including polypeptide variants and polypeptides with substantial sequence identity (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or

99% sequence identity) to the sequence of GenBank Accession No.NP_078966 (SEQ ID NO. 1), and that preferably retain the immunogenic activity of the corresponding native sequence polypeptide.

“Kallikrein polypeptides” or “kallikrein markers” comprise kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The amino acid sequences for native kallikrein polypeptides employed in the present invention include the sequences found in GenBank for each polypeptide as shown in Table 1, and in SEQ ID NO: 3 (kallikrein 5), NO.6 (kallikrein 6), NO. 10 (kallikrein 7), NO. 13 (kallikrein 8), NO. 16 (kallikrein 10), and NOs. 19 and 20 (kallikrein 11), or a portion thereof. Other useful polypeptides are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity), and preferably retain the immunogenic activity of the corresponding native-sequence kallikrein polypeptide.

A “native-sequence polypeptide” comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

The term “native-sequence polypeptide” specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants.

The term “polypeptide variant” means a polypeptide having at least about 70-80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with a native-sequence polypeptide, in particular having at least 70-80%, 85%, 90%, 95% amino acid sequence identity to the sequences identified in the GenBank Accession Nos. in Table 1 and Accession No. NP_078966, AF414442 and AAL65133 and shown in SEQ ID NOS: 1, 2, 3, 6, 10, 13, 16, 19 and 20. Such variants include, for instance, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of SEQ ID NOS: 1, 2, 3, 6, 10, 13, 16, 19 and 20, including variants from other species, but excludes a native-sequence polypeptide.

An allelic variant may also be created by introducing substitutions, additions, or deletions into a nucleic acid encoding a native polypeptide sequence such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations may be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. In an embodiment, conservative substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which an amino acid residue is replaced with an amino acid residue with a similar side chain. Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g. Ala, Val, Leu, Iso, Pro, Trp), beta-branched side chains (e.g. Thr, Val, Iso), and aromatic side chains (e.g. Tyr, Phe, Trp, His). Mutations can also be introduced randomly along part or all of the native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed and the activity of the polypeptide may be determined.

Polypeptide variants include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of a native polypeptide which include fewer amino acids than the full length polypeptides. A portion of a polypeptide can be a polypeptide which is for example, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids in length. Portions in which regions of a polypeptide are deleted can be prepared by recombinant techniques and can be evaluated for one or more functional activities such as the ability to form antibodies specific for a polypeptide.

A naturally occurring allelic variant may contain conservative amino acid substitutions from the native polypeptide sequence or it may contain a substitution of an amino acid from a corresponding position in a CA125 or kallikrein polypeptide homolog, for example, the murine CA125 or kallikrein polypeptide.

Percent identity of two amino acid sequences, or of two nucleic acid sequences identified herein is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a CA125 or kallikrein polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various conventional ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., *Nucleic Acids Research* 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Altschul, S.F. et al. *J. Molec. Biol.* 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. *J. Mol. Biol.* 215: 403-410, 1990). Skilled artisans can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Methods to determine identity and similarity are codified in publicly available computer programs.

CA125 and kallikrein polypeptides include chimeric or fusion proteins. A "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a CA125 or kallikrein polypeptide operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same CA125 or kallikrein polypeptide). Within the fusion protein, the term "operably linked" is intended to indicate that the CA125 or kallikrein polypeptide and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the CA125 or kallikrein polypeptide. A useful fusion protein is a GST fusion protein in which a kallikrein polypeptide is fused to the C-terminus of GST sequences. Another example of a fusion protein is an immunoglobulin fusion protein in which all or part of a CA125 or kallikrein polypeptide is fused to sequences derived from a member of the immunoglobulin protein family. Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.

CA125 and kallikrein polypeptides may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

"CA125 polynucleotides" or "polynucleotides encoding CA125" include nucleic acids that encode a native-sequence polypeptide, a polypeptide variant including a portion of a CA125 polypeptide, an isoform, precursor, and chimeric polypeptide. A nucleic acid sequence encoding native CA125 employed in the

- 11 -

present invention includes the nucleic acid sequence in GenBank Accession No. AF414442 and SEQ ID NO. 2, or a fragment thereof.

“Kallikrein polynucleotides” or “polynucleotides encoding kallikrein markers/polypeptides” refers to kallikrein 5 nucleic acids (KLK5), kallikrein 6 nucleic acids (KLK6), kallikrein 7 nucleic acids (KLK7),
5 kallikrein 8 nucleic acids (KLK8), kallikrein 10 nucleic acids (KLK10), and/or kallikrein 11 nucleic acids (KLK11). The term includes nucleic acids that encode a native-sequence polypeptide, a polypeptide variant including a portion of a kallikrein polypeptide, an isoform, precursor, and chimeric polypeptide.

The polynucleotide sequences encoding native kallikrein polypeptides employed in the present invention include the nucleic acid sequences of the GenBank Accession Nos. identified in Table 1, and in
10 SEQ ID NOS: 4 and 5 (KLK5), NOS. 7, 8, and 9 (KLK6), NOS. 11 and 12 (KLK 7), NOS. 14 and 15 (KLK8), NOS. 17 and 18 (KLK10), and NOS. 21 and 22 (KLK11), or a fragment thereof.

Polynucleotides encoding kallikrein polypeptides and CA125 include nucleic acid sequences complementary to these polynucleotides, and polynucleotides that are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%,
15 98%, or 99% sequence identity).

CA125 and kallikrein polynucleotides also include sequences which differ from a nucleic acid sequence of GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 4, 5, 7, 8, 9, 11, 12, 14, 15, 17, 18, 21, and 22, due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a CA125 or kallikrein polypeptide may result in silent mutations which do
20 not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to natural allelic variation. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of CA125 or a kallikrein polypeptide.

CA125 and kallikrein polynucleotides also include nucleic acids that hybridize under stringent conditions, preferably high stringency conditions to a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 4, 5, 7, 8, 9, 11, 12, 14, 15, 17, 18, 21, and 22. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By
30 way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

CA125 and kallikrein polynucleotides also include truncated nucleic acids or fragments and variant forms of the polynucleotides that arise by alternative splicing of an mRNA corresponding to a DNA.

35 The CA125 and kallikrein polynucleotides are intended to include DNA and RNA (e.g. mRNA) and can be either double stranded or single stranded. A polynucleotide may, but need not, include additional coding or non-coding sequences, or it may, but need not, be linked to other molecules and/or carrier or support materials. The polynucleotides for use in the methods of the invention may be of any length suitable for a particular method.

A plurality of kallikrein polypeptides or kallikrein polynucleotides are generally detected in the present invention. "Plurality" refers to 2, 3, 4, 5, or 6 kallikrein polypeptides or polynucleotides, in particular 3, 4, 5, or 6, preferably 4, 5, or 6, more preferably 5 or 6 kallikrein polypeptides or polynucleotides.

In an embodiment a plurality of kallikrein polypeptides is selected from the group consisting of
 5 kallikrein 5, kallikrein 7, and kallikrein 8; kallikrein 5, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; or kallikrein 5, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. In another embodiment, a plurality of kallikrein polypeptides is selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.

10 In an embodiment, a plurality of kallikrein polynucleotides is selected from the group consisting of KLK5, KLK7, and KLK8; KLK5, KLK8 and KLK10; KLK7, KLK8 and KLK10; KLK5, KLK7, KLK8, and KLK10; KLK7, KLK8, KLK10 and KLK11, or KLK5, KLK7, KLK8, KLK10 and KLK11. In another embodiment, a plurality of kallikrein polynucleotides is selected from the group consisting of KLK5, KLK6, KLK7, KLK8, KLK10, and KLK11.

15 **General Methods**

A variety of methods can be employed for the diagnostic and prognostic evaluation of ovarian cancer involving kallikrein polypeptides, and optionally CA125 polypeptide, and polynucleotides encoding the polypeptides, and the identification of subjects with a predisposition to such disorders. Such methods may, for example, utilize polynucleotides encoding kallikrein polypeptides, and optionally CA125, and
 20 fragments thereof, and binding agents (e.g. antibodies aptamers) against kallikrein polypeptides, and optionally CA125 polypeptide, including peptide fragments. In particular, the polynucleotides and antibodies may be used, for example, for (1) the detection of either over- or under-expression of kallikrein polynucleotides, and optionally CA125, relative to a non-disorder state; and (2) the detection of either an over- or an under-abundance of kallikrein polypeptides, and optionally CA125, relative to a non-disorder
 25 state or the presence of modified (e.g., less than full length) kallikrein polypeptides, and optionally CA125, that correlate with a disorder state, or a progression toward a disorder state.

The invention also contemplates a method for detecting ovarian cancer comprising producing a profile of levels of a plurality of kallikrein markers, and optionally CA125, in cells from a patient, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and
 30 comparing the profile with a reference to identify a protein profile for the test cells indicative of disease.

The methods described herein may be used to evaluate the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such methods can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of disease. The methods can be used to detect the presence of cancer metastasis, as well as confirm the absence or removal
 35 of all tumor tissue following surgery, cancer chemotherapy, and/or radiation therapy. They can further be used to monitor cancer chemotherapy and tumor reappearance.

The methods described herein can be adapted for diagnosing and monitoring ovarian cancer by detecting a plurality of kallikrein polypeptides, and optionally CA125 polypeptide, or nucleic acids encoding the polypeptides in biological samples from a subject. These applications require that the amount of

- 13 -

polypeptides or nucleic acids quantitated in a sample from a subject being tested be compared to a predetermined standard. The standard may correspond to levels quantitated for another sample or an earlier sample from the subject, or levels quantitated for a control sample. Levels for control samples from healthy subjects or ovarian cancer subjects may be established by prospective and/or retrospective statistical studies.

- 5 Healthy or normal subjects who have no clinically evident disease or abnormalities may be selected for statistical studies. Diagnosis may be made by a finding of statistically different levels of a plurality of kallikrein polypeptides, and optionally CA125, or nucleic acids encoding same, compared to a control sample or previous levels quantitated for the same subject. A "significant difference" in levels of kallikrein markers or polynucleotides encoding the kallikrein markers in a patient sample compared to a control or
10 standard (e.g. normal levels or levels in other samples from a patient) may represent levels that are higher or lower than the standard error of the detection assay, preferably the levels are at least about 1.5, 2, 3, 4, 5, or 6 times higher or lower, respectively, than the control or standard. The difference in levels of markers or polynucleotides may be a "statistically significant difference"

Nucleic Acid Methods/Assays

- 15 As noted herein an ovarian cancer may be detected based on the levels of polynucleotides encoding kallikrein polypeptides, and optionally CA125, in a sample. Techniques for detecting polynucleotides such as polymerase chain reaction (PCR) and hybridization assays are well known in the art.

- Nucleotide probes for use in the detection of nucleic acid sequences in samples may be constructed using conventional methods known in the art. Suitable probes may be based on nucleic acid sequences
20 encoding at least 5 sequential amino acids from regions of nucleic acids encoding kallikrein polypeptides, and optionally CA125, preferably they comprise 15 to 40 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as ^{32}P , ^3H , ^{14}C or the like. Other detectable substances that may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a
25 labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect polynucleotides
30 encoding kallikrein polypeptides, and optionally CA125, preferably in human cells. The nucleotide probes may also be useful in the diagnosis of ovarian cancer involving polynucleotides encoding kallikrein polypeptides, and optionally CA125, in monitoring the progression of such disorder; or monitoring a therapeutic treatment.

- Probes may be used in hybridization techniques to detect nucleic acids encoding a plurality of
35 kallikrein polypeptides, and optionally CA125. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with probes under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

- 14 -

The detection of polynucleotides encoding kallikrein polypeptides and optionally CA125, may involve the amplification of specific gene sequences using an amplification method such as polymerase chain reaction (PCR), followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

5 By way of example, oligonucleotide primers may be employed in a PCR based assay to amplify a portion of nucleic acids encoding each of a plurality of kallikrein polypeptides, and optionally CA125, derived from a sample, wherein the oligonucleotide primers are specific for (i.e. hybridize to) polynucleotides encoding each of the plurality of kallikrein polypeptides, and optionally CA125. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel
10 electrophoresis.

In order to maximize hybridization under assay conditions, primers and probes employed in the methods of the invention generally have at least about 60%, preferably at least about 75% and more preferably at least about 90% identity to a portion of polynucleotides encoding a plurality of kallikrein polypeptides, and CA125. The primers and probes may be at least 10 nucleotides, and preferably at least 20
15 nucleotides in length. In an embodiment the primers and probes are at least about 10-40 nucleotides in length.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of expression of polynucleotides encoding kallikrein polypeptides, and optionally CA125. For example, RNA may be isolated from a cell type or tissue known to express these
20 polynucleotides and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.

The primers and probes may be used in the above-described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

In an aspect of the invention, a method is provided employing reverse transcriptase-polymerase
25 chain reaction (RT-PCR), in which PCR is applied in combination with reverse transcription. Generally, RNA is extracted from a sample tissue using standard techniques (for example, guanidine isothiocyanate extraction as described by Chomcynski and Sacchi, Anal. Biochem. 162:156-159, 1987) and is reverse transcribed to produce cDNA. The cDNA is used as a template for a polymerase chain reaction. The cDNA is hybridized to sets of primers specifically designed against each of a plurality of kallikrein polynucleotide
30 sequences, and optionally CA125. Once the primer and template have annealed a DNA polymerase is employed to extend from the primer, to synthesize a copy of the template. The DNA strands are denatured, and the procedure is repeated many times until sufficient DNA is generated to allow visualization by ethidium bromide staining and agarose gel electrophoresis.

Amplification may be performed on samples obtained from a subject with suspected ovarian cancer
35 and an individual who is not afflicted with ovarian cancer. The reaction may be performed on several dilutions of cDNA spanning at least two orders of magnitude. A statistically significant difference in expression in several dilutions of the subject sample as compared to the same dilutions of the non-cancerous sample may be considered positive for the presence of ovarian cancer.

Oligonucleotides or longer fragments derived from polynucleotides encoding each of a plurality of

kallikrein polypeptides and optionally CA125, may be used as targets in a microarray. The microarray can be used to simultaneously monitor the expression levels of large numbers of genes. The information from the microarray may be used to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

5 The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

10 Thus, the invention also includes an array comprising a plurality of polynucleotides encoding kallikrein marker(s), and optionally CA125 polynucleotides. The array can be used to assay expression of kallikrein polynucleotides, and optionally CA125 polynucleotides in the array. The invention allows the quantitation of expression of a plurality of kallikrein polynucleotides, and optionally CA125 polynucleotides.

 In an embodiment, the array can be used to monitor the time course of expression of a plurality of
15 kallikrein polynucleotides, and optionally CA125 polynucleotides, in the array. This can occur in various biological contexts such as tumor progression.

 The array is also useful for ascertaining differential expression patterns of a plurality of kallikrein polynucleotides and optionally CA125 polynucleotides, in normal and abnormal cells. This provides a battery of polynucleotides that could serve as molecular targets for diagnosis or therapeutic intervention.

20 Protein Methods

 Binding agents specific for a plurality of kallikrein markers and CA125 may be used for a variety of diagnostic and assay applications. There are a variety of assay formats known to the skilled artisan for using a binding agent to detect a target molecule in a sample. (For example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). In general, the presence or absence of an ovarian
25 cancer in a subject may be determined by (a) contacting a sample from the subject with binding agents for a plurality of kallikrein polypeptides, and optionally CA125; (b) detecting in the sample levels of polypeptides that bind to the binding agents; and (c) comparing the levels of polypeptides with a predetermined standard or cut-off value.

 "Binding agent" refers to a substance such as a polypeptide or antibody that specifically binds to a
30 kallikrein or CA125 polypeptide. A substance "specifically binds" to a polypeptide if it reacts at a detectable level with the kallikrein or CA125 polypeptide, and does not react detectably with peptides containing unrelated sequences or sequences of different polypeptides. Binding properties may be assessed using an ELISA, which may be readily performed by those skilled in the art (see for example, Newton et al., Develop. Dynamics 197: 1-13, 1993).

35 A binding agent may be a ribosome, with or without a peptide component, an aptamer, an RNA molecule, or a polypeptide. A binding agent may be a polypeptide that comprises a kallikrein polypeptide or CA125 polypeptide sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence. By way of example a kallikrein polypeptide sequence may be a peptide portion of a kallikrein polypeptide that is capable of modulating a function mediated by the kallikrein polypeptide.

An aptamer includes a DNA or RNA molecule that binds to polynucleotides and polypeptides. An aptamer that binds to a polypeptide (or binding domain) of a kallikrein polypeptide or a polynucleotide encoding a kallikrein polypeptide can be produced using conventional techniques, without undue experimentation. [For example, see the following publications describing *in vitro* selection of aptamers: Klug et al., Mol. Biol. Reports 20:97-107 (1994); Wallis et al., Chem. Biol. 2:543-552 (1995); Ellington, Curr. Biol. 4:427-429 (1994); Lato et al., Chem. Biol. 2:291-303 (1995); Conrad et al., Mol. Div. 1:69-78 (1995); and Uphoff et al., Curr. Opin. Struct. Biol. 6:281-287 (1996)].

In certain other preferred embodiments, the binding agent is an antibody.

In an aspect the present invention provides a diagnostic method for monitoring or diagnosing ovarian cancer in a subject by quantitating a plurality of kallikrein polypeptides, and optionally CA125, in a biological sample from the subject comprising reacting the sample with antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, which are directly or indirectly labelled with detectable substances, and detecting the detectable substances.

In an aspect of the invention, a method for detecting ovarian cancer is provided comprising:

- 15 (a) obtaining a sample suspected of containing a plurality of kallikrein polypeptides, and optionally CA125, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11;
- (b) contacting the sample with antibodies that specifically bind to the plurality of kallikrein polypeptides, and optionally CA125, under conditions effective to bind the antibodies and form complexes;
- 20 (c) measuring the amount of kallikrein polypeptides, and optionally CA125, present in the sample by quantitating the amount of the complexes; and
- (d) comparing the amount of kallikrein polypeptides, and optionally CA125, present in the samples with the amount of polypeptides in a control, wherein a change or significant difference in the amount of polypeptides in the sample compared with the amount in the control is indicative of ovarian cancer.
- 25

In an embodiment, the invention contemplates a method for monitoring the progression of ovarian cancer in an individual, comprising:

- 30 (a) contacting antibodies which bind to each of a plurality of kallikrein polypeptides, and optionally CA125, with a sample from the individual so as to form binary complexes comprising each of the antibodies and polypeptides in the sample;
- (b) determining or detecting the presence or amount of complex formation in the sample;
- (c) repeating steps (a) and (b) at a point later in time; and
- 35 (d) comparing the result of step (b) with the result of step (c), wherein a difference in the amount of complex formation is indicative of the stage and/or progression of the ovarian cancer in said individual.

The amount of complexes may also be compared to a value representative of the amount of the complexes from an individual not at risk of, or afflicted with, ovarian cancer at different stages.

Thus, antibodies specifically reactive with each of a plurality of kallikrein polypeptides, and CA125, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect a plurality of kallikrein polypeptides, and optionally CA125, in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the levels of expression of a plurality of kallikrein polypeptides, and optionally CA125, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of a plurality of kallikrein polypeptides, and optionally CA125. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on ovarian cancer involving a plurality of kallikrein polypeptides, and optionally CA125, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

Antibodies may be used in any known immunoassays that rely on the binding interaction between antigenic determinants of a plurality of kallikrein polypeptides, and optionally CA125, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests. These terms are well understood by those skilled in the art. A person skilled in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

In particular, the antibodies may be used in immunohistochemical analyses, for example, at the cellular and sub-subcellular level, to detect a plurality of kallikrein polypeptides, and optionally CA125, to localize them to particular ovarian tumor cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

Antibodies for use in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (e.g. a Fab or (Fab)₂ fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain F_v molecules (Ladner et al, U.S. Pat. No. 4,946,778), chimeric antibodies, for example, antibodies which contain the binding specificity of murine antibodies, but in which the remaining portions are of human origin, or derivatives, such as enzyme conjugates or labeled derivatives.

Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art. Isolated native or recombinant kallikrein polypeptides or CA125 may be utilized to prepare antibodies. See, for example, Kohler et al. (1975) Nature 256:495-497; Kozbor et al. (1985) J. Immunol Methods 81:31-42; Cote et al. (1983) Proc Natl Acad Sci 80:2026-2030; and Cole et al. (1984) Mol Cell Biol 62:109-120 for the preparation of monoclonal antibodies; Huse et al. (1989) Science 246:1275-1281 for the preparation of monoclonal Fab fragments; and, Pound (1998) Immunochemical Protocols, Humana Press, Totowa, N.J for the preparation of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies. The antibodies specific for kallikrein polypeptides or CA125 used in the methods of the invention may also be obtained from scientific or commercial sources.

In an embodiment of the invention, antibodies are reactive against kallikrein polypeptides or CA125 if they bind with a K_a of greater than or equal to 10⁻⁷ M.

Antibodies that bind to kallikrein polypeptides or CA125 may be labelled with a detectable

substance and localised in biological samples based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g., ^3H , ^{14}C , ^{35}S , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol, enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods), and predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a kallikrein polypeptide or CA125. The second antibody may be labeled with a detectable substance to detect the primary antigen-antibody reaction. By way of example, if the antibody having specificity against a kallikrein polypeptide is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art. (See for example Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wichek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988 re methods for conjugating or labelling the antibodies with enzyme or ligand binding partner).

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect a plurality of kallikrein polypeptides, and optionally CA125. Generally, antibodies may be labeled with detectable substances and kallikrein polypeptides, and optionally CA125, may be localised in tissues and cells based upon the presence of the detectable substance.

In the context of the methods of the invention, the sample, binding agents (e.g. antibodies) for a plurality of kallikrein polypeptides, and CA125 may be immobilized on a carrier or support. Examples of suitable carriers or supports are agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, liposomes, carboxymethyl cellulose, polyacrylamides, polystyrene, gabbros, filter paper, magnetite, ion-exchange resin, plastic film, plastic tube, glass, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Thus, the carrier may be in the shape of, for example, a tube, test plate, well, beads, disc, sphere, etc. The immobilized material may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling. Binding agents (e.g. antibodies) may be indirectly immobilized using second binding agents specific for the first binding agent. For example, mouse antibodies specific for a kallikrein polypeptide may

be immobilized using sheep anti-mouse IgG Fc fragment specific antibody coated on the carrier or support.

Where radioactive labels are used as a detectable substance, a plurality of kallikrein polypeptides, and optionally CA125, may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

Time-resolved fluorometry may be used to detect a signal. For example, the method described in Christopoulos TK and Diamandis EP Anal Chem 1992:64:342-346 may be used with a conventional time-resolved fluorometer.

Therefore, in accordance with an embodiment of the invention, a method is provided wherein antibodies specific for each of a plurality of kallikrein polypeptides, and optionally CA125, are labelled with enzymes, substrates for the enzymes are added wherein the substrates are selected so that the substrates, or a reaction product of the enzymes and substrates, form fluorescent complexes with lanthanide metals. Lanthanide metals are added and the plurality of kallikrein polypeptides, and optionally CA125, are quantitated in the sample by measuring fluorescence of the fluorescent complexes. Antibodies specific for CA125 and each of a plurality of kallikrein polypeptides may be directly or indirectly labelled with enzymes. Enzymes are selected based on the ability of a substrate of the enzyme, or a reaction product of the enzyme and substrate, to complex with lanthanide metals such as europium and terbium. Examples of suitable enzymes include alkaline phosphatase and β -galactosidase.

Examples of enzymes and substrates for enzymes that provide such fluorescent complexes are described in U.S. Patent No. 5,312,922 to Diamandis. By way of example, when the antibody is directly or indirectly labelled with alkaline phosphatase the substrate employed in the method may be 4-methylumbelliferyl phosphate, 5-fluorosalicyl phosphate, or diflunisal phosphate. The fluorescence intensity of the complexes is typically measured using a time-resolved fluorometer e.g. a CyberFluor 615 Imunoanalyzer (Nordion International, Kanata, Ontario).

Antibodies specific for a plurality of kallikrein polypeptides and CA125 may also be indirectly labelled with enzymes. For example, an antibody may be conjugated to one partner of a ligand binding pair, and the enzyme may be coupled to the other partner of the ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein. In another embodiment, antibodies specific for the anti-kallikrein antibodies or anti-CA125 antibodies are labeled with an enzyme.

In accordance with an embodiment, the present invention provides means for determining a plurality of kallikrein polypeptides, and optionally CA125, in a sample, in particular a serum sample, by measuring a plurality of kallikrein polypeptides, and optionally CA125, by immunoassay. It will be evident to a skilled artisan that a variety of immunoassay methods can be used to measure a plurality of kallikrein polypeptides and CA125 in serum. In general, an immunoassay method may be competitive or noncompetitive. Competitive methods typically employ immobilized or immobilizable antibodies to each of a plurality of kallikrein polypeptides, and optionally CA125, and a labeled form of each of a plurality of kallikrein polypeptides, and optionally CA125. Kallikrein polypeptides and CA125 and labeled kallikrein polypeptides and CA125 compete for binding to anti-kallikrein antibodies and anti-CA125 antibodies. After separation of the resulting labeled kallikrein polypeptides and CA125 that have become bound to anti-

- 20 -

kallikrein polypeptides and anti- CA125 (bound fraction) from that which has remained unbound (unbound fraction), the amount of the label in either bound or unbound fraction is measured and may be correlated with the amount of kallikrein polypeptides, and optionally CA125, in the test sample in any conventional manner, e.g., by comparison to a standard curve.

5 In an aspect, a non-competitive method is used for the determination of a plurality of kallikrein polypeptides, and optionally CA125, with the most common method being the "sandwich" method. In this assay, two types of antibodies specific for each of a plurality of kallikrein polypeptides, and optionally CA125 are employed. One type of antibody is directly or indirectly labeled (sometimes referred to as the "detection antibody") and the other is immobilized or immobilizable (sometimes referred to as the "capture antibody"). The capture and detection antibodies can be contacted simultaneously or sequentially with a test sample. Sequential methods can be accomplished by incubating capture antibodies with the sample, and adding the detection antibodies at a predetermined time thereafter (sometimes referred to as the "forward" method); or the detection antibodies can be incubated with the sample first and then the capture antibodies added (sometimes referred to as the "reverse" method). After the necessary incubation(s) have occurred, to
10 complete the assay, the capture antibodies are separated from the liquid test mixture, and labels are measured in at least a portion of the separated capture antibody phase or the remainder of the liquid test mixture. Generally the labels are measured in the capture antibody phase since it comprises kallikrein polypeptides, and optionally CA125, bound by ("sandwiched" between) the capture and detection antibodies. In an embodiment, the label may be measured without separating the capture antibodies and liquid test mixture.

20 In a typical two-site immunometric assay for a plurality of kallikrein polypeptides, and optionally CA125, one or both of the capture and detection antibodies are polyclonal antibodies or one or both of the capture and detection antibodies are monoclonal antibodies (i.e. polyclonal/polyclonal, monoclonal/monoclonal, or monoclonal/polyclonal). The labels used with the detection antibodies can be selected from any of those known conventionally in the art. The labels may be an enzyme or a
25 chemiluminescent moiety, but it can also be a radioactive isotope, a fluorophor, a detectable ligand (e.g., detectable by a secondary binding by a labeled binding partner for the ligand), and the like. Preferably antibodies are labelled with enzymes which are detected by adding substrates that are selected so that a reaction product of the enzymes and substrates forms fluorescent complexes. Capture antibodies may be selected so that they provide a means for being separated from the remainder of the test mixture.
30 Accordingly, the capture antibodies can be introduced to the assay in an already immobilized or insoluble form, or can be in an immobilizable form, that is, a form which enables immobilization to be accomplished subsequent to introduction of the capture antibodies to the assay. An immobilized capture antibody may comprise an antibody covalently or noncovalently attached to a solid phase such as a magnetic particle, a latex particle, a microtiter plate well, a bead, a cuvette, or other reaction vessel. An example of an
35 immobilizable capture antibody is antibody which has been chemically modified with a ligand moiety, e.g., a hapten, biotin, or the like, and which can be subsequently immobilized by contact with an immobilized form of a binding partner for the ligand, e.g., an antibody, avidin, or the like. In an embodiment, a capture antibody may be immobilized using a species specific antibody for the capture antibody that is bound to the solid phase.

- 21 -

A particular sandwich immunoassay method of the invention employs two types of antibodies, first antibodies are reactive against each of a plurality of kallikrein polypeptides, and optionally CA125, and second antibodies having specificity against antibodies reactive against each of a plurality of kallikrein polypeptides, and optionally CA125, labelled with enzymatic labels, and fluorogenic substrates for the enzymes. An enzyme may be alkaline phosphatase (ALP) and the substrate is 5-fluorosalicyl phosphate. ALP cleaves phosphate out of the fluorogenic substrate, 5-fluorosalicyl phosphate, to produce 5-fluorosalicic acid (FSA). 5-Fluorosalicic acid can then form a highly fluorescent ternary complex of the form FSA-Tb(3+)-EDTA, which can be quantified by measuring the Tb3+ fluorescence in a time-resolved mode. Fluorescence intensity is measured using a time-resolved fluorometer as described herein.

The above-described immunoassay methods and formats are intended to be exemplary and are not limiting.

Computer Systems

Computer readable media comprising a plurality of kallikrein markers, and optionally CA125, is also provided. "Computer readable media" refers to any medium that can be read and accessed directly by a computer, including but not limited to magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. Thus, the invention contemplates computer readable medium having recorded thereon markers identified for patients and controls.

"Recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising information on a plurality of kallikrein markers, and optionally CA125.

A variety of data processor programs and formats can be used to store information on a plurality of kallikrein markers, and optionally CA125, on computer readable medium. For example, the information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the marker information.

By providing the marker information in computer readable form, one can routinely access the information for a variety of purposes. For example, one skilled in the art can use the information in computer readable form to compare marker information obtained during or following therapy with the information stored within the data storage means.

The invention provides a medium for holding instructions for performing a method for determining whether a patient has ovarian cancer or a pre-disposition to ovarian cancer, comprising determining the presence or absence of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, and based on the presence or absence of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, determining whether the patient has ovarian cancer or a pre-disposition to

- 22 -

ovarian cancer, and optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

The invention also provides in an electronic system and/or in a network, a method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a plurality of kallikrein markers, and optionally CA125, and/or polynucleotides encoding same, comprising determining the presence or absence of a plurality of kallikrein markers, and optionally CA125, and/or polynucleotides encoding same, and based on the presence or absence of the plurality of kallikrein markers, and optionally CA125, and/or polynucleotides encoding same, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer, and optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

The invention further provides in a network, a method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a plurality of kallikrein markers, optionally CA125 and/or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on a plurality of kallikrein markers, optionally CA125 and/or polynucleotides encoding same associated with samples from the subject; (b) acquiring information from the network corresponding to the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same; and (c) based on the phenotypic information and information on the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer; and (d) optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

The invention still further provides a system for identifying selected records that identify an ovarian cancer cell. A system of the invention generally comprises a digital computer; a database server coupled to the computer; a database coupled to the database server having data stored therein, the data comprising records of data comprising a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records which match the desired selection criteria.

In an aspect of the invention a method is provided for detecting an ovarian cancer cell using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:

- (a) creating records of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, isolated from a sample suspected of containing an ovarian cancer cell;
- (b) providing a database comprising records of data comprising a plurality of kallikrein markers, optionally CA125, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and/or comprising polynucleotides encoding same; and
- (c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records of step (a) which provide a match of the desired selection criteria of the database of step (b) the presence of a match being a

- 23 -

positive indication that the markers of step (a) have been isolated from a cell that is an ovarian cancer cell.

The invention contemplates a business method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, associated with samples from the subject; (b) acquiring information from a network corresponding to the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same; and (c) based on the phenotypic information, information on a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, and acquired information, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer; and (d) optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

Imaging Methods

Antibodies specific for each of a plurality of kallikrein polypeptides, and optionally CA125, may also be used in imaging methodologies in the management of ovarian cancer. The invention provides a method for imaging tumors associated with a plurality of kallikrein polypeptides, and optionally CA125.

In an embodiment the method is an *in vivo* method and a subject or patient is administered imaging agents that carry imaging labels and are capable of targeting or binding to each of a plurality of kallikrein polypeptides, and optionally CA125. In the method each imaging agent is labeled so that it can be distinguished during the imaging. The imaging agents are allowed to incubate *in vivo* and bind to the plurality of kallikrein polypeptides, and optionally CA125, associated with ovarian tumors. The presence of label is localized to the ovarian cancer, and the localized label is detected using imaging devices known to those skilled in the art.

The imaging agents may be antibodies or chemical entities that recognize the plurality of kallikrein polypeptides, and optionally CA125. In an aspect of the invention an imaging agent is a polyclonal antibody or monoclonal antibody, or fragments thereof, or constructs thereof including but not limited to, single chain antibodies, bifunctional antibodies, molecular recognition units, and peptides or entities that mimic peptides. The antibodies specific for kallikrein polypeptides and CA125 used in the methods of the invention may be obtained from scientific or commercial sources, or isolated native or recombinant kallikrein and CA125 polypeptides may be utilized to prepare antibodies etc as described herein.

An imaging agent may be a peptide that mimics the epitope for an antibody specific for kallikrein polypeptide or CA125 and binds to kallikrein polypeptide or CA125. The peptide may be produced on a commercial synthesizer using conventional solid phase chemistry. By way of example, a peptide may be prepared that includes either tyrosine, lysine, or phenylalanine to which N_2S_2 chelate is complexed (See U.S. Patent No. 4,897,255). The anti-kallikrein peptide conjugate is then combined with a radiolabel (e.g. sodium ^{99m}Tc pertechnetate or sodium ^{188}Re perrhenate) and it may be used to locate a tumor producing a plurality of kallikrein polypeptides, and optionally CA125.

Imaging agents carry labels to image the plurality of kallikrein polypeptides and CA125. Agents may be labelled for use in radionuclide imaging. In particular, agents may be directly or indirectly labelled

with a radioisotope. Examples of radioisotopes that may be used in the present invention are the following:
²⁷⁷Ac, ²¹¹At, ¹²⁸Ba, ¹³¹Ba, ⁷Be, ²⁰⁴Bi, ²⁰⁵Bi, ²⁰⁶Bi, ⁷⁶Br, ⁷⁷Br, ⁸²Br, ¹⁰⁹Cd, ⁴⁷Ca, ¹¹C, ¹⁴C, ³⁶Cl, ⁴⁸Cr, ⁵¹Cr, ⁶²Cu,
⁶⁴Cu, ⁶⁷Cu, ¹⁶⁵Dy, ¹⁵⁵Eu, ¹⁸F, ¹⁵³Gd, ⁶⁶Ga, ⁶⁷Ga, ⁶⁸Ga, ⁷²Ga, ¹⁹⁸Au, ³H, ¹⁶⁶Ho, ¹¹¹In, ^{113m}In, ^{115m}In, ¹²³I, ¹²⁵I, ¹³¹I,
¹⁸⁹Ir, ^{191m}Ir, ¹⁹²Ir, ¹⁹⁴Ir, ⁵²Fe, ⁵⁵Fe, ⁵⁹Fe, ¹⁷⁷Lu, ¹⁵O, ^{191m-191}Os, ¹⁰⁹Pd, ³²P, ³³P, ⁴²K, ²²⁶Ra, ¹⁸⁶Re, ¹⁸⁸Re, ^{82m}Rb,
5 ¹⁵³Sm, ⁴⁶Sc, ⁴⁷Sc, ⁷²Se, ⁷⁵Se, ¹⁰⁵Ag, ²²Na, ²⁴Na, ⁸⁹Sr, ³⁵S, ³⁸S, ¹⁷⁷Ta, ⁹⁶Tc, ^{99m}Tc, ²⁰¹Tl, ²⁰²Tl, ¹¹³Sn, ^{117m}Sn,
¹²¹Sn, ¹⁶⁶Yb, ¹⁶⁹Yb, ¹⁷⁵Yb, ⁸⁸Y, ⁹⁰Y, ⁶²Zn and ⁶⁵Zn. Preferably the radioisotope is ¹³¹I, ¹²⁵I, ¹²³I, ¹¹¹I, ^{99m}Tc,
⁹⁰Y, ¹⁸⁶Re, ¹⁸⁸Re, ³²P, ¹⁵³Sm, ⁶⁷Ga, ²⁰¹Tl ⁷⁷Br, or ¹⁸F, and it is imaged with a photoscanning device.

Procedures for labeling biological agents with the radioactive isotopes are generally known in the art. U.S. Pat. No. 4,302,438 describes tritium labeling procedures. Procedures for iodinating, tritium labeling,
10 and ³⁵S labeling especially adapted for murine monoclonal antibodies are described by Goding, J. W. (supra, pp 124-126) and the references cited therein. Other procedures for iodinating biological agents, such as antibodies, binding portions thereof, probes, or ligands, are described in the scientific literature (see Hunter and Greenwood, Nature 144:945 (1962), David et al., Biochemistry 13:1014-1021 (1974), and U.S. Pat. Nos. 3,867,517 and 4,376,110). Iodinating procedures for agents are described by Greenwood, F. et al., Biochem.
15 J. 89:114-123 (1963); Marchalonis, J., Biochem. J. 113:299-305 (1969); and Morrison, M. et al., Immunochemistry, 289-297 (1971). ^{99m}Tc-labeling procedures are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), Tumor Imaging: The Radioimmunochemical Detection of Cancer, New York: Masson 111-123 (1982) and the references cited therein. Labelling of antibodies or fragments with technetium-99m are also described for example in U.S. Pat. No. 5,317,091, U.S. Pat. No. 4,478,815, U.S.
20 Pat. No. 4,478,818, U.S. Pat. No. 4,472,371, U.S. Pat. No. Re 32,417, and U.S. Pat. No. 4,311,688. Procedures suitable for ¹¹¹In-labeling biological agents are described by Hnatowich, D. J. et al., J. Immul. Methods, 65:147-157 (1983), Hnatowich, D. et al., J. Applied Radiation, 35:554-557 (1984), and Buckley, R. G. et al., F.E.B.S. 166:202-204 (1984).

An imaging agent may also be labeled with a paramagnetic isotope for purposes of an *in vivo*
25 method of the invention. Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340; Wolf, G L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93-95; Wesbey et al., (1984) Physiol. Chem. Phys. Med. NMR 16, 145-155; Runge et al., (1984) Invest. Radiol. 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

30 In the case of radiolabeled agents, the agents may be administered to the patient, localized to the tumor having a plurality of kallikrein polypeptides, and optionally CA125, with which the agents bind, and detected or "imaged" *in vivo* using known techniques such as radionuclear scanning using, for example, a gamma camera or emission tomography. [See for example, A. R. Bradwell et al., "Developments in Antibody Imaging", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al., (eds.),
35 pp. 65-85 (Academic Press 1985)]. A positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can also be used where the radiolabel emits positrons (e.g., ¹¹C, ¹⁸F, ¹⁵O, and ¹³N).

Whole body imaging techniques using radioisotope labeled agents can be used for locating both primary tumors and tumors which have metastasized. Antibodies specific for a plurality of kallikrein

- 25 -

polypeptides, and optionally CA125, or fragments thereof having the same epitope specificity, are bound to a suitable radioisotope, or a combination thereof, and administered parenterally. For ovarian cancer, administration preferably is intravenous. The bio-distribution of the labels can be monitored by scintigraphy, and accumulations of the labels can be related to the presence of ovarian cancer cells. Whole body imaging techniques are described in U.S. Pat. Nos. 4,036,945 and 4,311,688. Other examples of agents useful for diagnosis and therapeutic use that can be coupled to antibodies and antibody fragments include metallothionein and fragments (see, U.S. Pat. No. 4,732,864). These agents are useful in diagnosis, staging and visualization of cancer, in particular ovarian cancer, so that surgical and/or radiation treatment protocols can be used more efficiently.

10 Screening Methods

The invention also contemplates methods for evaluating test agents or compounds for their ability to inhibit ovarian cancer or potentially contribute to ovarian cancer. Test agents and compounds include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)₂, and Fab expression library fragments, and epitope-binding fragments thereof)], nucleic acids (e.g. antisense, interference RNA) and small organic or inorganic molecules. The agents or compounds may be endogenous physiological compounds or natural or synthetic compounds.

The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, the method comprising comparing:

- (a) levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a first sample obtained from a patient and exposed to the test agent, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and
- (b) levels of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting ovarian cancer in the patient.

The first and second samples may be portions of a single sample obtained from a patient or portions of pooled samples obtained from a patient.

In an aspect, the invention provides a method of selecting an agent for inhibiting ovarian cancer in a patient comprising:

- (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing a plurality of kallikrein markers, optionally CA125, and/or polynucleotides

- 26 -

encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

- 5 (d) selecting one of the test agents which alters the levels of the kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot containing that test agent, relative to other test agents.

Still another aspect of the present invention provides a method of conducting a drug discovery business comprising:

- 10 (a) providing one or more methods or assay systems for identifying agents that inhibit ovarian cancer in a patient;
- (b) conducting therapeutic profiling of agents identified in step (a), or further analogs thereof, for efficacy and toxicity in animals; and
- (c) formulating a pharmaceutical preparation including one or more agents identified in step (b) as having an acceptable therapeutic profile.

15 In certain embodiments, the subject method can also include a step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.

The invention also contemplates a method of assessing the ovarian carcinogenic potential of a test compound comprising:

- 20 (a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and
- (b) comparing a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

25 A significant difference between the levels of the markers in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses ovarian carcinogenic potential.

Kits

30 The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least a plurality of kallikrein nucleic acids or binding agents (e.g. antibodies) or CA125 nucleic acids or binding agents described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients, and to screen and identify those individuals afflicted with or exhibiting a predisposition to ovarian cancer.

35 Thus, the invention also contemplates kits for carrying out the methods of the invention. Such kits typically comprise two or more components required for performing a diagnostic assay. Components include but are not limited to compounds, reagents, containers, and/or equipment.

In an embodiment, a container with a kit comprises binding agents as described herein. By way of example, the kit may contain antibodies specific for a plurality of kallikrein polypeptides, and optionally

- 27 -

CA125, antibodies against the antibodies labelled with enzymes; and substrates for the enzymes. The kit may also contain microtiter plate wells, standards, assay diluent, wash buffer, adhesive plate covers, and/or instructions for carrying out a method of the invention using the kit.

5 In an aspect of the invention, the kit includes antibodies or antibody fragments which bind specifically to epitopes of each of a plurality of kallikrein polypeptides, and optionally CA125, and means for detecting binding of the antibodies to epitopes associated with tumor cells, either as concentrates (including lyophilized compositions), which may be further diluted prior to use or at the concentration of use, where the vials may include one or more dosages. Where the kits are intended for *in vivo* use, single dosages may be provided in sterilized containers, having the desired amount and concentration of agents.

10 Containers that provide a formulation for direct use, usually do not require other reagents, as for example, where the kit contains radiolabelled antibody preparations for *in vivo* imaging.

A kit may be designed to detect the level of polynucleotides encoding kallikrein polypeptides, and optionally CA125 polynucleotides, in a sample. Such kits generally comprise oligonucleotide probes or primers, as described herein, that hybridize to a plurality of polynucleotides encoding kallikrein polypeptides

15 and optionally CA125. Such oligonucleotides may be used, for example, within a PCR or hybridization procedure. Additional components that may be present within the kits include second oligonucleotides and/or diagnostic reagents to facilitate detection of a plurality polynucleotides encoding kallikrein polypeptides, and optionally CA125 polynucleotides.

The reagents suitable for applying the screening methods of the invention to evaluate compounds

20 may be packaged into convenient kits described herein providing the necessary materials packaged into suitable containers.

Applications

Kallikrein polypeptides (in particular, kallikrein 5, 6, 10 and 11), optionally in combination with CA125, are targets for ovarian cancer immunotherapy. Such immunotherapeutic methods include the use of

25 antibody therapy, *in vivo* vaccines, and *ex vivo* immunotherapy approaches.

In one aspect, the invention provides antibodies specific for a plurality of kallikrein polypeptides (for example, kallikreins 5, 6, 10 and 11) and optionally CA125, that may be used systemically to treat ovarian cancer. Preferably antibodies are used that target the tumor cells but not the surrounding non-tumor cells and tissue. Thus, the invention provides a method of treating a patient susceptible to, or having a cancer

30 that expresses a plurality of kallikrein polypeptides, and optionally CA125, comprising administering to the patient an effective amount of antibodies that bind specifically to a plurality of kallikrein polypeptides, and optionally CA125. In another aspect, the invention provides a method of inhibiting the growth of tumor cells expressing a plurality of kallikrein polypeptides, and optionally CA125, comprising administering to a patient antibodies which bind specifically to the plurality of kallikrein polypeptides, and optionally CA125,

35 in amounts effective to inhibit growth of the tumor cells. Antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, may also be used in a method for selectively inhibiting the growth of, or killing a cell expressing a plurality of kallikrein polypeptides, and optionally CA125, comprising reacting antibody immunoconjugates or immunotoxins with the cell in an amount sufficient to inhibit the growth of, or kill the cell.

By way of example, unconjugated antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, may be introduced into a patient such that the antibodies bind to cancer cells expressing a plurality of kallikrein polypeptides, and optionally CA125, and mediate growth inhibition of such cells (including the destruction thereof), and the tumor, by mechanisms which may include complement-mediated
5 cytotoxicity, antibody-dependent cellular cytotoxicity, altering the physiologic function of a plurality of kallikrein polypeptides, and optionally CA125, and/or the inhibition of ligand binding or signal transduction pathways. In addition to unconjugated antibodies, antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, conjugated to therapeutic agents (e.g. immunoconjugates) may also be
10 used therapeutically to deliver the agents directly to tumor cells expressing a plurality of kallikrein polypeptides, and optionally CA125, and thereby destroy the tumor. Examples of such agents include abrin, ricin A, *Pseudomonas* exotoxin, or diphtheria toxin, proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, and biological response modifiers such as lymphokines, interleukin-1, interleukin-2, interleukin-6, granulocyte
macrophage colony stimulating factor, granulocyte colony stimulating factor, or other growth factors.

15 Cancer immunotherapy using antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, may utilize the various approaches that have been successfully employed for cancers, including but not limited to colon cancer (Arlen et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsunenati et al., 1997, Blood 90: 2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J
20 Immunother Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54: 6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and breast cancer (Shepard et al., 1991, J Clin Immunol 11: 117-127).

In the practice of a method of the invention, antibodies specific for a plurality of kallikrein polypeptides, optionally in combination with antibodies specific for CA125, capable of inhibiting the growth
25 of cancer cells expressing a plurality of kallikrein polypeptides, and optionally CA125, are administered in a therapeutically effective amount to cancer patients whose tumors express or overexpress a plurality of kallikrein polypeptides, and optionally CA125. The invention may provide a specific, effective and long-needed treatment for ovarian cancer. The antibody therapy methods of the invention may be combined with other therapies including chemotherapy and radiation.

30 Patients may be evaluated for the presence and levels of a plurality of kallikrein polypeptides, and optionally CA125, expression and overexpression in tumors, preferably using immunohistochemical assessments of tumor tissue, quantitative imaging as described herein, or other techniques capable of reliably indicating the presence and degree of expression of a plurality of kallikrein polypeptides, and optionally
35 CA125. Immunohistochemical analysis of tumor biopsies or surgical specimens may be employed for this purpose.

Antibodies specific for a plurality of kallikrein polypeptides and CA125 useful in treating cancer include those that are capable of initiating a potent immune response against the tumor and those that are capable of direct cytotoxicity. In this regard, the antibodies may elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc

- 29 -

portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins. In addition, antibodies specific for a plurality of kallikrein polypeptides and CA125 that exert a direct biological effect on tumor growth are useful in the practice of the invention. Such antibodies may not require the complete immunoglobulin to exert the effect. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, antibody-dependent macrophage-mediated cytotoxicity (ADMMC), complement-mediated cell lysis, and others known in the art.

10 The anti-tumor activity of a combination of antibodies specific for a plurality of kallikrein polypeptides and optionally CA125, may be evaluated *in vivo* using a suitable animal model. Xenogenic cancer models, wherein human cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, may be employed.

15 The methods of the invention contemplate the administration of combinations, or "cocktails" of different individual antibodies recognizing epitopes of a plurality of kallikrein polypeptides, and optionally CA125. Such cocktails may have certain advantages inasmuch as they contain antibodies that bind to different epitopes and/or exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in combination may exhibit synergistic therapeutic effects. In addition, the administration of the antibodies may be combined with other therapeutic agents, including but not limited to chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL2, GM-CSF). The antibodies may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

20 The antibodies specific for a plurality of kallikrein polypeptides and optionally CA125, used in the practice of the method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the antibodies retains the anti-tumor function of the antibodies and is non-reactive with the subject's immune systems. Examples include any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16.sup.th Edition, A. Osal., Ed., 1980).

30 Antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Preferably, the route of administration is by intravenous injection. Antibody preparations may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

35 Treatment will generally involve the repeated administration of the antibody preparation via an acceptable route of administration such as intravenous injection (IV), at an effective dose. Dosages will depend upon various factors generally appreciated by those of skill in the art, including the type of cancer and the severity, grade, or stage of the cancer, the binding affinity and half life of the antibodies used, the

degree of expression of a plurality of kallikrein polypeptides, and optionally CA125, in the patient, the extent of circulating kallikrein polypeptide antigens, and optionally CA125 antigens, the desired steady-state antibody concentration level, frequency of treatment, and the influence of any chemotherapeutic agents used in combination with a treatment method of the invention.

5 Daily doses may range from about 0.1 to 100 mg/kg. Doses in the range of 10-500 mg antibodies per week may be effective and well tolerated, although even higher weekly doses may be appropriate and/or well tolerated. A determining factor in defining the appropriate dose is the amount of antibodies necessary to be therapeutically effective in a particular context. Repeated administrations may be required to achieve tumor inhibition or regression. Direct administration of antibodies specific for a plurality of kallikrein polypeptides and optionally CA125 is also possible and may have advantages in certain situations.

10 Patients may be evaluated for a plurality of kallikrein polypeptides and optionally CA125, preferably in serum, in order to assist in the determination of the most effective dosing regimen and related factors. The assay methods described herein, or similar assays, may be used for quantitating circulating kallikrein polypeptide and optionally CA125 levels in patients prior to treatment. Such assays may also be used for monitoring throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters, such as serum kallikrein polypeptides, and optionally CA125, levels.

15 The invention further provides vaccines formulated to contain a plurality of kallikrein polypeptides, and optionally CA125, or fragments thereof. The use in anti-cancer therapy of tumor antigens in a vaccine for generating humoral and cell-mediated immunity is well known and, for example, has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). These methods can be practiced by employing a plurality of kallikrein polypeptides, and optionally CA125, or fragments thereof, or nucleic acids and recombinant vectors capable of expressing and appropriately presenting the kallikrein and optionally CA125, immunogens.

20 By way of example, viral gene delivery systems may be used to deliver nucleic acids encoding a plurality of kallikrein polypeptides, and optionally CA125. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663). Non-viral delivery systems may also be employed by using naked DNA encoding a plurality of kallikrein polypeptides, and optionally CA125, or fragments thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response.

25 Various *ex vivo* strategies may also be employed. One approach involves the use of cells to present kallikrein and optionally CA125 antigens to a patient's immune system. For example, autologous dendritic cells which express MHC class I and II, may be pulsed with a plurality of kallikrein polypeptides, and optionally CA125, or peptides thereof that are capable of binding to MHC molecules, to thereby stimulate ovarian cancer patients' immune systems (See, for example, Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al., 1996, Prostate 29: 371-380).

30 Anti-idiotypic antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing the

polypeptides. The generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic antibodies that mimic an epitope on a kallikrein polypeptide or CA125 (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76). Such antibodies can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against tumor antigens.

Genetic immunization methods may be utilized to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing a plurality of kallikrein polypeptides, and optionally CA125. Constructs comprising DNA encoding kallikrein and optionally CA125 polypeptides/immunogens and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded kallikrein or CA125 polypeptides/immunogens. The polypeptides/immunogens may be expressed as cell surface proteins or be secreted. Expression of the polypeptides/immunogens results in the generation of prophylactic or therapeutic humoral and cellular immunity against the cancer. Various prophylactic and therapeutic genetic immunization techniques known in the art may be used.

The invention further provides methods for inhibiting cellular activity (e.g., cell proliferation, activation, or propagation) of a cell expressing a plurality of kallikrein polypeptides, and optionally CA125. This method comprises reacting immunoconjugates of the invention (e.g., a heterogeneous or homogenous mixture) with the cell so that the kallikrein polypeptides, and optionally CA125, form complexes with the immunoconjugates. A subject with a neoplastic or preneoplastic condition can be treated when the inhibition of cellular activity results in cell death.

In another aspect, the invention provides methods for selectively inhibiting a cell expressing a plurality of kallikrein polypeptides, and optionally CA125, by reacting a combination of immunoconjugates of the invention with the cell in an amount sufficient to inhibit the cell. Amounts include those that are sufficient to kill the cell or sufficient to inhibit cell growth or proliferation.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver nucleic acids encoding a plurality of kallikrein polypeptides, and optionally CA125, to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct recombinant vectors that will express antisense nucleic acid molecules for kallikrein polypeptides and CA125. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

Genes encoding a plurality of kallikrein polypeptides, and optionally CA125, can be turned off by transfecting a cell or tissue with vectors that express high levels of a desired kallikrein or CA125 polypeptide-encoding fragments. Such constructs can inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of genes encoding kallikrein polypeptides, and optionally CA125, i.e., the promoters, enhancers, and introns. Preferably, oligonucleotides are derived from the transcription initiation site, eg, between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed

- 32 -

so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding a plurality of kallikrein polypeptides, and optionally CA125.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

Kallikrein polypeptides, optionally CA125 polypeptide, and/or polynucleotides encoding the polypeptides, and fragments thereof, antibodies and/or agents identified using a method of the invention, or combinations thereof, may be used in the treatment of ovarian cancer or diseases, conditions or syndromes associated with ovarian cancer, in a subject. A combination of kallikrein polypeptides and/or polynucleotides encoding the kallikreins (e.g. kallikreins 7 and 8) and inhibitors (antisense, antibodies, or agents) of other kallikreins (e.g. kallikreins 5, 6, 10 and 11) and/or CA125 may be used in a prognostic or therapeutic method of the invention. The polypeptides, polynucleotides, and agents may be formulated into compositions for administration to subjects suffering from ovarian cancer. Therefore, the present invention also relates to a composition comprising a plurality of kallikrein polypeptides and optionally CA125, or nucleic acids encoding the polypeptides, or a fragment thereof, or an agent identified using a method of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing ovarian cancer in a subject is also provided comprising administering to a patient in need thereof, a plurality of kallikrein polypeptides and optionally CA125, or nucleic acids encoding the polypeptides, an agent identified in accordance with a method of the invention, and/or a composition of the invention.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to

protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the substance.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The compositions are indicated as therapeutic agents either alone or in conjunction with other therapeutic agents or other forms of treatment (e.g. chemotherapy or radiotherapy). The compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies.

The following non-limiting examples are illustrative of the present invention:

Example 1

To investigate the additional discriminatory value of the kallikreins to CA125 a logistic regression model was developed. Included in the study were serum samples from 39 ovarian cancer patients and 194 non-cancer females. The age of the patients was as follows: median = 59, range 32-82. The age of the controls was as follows: median = 46; range = 22-77. The model was adjusted for the following variables: $f(x) = -0.29 \text{ hK5} + 0.12 \text{ hK6} - 0.65 \text{ hK7} - 0.6 \text{ hK8} + 1.09 \text{ hK10} + 0.98 \text{ hK11} + 0.057 \text{ CA125} - 0.62$. For these data, the crude odds ratio and the 95% confidence interval were found to be 2.71 and 1.91-3.84 ($p < 0.001$). The log likelihood scores for this multivariate logistic regression model, which incorporated the combined variables for each patient was calculated. From these data, by picking different thresholds for the regression function values, a ROC curve was devised which shows the added value of using kallikreins and CA125 together in a multivariate function. (AUC, 0.99; 95%CI, 0.96-1.00). (See Figure 8.) Statistically significant correlations between age and other studied variables were not observed.

Example 2

Statistically significant differences in serum kallikrein concentration was found between patient and control subjects for kallikreins hK5 ($p < 0.0001$), hK7 ($p = 0.007$), hK8 ($p = 0.005$), hK10 ($p = 0.0003$) and CA125 ($p < 0.0001$) by the Mann-Whitney test. The diagnostic sensitivity (SENS) and specificity (SPEC) for each one of these markers were as follows (SENS/SPEC; both as %): 31/95 (hK5); 62/71 (hK7); 62/70 (hK10); 54/54 (hK11); 89/94 (CA125). When these data were combined in a logistic regression model, kallikreins 5 and 10 did not contribute to a great extent to the sensitivity and specificity of CA125. The area under the curve of CA125 alone (93%) improved by a further 1% when adding hK6, by 2% when adding hK11, 3% when adding hK7 and 5% when adding hK8. The combination of CA125 and hK8 resulted in an AUC of 98%.

Below is a summary of each marker and its ability to separate the cases and controls.

- 34 -

- hK5: high values associated with cancer
 test+ is $hK5 > 0.10$, test- is $hK5 \leq 0.10$
 sensitivity=31%, specificity=95%,
 AUC=.62, $p(AUC)=.02$
 5 Wilcoxon rank sum test has $p < .0001$.
 Of the 233 persons analyzed, 207 have value zero for hK5 (27 cases, 180 controls).
 Possible good marker
- hK6: high values associated with cancer
 10 test+ is $hK6 > 6.3$, test- is $hK6 \leq 6.3$
 sensitivity=69%, specificity=40%,
 AUC=.50, $p(AUC)=1.00$
 Wilcoxon rank sum test has $p=.91$.
 Not a good marker
- hK7: low values associated with cancer
 15 test+ is $hK7 < 2.05$, test- is $hK7 \geq 2.05$
 sensitivity=62%, specificity=71%,
 AUC=.64, $p(AUC)=.006$
 20 Wilcoxon rank sum test has $p=.007$.
 Possible good marker
- hK8: low values associated with cancer
 test+ is $hK8 < 13.0$, test- is $hK8 \geq 13.0$
 25 sensitivity=72%, specificity=42%,
 AUC=.64, $p(AUC)=.006$
 Wilcoxon rank sum test has $p=.005$
 Possible good marker
- hK10: high values associated with cancer
 30 test+ is $hK10 > 1.42$, test- is $hK10 \leq 1.42$
 sensitivity=62%, specificity=70%,
 AUC=.68, $p(AUC)=.0004$
 Wilcoxon rank sum test has $p=.0003$.
 35 Best single kallikrein marker
- hK11: high values associated with cancer
 test+ is $hK11 > 0.14$, test- is $hK11 \leq 0.14$
 40 sensitivity=54%, specificity=54%,
 AUC=.58, $p(AUC)=.12$
 Wilcoxon rank sum test has $p=.11$.
 Not a good marker
- CA125: high values associated with cancer
 45 test+ is $Ca125 > 34$, test- is $Ca125 \leq 34$
 sensitivity=89%, specificity=94%,
 AUC=.933, $p(AUC) < .0001$
 Wilcoxon rank sum test has $p < .0001$.
 Good marker
- 50 After some further multivariate analysis of only the kallikrein markers, the combination of hK 7, 8, 10 and 11 was a preferred set. This combination was arrived at by looking at the incremental AUC as markers were combined. Below is a summary of all the models tried:
- 55 hK10 alone, AUC=.68
 hK10+hK7: AUC=.88

- 35 -

hK10+hK7+hK8: AUC=.90
 hK10+hK7+hK8+hK11: AUC=.925
 Multivariate model of hK7, hK8, hK10, hK11, call it hK7_8_10_11

- 5 hK7_8_10_11:
 Calculate $SA = 2.00 - 1.49(hK7) - .34(hK8) + 1.16(hK10) + 3.50(hK11)$
 high values associated with cancer
 test+ is $SA > -1.15$, test- is $SA \leq -1.15$
 sensitivity=87%, specificity=89%,
 10 AUC=.93, $p(AUC) < .0001$
 Wilcoxon rank sum test has $p < .0001$.
 Good marker

The hK marker that added the most to CA125 was also investigated.

- 15 CA125 alone, AUC=.933
 CA125+hK8: AUC=.978
 Multivariate model of Ca125, hK8, call it Ca125_hK8

- 20 Ca125_hK8:
 $SC = -1.71 + .086(Ca125) - .47(hK8)$
 high values associated with cancer
 test+ is $SC > -2.52$, test- is $SC \leq -2.52$
 sensitivity=97%, specificity=90%,
 AUC=.978, $p(AUC) < .0001$
 25 Wilcoxon rank sum test has $p < .0001$.
 Good marker

Below is a summary of the above analyses:

- a) The preferred kallikrien marker alone is hK10, AUC=.68
 30 b) CA125 has an AUC of .933
 c) The preferred combination of kallikrein markers increases the AUC up to .925, which is close to the CA125 AUC of .933
 d) Adding a kallikrein marker to CA125 can increase the AUC up to .978
 35 How does CA125 alone compare with the multivariate kallikrein model hK7_8_10_11?
 (based on 39 cases and 186 controls evaluated with CA125)

	Sensitivity	Specificity	misclassification
40 CA125	90%	94%	12FP, 4FN, total 16 pts misclassified
hK7_8_10_11	85%	89%	31FP, 4FN, total 35 pts misclassified
both positive	77%	100%	0FP, 9FN, total 9 pts misclassified
either positive	97%	82%	33FP, 1FN, total 34 pts misclassified

How does CA125 alone compare with the multivariate model of CA125 plus hK8?

- 45 (based on 39 cases and 186 controls evaluated with CA125)
- | | Sensitivity | Specificity | misclassification |
|-----------|-------------|-------------|---------------------------------------|
| CA125 | 90% | 94% | 12FP, 4FN, total 16 pts misclassified |
| CA125_hK8 | 95% | 91% | 17FP, 2FN, total 19 pts misclassified |

Kallikrein markers approach CA125 in terms of AUC and sensitivity, but their specificity is not as high. Adding hK8 to CA125 improves sensitivity but specificity is lower than CA125 alone.

Summary

- 5 a) The best kallikrein marker alone is hK10, area under the ROC curve (AUC) = .68.
- b) CA125 has an AUC of .933. Adding a single kallikrein marker to CA125 can get the AUC up to .978. Adding hK8 to CA125 improves sensitivity but specificity is lower compared with CA125 alone.
- 10 c) The best combination of kallikrein markers gets the AUC up to .925, which is close to the CA125 AUC of .933. Kallikrein markers approach CA125 in terms of AUC and sensitivity, but their specificity is lower.

15 The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

20 All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the domains, cell lines, vectors, methodologies etc. which are reported therein

25 which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

 It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more

30 antibodies and equivalents thereof known to those skilled in the art, and so forth.

 Below full citations are set out for the references referred to in the specification.

Table 1

Kallikrein Polypeptide	Kallikrein Nucleic Acid Designation	GenBank Accession No.
Kallikrein 5	KLK5	AAD26429, AF135028, AF168768
Kallikrein 6	KLK6	AAB66483, AF013988 (CDS 174..881), AF149289 (CDS join 3567..3606, 4346..4502, 8122..8369, 9791..9927, 11805..11957) U62801 (CDS 246..980)
Kallikrein 7	KLK7	AAC37551, L33404 (CDS 16..777), AF166330 (CDS join 3237..3309, 3722..3869, 4566..4813, 5129..5265, 7362..7517) (mRNA join(1756..1785, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..8265) /product="stratum corneum chymotryptic enzyme" /note="alternatively spliced" ; mRNA join (1756..1785, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..7991) /note="alternatively spliced"; mRNA join (1821..1864, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..8265) /product="stratum corneum chymotryptic enzyme" /note="alternatively spliced"; mRNA join (1821..1864, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..7991) /note="alternatively spliced"
Kallikrein 8	KLK8	BAA28673, AB009849 (CDS 35..817), AF095743 (CDS join 1035..1104, 1619..1778, 1944..2206, 4304..4437, 5974..6129, mRNA 500..670, 1027..1104, 1619..1778, 1944..2206, 4304..4437, 5974..6174), AB010780 (CDS join 1..39, 418..712, 878..>946), AF055982
Kallikrein 10	KLK10	AAC14266, AF055481 (CDS join 614..701, 2455..2635, 3589..3863, 4195..4328, 4793..4945, mRNA join 48..120, 605..701, 2455..2635, 3589..3863, 4195..4328, 4793..5474), NM_002776 (CDS 220..1050)
Kallikrein 11	KLK11	BAA33404, AAD47815, AB012917 (CDS 26..874), AF164623 (CDS 4224..4263, 5061..5217, 5545..5810, 6627..6763, 7158..7310) (mRNA join (2313..2398, 4189..4263, 5061..5217, 5545..5810, 6627..6763, 7158..7622)

- 38 -

Table 2

Descriptive statistics for hk5, hk6, hk7, hk8, hk10 and hk11 serum protein levels in controls and patients with ovarian cancer

	Mean	Standard Error	Median	Range	p value*
<u>hk5 (ng/ml)</u>					
Non cancer (N=194)	0.063	0.029	0.00	0.00-4.50	
Cancer (N=39)	0.48	0.18	0.00	0.00-5.70	
% Increase**	661%	--	--	--	<0.001
<u>hk6(ng/ml)</u>					
Non cancer (N=194)	6.96	0.18	6.60	1.60-15.30	
Cancer (N=39)	9.88	2.20	6.60	1.50-70.80	
% Increase**	42%	--	--	--	0.91
<u>hk7(ng/ml)</u>					
Non cancer (N=194)	2.60	0.071	2.67	0.30-6.00	
Cancer (N=39)	2.49	0.41	1.80	0.00-10.80	
% Decrease**	4%	--	33%	--	0.007
<u>hk8(ng/ml)</u>					
Non cancer (N=194)	11.74	0.27	11.70	2.40-22.20	
Cancer (N=39)	11.91	1.88	6.90	0.00-46.20	
% Decrease**	--	--	41%	--	0.005
<u>hk10(ng/ml)</u>					
Non cancer (N=194)	1.16	0.051	1.08	0.00-4.20	
Cancer (N=39)	6.51	2.46	1.59	0.27-90.0	
% Increase**	461%	--	40%	--	<0.001
<u>hk11(ng/ml)</u>					
Non cancer (N=194)	0.21	0.018	0.12	00-1.30	
Cancer (N=39)	0.79	0.21	0.18	0.00-5.52	
% Increase**	276%	--	50%		0.011

* Calculated by the Mann Whitney test

** Calculated by assuming that value in non-cancerous tissue is 100%

Table 3
Correlations between the studied variables in 194 non-cancer cases

variable		hK5	hK6	hK7	hK8	hK10	hK11	CA125
hK5	r_s	1.000	0.034	-0.053	0.066	0.134	0.150	0.101
	p		0.642	0.462	0.359	0.062	0.037	0.172
hK6	r_s	0.034	1.000	0.114	0.298	0.191	0.120	-0.160
	p	0.642		0.115	0.000	0.008	0.097	0.029
hK7	r_s	-0.053	0.114	1.000	0.497	0.321	0.399	0.135
	p	0.462	0.115		0.000	0.000	0.000	0.066
hK8	r_s	0.066	0.298	0.497	1.000	0.263	0.396	0.048
	p	0.359	0.000	0.000		0.000	0.000	0.519
hK10	r_s	0.134	0.191	0.321	0.263	1.000	0.176	0.035
	p	0.062	0.008	0.000	0.000		0.014	0.638
hK11	r_s	0.150	0.120	0.399	0.396	0.176	1.000	0.125
	p	0.037	0.097	0.000	0.000	0.014		0.090
CA125	r_s	0.101	-0.160	0.135	0.048	0.035	0.125	1.000
	p	0.172	0.029	0.066	0.519	0.638	0.090	

Table 4
Correlations between the studied variables in 39 ovarian cancer cases

variable		hK5	hK6	hK7	hK8	hK10	hK11	CA125
hK5	r_s	1.000	0.475	0.553	0.554	0.618	0.584	0.507
	p		0.002	0.000	0.000	0.000	0.000	0.001
hK6	r_s	0.475	1.000	0.327	0.513	0.470	0.661	0.530
	p	0.002		0.042	0.001	0.003	0.000	0.001
hK7	r_s	0.553	0.327	1.000	0.695	0.690	0.748	0.262
	p	0.000	0.042		0.000	0.000	0.000	0.107
hK8	r_s	0.554	0.513	0.695	1.000	0.602	0.783	0.443
	p	0.000	0.001	0.000		0.000	0.000	0.005
hK10	r_s	0.618	0.470	0.690	0.602	1.000	0.706	0.548
	p	0.000	0.003	0.000	0.000		0.000	0.000
hK11	r_s	0.584	0.661	0.748	0.783	0.706	1.000	0.556
	p	0.000	0.000	0.000	0.000	0.000		0.000
CA125	r_s	0.507	0.530	0.262	0.443	0.548	0.556	1.000
	p	0.001	0.001	0.107	0.005	0.000	0.000	

Table 5

	CANCER				CONTROL				sd		min	max	Wilcoxon		p(logistic)		AUC (se)		CUTPOINT	SENSITIVITY	SPECIFICITY
	n	mean	median	sd	n	mean	median	sd	n	mean	min	max	p(mean)	p(median)							
HK5	39	0.48	0.00	1.14	0.00	184	0.06	0.00	0.40	0.00	0.00	4.50	0.03	<0.001	0.005	0.62 (0.05)	0.0200	>0.10	31%	95% HK5	
HK6	39	9.89	0.60	13.77	1.50	184	5.97	0.60	2.60	1.60	0.00	15.30	0.20	0.0000	0.0570	0.50 (0.05)	1.0000	>6.30	69%	40% HK6	
HK7	39	2.49	1.80	2.54	1.00	184	2.60	2.87	0.99	0.30	0.00	8.00	0.78	0.0070	0.6500	0.84 (0.05)	0.0060	<2.05	62%	71% HK7	
HK8	39	11.91	0.90	11.80	0.00	184	11.74	11.70	3.80	2.40	22.20	0.83	0.03	0.0050	0.8700	0.84 (0.05)	0.0060	<13.0	72%	42% HK8	
HK10	39	6.52	1.59	15.40	0.27	184	1.17	1.08	0.72	0.00	4.30	0.04	0.0003	0.0002	0.68 (0.05)	0.0004	>1.42	62%	70% HK10		
HK11	39	0.60	0.18	1.36	0.00	184	0.21	0.12	0.26	0.00	1.30	0.01	0.1100	0.0008	0.58 (0.05)	0.1200	>0.14	54%	54% HK11		
CA125	39	649	277	971	20	494	24	21	9	0	84	0.00	<0.001	<0.001	0.933 (0.026)	<0.001	>34	80%	94% CA125		
HK7 & 10 11	39	4.51	0.50	15.8	184	-3.84	-3.68	2.07	-10.05	1.07	0.00	1.07	0.002	<0.001	<0.001	0.925 (0.030)	<0.001	>-1.32	85%	60% HK7 & 10 11	
CA125 HK8	39	48.64	15.02	82.86	186	-5.07	-4.92	1.91	-2.49	0.90	0.00	0.90	0.002	<0.001	<0.001	0.976 (0.017)	<0.001	>-2.52	97%	90% CA125 HK8	

We Claim:

1. A method for detecting a plurality of kallikrein markers associated with ovarian cancer in a patient comprising:
 - 5 (a) obtaining a sample from a patient;
 - (b) detecting in the sample a plurality of kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
 - (c) comparing the detected amounts with amounts detected for a standard.
- 10 2. A method for diagnosing and monitoring ovarian cancer in a subject comprising detecting in a sample from the subject a plurality of kallikrein markers, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein.
3. A method as claimed in claim 1 or 2 wherein the plurality of kallikrein markers are detected using
 - 15 antibodies that bind to each of the plurality of kallikrein markers or parts thereof
4. A method as claimed in claim 1, 2, 3 which further comprises detecting CA125.
5. A method of detecting ovarian cancer in a patient, the method comprising comparing:
 - (a) levels of a plurality of kallikrein markers, and optionally CA125, in a sample from the
 - 20 patient, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
 - (b) normal levels of expression of the plurality of kallikrein markers, and optionally CA125, in a control sample, wherein a significant difference in levels of kallikrein markers and optionally CA125, relative to the corresponding normal levels, is indicative of ovarian cancer.
- 25 6. A method for monitoring the progression of ovarian cancer in a patient, the method comprising: (a) detecting in a sample from the patient at a first time point, a plurality of kallikrein markers, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the
 - 30 progression of ovarian cancer.
7. A method for determining in a patient whether ovarian cancer has metastasized or is likely to metastasize in the future, the method comprising comparing (a) levels of a plurality of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein
 - 35 10, and kallikrein 11; and (b) normal levels or non-metastatic levels of the kallikrein markers and optionally CA125, in a control sample wherein a significant difference between the levels of expression in the patient sample and the normal levels or non-metastatic levels is an indication that the ovarian cancer has metastasized.
8. A method for assessing the aggressiveness or indolence of ovarian cancer comprising comparing:

- (a) levels of expression of a plurality of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (b) normal levels of expression of the plurality of markers and optionally CA125, in a control sample, wherein a significant difference between the levels in the patient sample and normal levels is an indication that the cancer is aggressive or indolent.
- 5
9. A method for diagnosing and monitoring ovarian cancer in a sample from a subject comprising isolating nucleic acids from the sample; and detecting in the sample polynucleotides encoding a plurality of kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.
- 10
10. A method as claimed in claim 9 wherein significant differences in the levels of the polynucleotides in the sample compared to a control is indicative of disease, disease stage, and/or prognosis.
11. A method for determining the presence or absence of ovarian cancer in a subject comprising: (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (b) detecting in the sample a level of nucleic acids in the sample that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of ovarian cancer in the subject.
- 15
- 20
12. A method as claimed in claim 11, wherein the nucleic acids are mRNA and the levels of nucleic acids are detected by polymerase chain reaction.
13. A method as claimed in claim 11 wherein the nucleic acids are mRNA and the amounts of mRNA are detected using a hybridization technique, employing oligonucleotide probes that hybridize to kallikrein markers, and optionally CA125.
- 25
14. A method for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, the method comprising comparing: (a) levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a first sample obtained from a patient and exposed to the test agent, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and (b) levels of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting ovarian cancer in the patient.
- 30
- 35
15. A method of claim 14 wherein the first and second samples are portions of a single sample obtained from the patient.
16. A method of claim 14 wherein the first and second samples are portions of pooled samples obtained

- 44 -


from the patient.

17. A method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient, the method comprising comparing: (a) levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a first sample obtained from the patient, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a second sample obtained from the patient following therapy, wherein a significant difference in the levels of expression of the kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.
18. A method of selecting an agent for inhibiting ovarian cancer in a patient the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately exposing aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (d) selecting one of the test agents which alters the levels of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot containing that test agent, relative to other test agents.
19. A method of inhibiting ovarian cancer in a patient, the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (d) administering to the patient at least one of the test agents which alters the levels of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot containing that test agent, relative to other test agents.
20. A method of assessing the ovarian cell carcinogenic potential of a test compound, the method comprising: (a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and (b) comparing expression of a plurality of markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and wherein a significant difference in levels of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot maintained in the presence of the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses ovarian cell carcinogenic potential.
21. A method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer, the method comprising inhibiting expression of genes encoding kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5,

- kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.
22. A method of any preceding claim wherein the plurality comprises at least three of the markers.
23. A method of any preceding claim wherein the plurality comprises at least five of the markers.
24. A method of any preceding claim wherein the plurality of kallikrein markers is selected from the group consisting of kallikrein 5, kallikrein 7, and kallikrein 8; kallikrein 5, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; kallikrein 5, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.
- 10 25. A method of any proceeding claims wherein the kallikrein markers are kallikrein 7, kallikrein 8, kallikrein 10 and kallirkein 11.
26. A method of any preceding claim wherein the patient sample comprises serum obtained from the patient.
27. A kit for carrying out a method as claimed in any preceding claim.
- 15 28. A kit for assessing whether a patient is afflicted with ovarian cancer, the kit comprising reagents that specifically bind with a plurality of kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.
- 20 29. A kit for assessing the suitability of each of a plurality of agents for inhibiting ovarian cancer in a patient, the kit comprising: (a) the plurality of agents; and (b) reagents for detecting a plurality of kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.
- 25 30. A kit as claimed in claim 28 or 29 wherein the reagents are antibodies that specifically bind with protein or protein fragments corresponding to kallikrein markers and optionally CA125.


1/8

Figure 1




2/8

Figure 2




3/8

Figure 3




4/8

Figure 4




5/8

Figure 5




6/8

Figure 6




7/8

Figure 7



8/8

Figure 8



Sequence Listing

SEQ ID NO. 1

CA125 amino acid

```

5      1 mlkpsglpgs ssptrsmltg srstkatpem dsrgltgatls pktstgaivv tehtlpftsp
      61 dktlasptss vvgrrttqslg vmssalpest srgmthseqr tpslspqvn gtpsrmypat
      121 smvsglsspr trtsstegnfn tkeastytlv vettsgpvte kytvptetst tegdstetpw
      181 dtryipvkit spmktfadst askenapvsm tpaettvtds httpgrtnpsf gtlyssfldl
      241 spkgtpnsrg etslelilst tgyffsssep gsaghsrist saplssasv ldnkisetsi
10     301 fsgqsltspl spgvpearas tmpnsaifps mtlснаetса ervrstissl gtpsistkqt
      361 aetiltfhaf aetmdipsth iaktlasewl gspgtlggts tsalttttsp tllvseentn
      421 hhstsgkete gtlntsmtpl etsapgeese mtatlvpitlg fttldskirs psqvssshpt
      481 relrttgsts grqssstaah gssdilratt sstskasswt sestagqfse pqhtqwvets
      541 psmkterppa stsvaapitt svpsvsgfft tlktsstkgi wleetsadtl igestagptt
15     601 hqfavptgis mtggsestrgs qgthllltra tassetsadl tlatngvpvs vspavsktaa
      661 gsspppgtkp sytmvssvip etsalqssaf regtslgltp lntrhpfsep epdsaghtki
      721 stsiplllsa svledkvsat stfshhkats sittgtpeis tktkpssavl ssmtlснаat
      781 spervrnats plthpspsge etagsvltls tsaettdspn ihptgtltse ssesptlsl
      841 psavgvkttf sstspsthlf tsgeeteets npsvsgpets vsrvrttlas tsvptpvfpt
20     901 mdtwptrsaq fssshlvsel ratsstsvtn stgsalpkis hltgtatmsq tnrdtfndsa
      961 apgattwpet sprfktglps atttvstsat slsatvmvsk ftspatssme atsirepstt
      1021 ilttettngp gsmavastni pigkgyiteg rldtshlpig ttassetsmd ftmakesvsm
      1081 svpsqsmda agsstpgrts qfvdtsfddv yhltsreiti prdgtssalt pgmtathpps
      1141 pdpgsarstw lgilsspsps ptpkvtmest fstqrvttsm imdtvetsrw nmpnlpstts
25     1201 ltpsniptsg aigkstlvpl dtpspatsle aseggltpls typestntps ihlgahasae
      1261 spstikltma svvkpgsytp ltfpsieith hvstarmays sgsspemtap getntgstwd
      1321 pttiyitttdp kdtssaqvst phsvrtlrtt enhpktesat paaysgspki sspnltspa
      1381 tkawtitdtt ehstqlhytk laekssgfet qsapgpvsav iptseptigss tleltsdvpg
      1441 eplvlapseq ttitlpmatw lstslteema stldldssps spmatfaifp pmstphels
30     1501 kseadtair ntdsttldqh lgirslgrtg dlrtvptipl tttwtsvieh stqagdtlsa
      1561 tmsphtvtqs lkdqtsipas aspslhlevy pelgtqgrss seattfwkrs tdtlsreiet
      1621 gptniqstpp mdntttgsss sgvtlgiahl pigtsspaet stnmalerrs statvsmagt
      1681 mglvtsapq rsisqslgrv ssvlseste gvtsskgs prlntqgnta lsslepsy
      1741 egsgmstsis ltasspttdv efiggstfwt kevttvmtsd iskssartes ssatlmstal
35     1801 gstentgkek lrtasmdlps ptpsmevtpw isltlsnapi ttdsldshg vhtssagtl
      1861 tdrslntgvt rasrlengsd tsakslsmgn sthtsmtdte ksevsstsih rpetvsggae
      1921 tltstpgnr aistltpfss ipveevistg itsgpdinsa pmthspitpp tivwtstgti
      1981 eqstqplhav ssekvsvtq stpyvnsav saspthensv ssgstsspy ssaslealde
      2041 tisrrnais wldtltelpl tttwpstsls ealsghsgv snpssttfe plfsaasta
40     2101 akqrnpetet hgpqntaast lntdassvtg lsetpvgsi ssevpplmai tarsdvsglt
      2161 sestansplg tassagtklt rtislptses lvsfrmkdp wtvsiplgsh pttntetsip
      2221 vnsagpppls tvasdvidtp sdgaesiptv sfspdpdev ttishfpekt thsfrtissl
      2281 theltsrvtp ipgdwmssam stkptgasp itlgeritit saapttspiv ltasftetst
      2341 vsldnettvk tsdildark nelpsdssss sdintssias stmdvktas isptsisgmt
45     2401 assepslfs drpqvptst etntatpsv ssntysldgg snvggtptl ppftithpve
      2461 tssallawr pvrtfstmv tdtasgenpt ssnsvtsvp apgtwasvgs ttdlpamgfl
      2521 ktspageahs llastiepat aftphlsaav vtgssatsea slttsseska ihsapgtptt
      2581 ptsganwets atpesllvvt etsdtltlsk ilvtdtilfs tvstppskfp stgtlagasf
      2641 ptllpdtpai pltateptss latsfdstpl vtiasdslgt vpettltmse tengdalvfk
50     2701 tvsnpdrip gitigvtes plhpsstsp kivaprntty egsitvalst lpagttgslv
      2761 fsqssenset talvdssagl erasvmltt gsqgmassgg irsgsthtg tktfsslplt
      2821 mnpgevtams eitnrltat qstapkgipv kptsaesgll tpvssasps kafaslttap
      2881 pstwgipqst ltfevseps ldtksaslpt pgqslntipd sdastassel skspeknpra
      2941 xmtstskais assfsgtft etpegsasps magheprvpt sgtgdpryas eemsypdpak
55     3001 assamtstsl asklttlfst gqaarsgss spislsteke tsflseptast srktsiflpg
      3061 smarqpnilv hlqtsaltls ptstlnmsqe eppeltssqt iaeeegtae tqtlfttpe
      3121 tptslpvss pteptarrks spetwassiv vpaktslvet tdtglvttik mssqaaggs
      3181 twpapaeetg tspagtepps pevsttlkim sskepsispe irstvrnspw ktpettvpme
      3241 ttvepvtlqs talgsgtsi shlptgttsp tksptenmla tervslspsp pawtnlysg

```


	3301	tpggtrqsla	tmssvslesp	tarsitgtgq	qsspelvskt	tgmefsmwhg	stgggttgdh
	3361	vsletssnil	edpvtspnsv	ssltckskhk	tetwvsttai	psvlnnkim	aaeqqtsrsv
	3421	deaysstssw	sdqtsgsdit	lgaspdvnt	lyitstaqt	slvslpsgdq	gitsltnpsg
	3481	gktsasssvt	speigletlr	anvsavksdi	aptaghsqt	sspaevsild	vttaptpgis
5	3541	ttittmgtns	istttpnpev	gmstmdstpa	terrttsteh	pstwsstaas	dswtvtmdts
	3601	nlkvarspgt	istmhttsfl	assteldsms	tphgritvig	tslvtpssda	savktetsts
	3661	ertlpsdtt	astpistfsr	vqrmsisvpd	ilstswtpss	teaedvpvsm	vstdhaastkt
	3721	dpntplstfl	fdslstldwd	tgrslssata	ttsapqgatt	pgeltletmi	spatsqlpfs
	3781	ighitsavtp	aamarssgv	fserpdtskk	aeqtstqlpt	ttsahpggv	rsaattldvi
10	3841	phtaktptat	fqrqggtalt	tearatsdsw	nekekstpsa	pwitemmns	sedtikevts
	3901	sssvlkdpay	aghklgiwdd	fipkfgkaah	mrelpllspp	qdkeaihpst	ntvettgwvt
	3961	ssehashsti	pahsasklt	spvvtststre	qaivsmsttt	wpestrarte	pnsfltielr
	4021	dvspymdts	ttqtsiissp	gstaitkgpr	teitsskris	ssflaqsmrs	sdpseaitr
	4081	lsnfampes	ggmilamqts	ppgatslsap	tldtsatasw	tgtplattqr	ftysekttlf
15	4141	skgpedtsqp	sppsveetss	ssslvpihat	tspsnillts	qghspsstpp	vtsvflsets
	4201	glgkttmdmr	islepgtslp	pnlsstagea	lstyeasrdt	kaihhsadta	vtmneatsse
	4261	yspipgthkp	skatsplvts	himgditsst	svfgssette	ietvssvngg	lqerstsqva
	4321	ssatetstvi	thvssgdatt	hvtktqatfs	sgtsissphq	fitstntftd	vstnpstali
	4381	mtessgvtit	tqgtgtgaat	qgpylldtst	mpyltetpla	vtpdfmqsek	ttliskgpkd
20	4441	vtwtspssva	etsypsltp	flvttippat	stlqgqhtss	pvsatsvlts	glvkttdmln
	4501	tsmepvtmsp	qnlmnpnei	latlaattdd	etihpsinka	vtmngtassa	hvlhstlpvs
	4561	sepstatspm	vpasmgdal	asisipgset	tdiegeptss	ltagrkenat	lqemnsttes
	4621	niilsnsvsg	aiteatkmev	psfdatfipt	paqstkfpdi	fsvassrlsn	spmtisthm
	4681	tttqtgssga	tskiplaldt	stletsagtp	svvtgefahs	kittamndv	kdvsgttnppf
25	4741	qdeasspsag	apvlvtllps	svaftpqwhs	tsppvsmssv	ltsslvktag	kvdtsletvt
	4801	sspqmsntli	ddisvtsaat	tdietthpsi	ntvvtnvggt	gsafeshstv	saypepskvt
	4861	spnvtsttme	dttsirsipk	skttrtete	ttssltpklr	etsisqeits	stetstvyk
	4921	eltgattevs	rtadvtsst	sfpqpdqstv	sldistetnt	rlstspimte	saeitittqt
	4981	gphgatsqdt	ftmdpsnttp	qagihsamth	gfsqldvttl	msripqdvsw	tpppsvdkts
30	5041	spssflsapa	mttspilis	lpedklsspm	tslltsglvk	itdlrlrle	pvtsslpnfs
	5101	stsdkilats	kdsdkdkeif	psinteetnv	kannsgghesh	spaladsetp	kattqmvitt
	5161	tvqdpapsts	mpvhgssett	nikreptyfl	tprlretsts	qessfptdts	fllskvptgt
	5221	itevsstgvn	ssskistpdh	dkstvpdtdf	tgeiprvfts	siktksaemt	ittqasppes
	5281	ashstlpldt	sttllsqggt	stvtqgfpys	evttlmgmpp	gnvswmttpp	veetssvss
35	5341	msspamtaps	pvasstspqi	psplpvtal	ptsvlvttd	vlgttspeav	tsppnlssi
	5401	therpatyk	tahteaaamh	stntavtnvg	tsqsgghksqs	svladsetsk	atplmstst
	5461	lgdtsvstst	pnlsqtnqiq	teptaslspr	lresstsekt	ssttetntaf	syptgaitq
	5521	asrteisser	tsisdldrpt	iapdistgmi	trlftspimt	ksaemtvtq	tttpgatagg
	5581	ilpwtsttl	fqqgthstvs	qgfhphseitt	lrsrtpgdvs	wmttppveet	ssgflmsps
40	5641	mtspspvst	spesipsapl	pvtalltsvl	vttnvlgtt	spetvtspp	nlsaptqerl
	5701	tttkdtahte	amhasmhtnt	avanvgtsis	ghesqssvpa	dshtskatsp	mgitfamgdt
	5761	svststpaff	etriqtstst	slipglrdtr	tseeintvte	tsvlsevp	tttlevsrte
	5821	vtssrttis	gpdhskmspy	istetitrls	tfpfvtgste	maitnqtgpi	gtisqatl
	5881	dtssstasweg	thspvtgrfp	hseetttsmr	stkgvswqsp	psveetssps	spvplpait
45	5941	hsslysavsg	ssptsalpvt	sltsgrrrkt	idmldthsel	vtsslpssas	fsgelstsea
	6001	stntetihfs	entaetnmgt	tnsmhklhss	vsihsqpsgh	tppkvtgsmm	edaivststp
	6061	gspektknvdr	dstspltpel	kedstaltvm	sttesntvfs	svsldaatev	sraevtyydp
	6121	tfmpasaqst	kspdispeas	sshnsapplt	isthktiatq	tgpsgvtslg	qltldtstia
	6181	tsagtpstart	qdfvdsetts	vmndldndvl	ktspfsaeaa	nsllsqapll	vttapsvpts
50	6241	tlqehstss	svtstvppt	lakitdmtdn	lepvtrspqn	lrntlatsea	tttdthmpps
	6301	intamanvgt	tsppnefyft	vspdsdpyka	tsavvitsts	gdsivstsm	rssamkkies
	6361	ettflslifrl	retstsqkig	sssdstsvfd	kaftaattev	serteltssr	tslqgtekpt
	6421	mtpdtstsv	tmlstfaglt	kseertiatq	tgphratsqg	tltdwtstitt	sqagthsam
	6481	hgfsqldlsl	ltsrvpeyis	gtsppsvekt	ssssllslp	aitspspvpt	tlpesrpsp
55	6541	vhltslptsg	lvkttdmlas	vaslppnlgs	tshkipttse	dikdtekmy	stniavtnvg
	6601	tttsekesys	svpayseppk	vtspmvtsfn	irdtivistm	pgsseitrie	mestfsvahg
	6661	lkgststsqdp	ivsteksavl	hklttgatet	srtevassrr	tsipgpdhat	espdistevi
	6721	pslpislgit	essnmitti	tgpplgstsq	gtftldtptt	ssragthsm	tqefphsemt
	6781	tvnmkdpeil	swtippsiek	tsfssslmps	pamtsppvss	tlpktihttp	spmtalltps
60	6841	lvmttdtlgt	spepttsspp	nlststshvil	ttddedtaie	amhpststaa	tnvettcsgh
	6901	gsqssvltlds	ektkatapmd	ttstmghtt	stsmssvset	tkikrestys	ltplrltsi

5 6961 sqnasfsttd sivilsevpptg ttaevsrtev tssgrtaipg psqstvlpei strtmtrlfa
 7021 sptmtesaem tiptqtgpgs stsqdtltld tttktsqakt hstltqrfph semttlmarg
 7081 pgdmswqssp slenpsslps llslpattsp ppisstlpvt isssplpvts lltsspvttt
 7141 dmlhtspelv tassppklsht sderlittgkd ttnteavhps tntaasnvei psfghespps
 7201 aladsetska tšpmfitstq edttvaistp hfletsriqk esisslsplk retgssvets
 7261 saietsavls evsigattei srtevtsssr tsisgsaest mlpeisttrk ikkfptapil
 7321 aessemtikt qtsppgstse stfldtstt pslvithstm tqrlphseit tlvsrgagdv
 7381 prpsslpvee tšppssqlsl samispspvs stlpasshss sasvtspltp gqvkttevl
 7441 asaepetssp pslsstsvei latsevttdt ekihpfpnta vtkvgtsessg hespsavlpd
 10 7501 settkatsam gtisimgdts vstltplasn trkigsepas slttrlrts tseetslate
 7561 antvlskvst gattevsrte aisfsrtsms gpegstmsqd isigtipris assvltesak
 7621 mtittqtgpps estlestlnl ntattpswve thsiviqgfp hpemttmgr gpvgvswpsp
 7681 pfvketspps splslpavts phpvsttfla hippslpvt sltsgpatt tdilgtstep
 7741 gtsassslst tsherlittk dtahteavhp stntggtnva tssgyksqs svladsspmc
 15 7801 ttstmgdtsv ltstpaflet rriqtelass ltpglressg segtssgktn stvlskvptg
 7861 atteiskedv tsippagast ispdistrtv swfstspvmt esaeitmntg tsplgattqg
 7921 tstlatsett sltmthstis qgfshsqmet lmrrgpedvs wmspllekt rpsfslmssp
 7981 attspspvss tlpesissss lpvtsalltg lakttdmlhk ssepvtspna nlsstsvail
 8041 atsevttdte kthpsnrtv tdvgtsssg estsfvlads qtskvtspmv itstmedtsv
 20 8101 ststpgffet sriqteptss ltlglrktss segtslatem stvlsgvptg ataevsrtev
 8161 tsssrtsisg faqltvspet stetitrlpt ssimtesaem miktqtdppg stpesthtvd
 8221 isttpnwvet hstvtqrfsh semttlvrs pgdmlwpsqs sveetssass llslpattsp
 8281 spvstlved fpsaslpvts lltpglvitt drmgisrepg tsstsnlss sherlttled
 8341 tvdtedmqps thtavnrtv sigshesqss vlsdsetpka tšpmgttyt getsvssis
 25 8401 dffetsriqi eptssltsgl retsseris sategstvl evpsgattev srtevisrg
 8461 tsmgpdqft ispdisteai trlstspimt esaesaitie tšpggatseg tltldtstt
 8521 fwsgthstas pgfshsemmt lmsrtpgdvp wpslpvveea ssvssslsp amtstssffa
 8581 lpesissph pvtalltlgp vkttdmlrts sepetsppn lsssaaila tsevtkdrek
 8641 ihpsantpvr nvgtvlykhl spssvldlv tktptspmat tstlgtsvs tšpafpemt
 30 8701 mtqptssls glreistsge tssatersas lsgmptgatt kvsrtealsl grtstpgpaq
 8761 stispeiste titristplt ttgsaemtit pktghagass qgtftldtss raswpgthsa
 8821 athrsphsgm ttpmsrgped vswpssrpsve ktsppsslv lsavtsspsl ystpsesshs
 8881 splrvtslft pvmmkttdml dtselepvtss ppsmmtssde slatskatne teaiqlsent
 8941 avtqmgtsa rgefysypg lpepskvts vvtssstikdi vsttipasse itriemests
 35 9001 tltptprets tsqeihsatk pstvpykalt satiedsmtd vmsssrpsp dqtmsqdis
 9061 sevitrlsts pikaestemt ittqtgspga tsrgtltldt sttfmsgths tasqgfshsq
 9121 mtalmsrtpp dvpwlsghpsv eeassasfsl aspvmtsssp vssltpldsih ssalplstll
 9181 tsglvkttel lgtsssepets sppnlsssa eilattevtt dteklemtv vtsgythesp
 9241 ssvladsvtt katssmgity ptgdnvlt tšpafsdtsri qtskkslsltp glmetsisee
 40 9301 tssatekstv lssvptgatt evsrteaiss srtsipgpaq stmsstdtss titristplt
 9361 rkestdmait pktgpgats qgtftldess taswpgthsa ttqrfpqsvv ttpmsrgped
 9421 vswpsslave knsppsslv sssvtspspl ystpsgsshs spvpvtslft slmmkatdml
 9481 daslepetts apnmmtssde slatskatte teaihvfent aashvettsa teelyssspg
 9541 fseptkviss vvtssssirdn mvsttmgss gitrieiesm sstlpglret rtsqdisst
 45 9601 etstvlykms sgatpevsrt evmpssrtsi ppgaqstmsl disdevvtrl stspimtesa
 9661 eititttqgy slatsqvltl lgtssmtflg thstmsqgls hsemtnlmar gpeslwtsp
 9721 rfvettrss sltslpltt lpsvstlld sspsslpvt slilpglvkt tevltdassep
 9781 ktsspnls tsveipats imtdtekihp ssntavakvr tsssvheshs svladsetti
 9841 tipsmgitsa vddtvttsn pafsettript teptfsltp fretstseet tsitetsavl
 50 9901 ygvptsatte vsmteimssn rthipdsdgs tmspditev itrssssmm sestqmtitt
 9961 qksspgataq stltlattta plarthstvp prflhsemt lmsrpenps wksspfvekt
 10021 sssssllslp vttspssst lpqsspsf svtslltpgm vkttdtstep gtslspnlsg
 10081 tsveilaase vttdekihp sssmavtnvg tssghelys svaihsepsk atypvgtpss
 10141 maetsistem panfettgfe aepfshltg frktnmsldt ssvtptntps spgsthlgs
 55 10201 sktdftssak tšpdpwps qyteipvdii tšfnaspsit estgitsfpe srtfmsvtes
 10261 thhlstdllp saetistgtv mpssseamts fattgvprai sgsgspfsrt espggdats
 10321 tiaeslpst pvpfssstft ttdsstipal heitsssatp yrvdtslgt ssttegrlvm
 10381 vstldtssqp grtsstpld trmtesvelg tvtsayqvps lstrlrltdg imehickipn
 10441 eaahrgttr vkpggtstsp aspkglltgg tkrmetttta lkttttalt tsratltsv
 60 10501 ytpitlgtltp lnasrqmast iltemmittp yvfpdvpett sslatslgae tatalprtt
 10561 svlnresett aslvrsrgae ršpviqtlv sssepdtas wvhpaeitp tvskttpnff

10621 hseltdvssst atshgadvs aiptnispse ldaltplvti sgttdtsttfp tltskphete
 10681 trttwlthpa etsstiprti pnfshhesda tpsiatspga etssaipimt vspgaedlvt
 10741 sqvtssgtdr nmtiptltls pgepktiasl vthpeagtss aiptstispa vsrlvtsmvt
 10801 slaaktsttn raltnspegp attvslvthp agtsptvpwt tsiffhkskd ttpsmtshg
 5 10861 aesssavptp tvstevpgvv tplvtssrav isttipiltl spgepettps matshgeaas
 10921 saiptptvop gvpvvtslv tssravtatt ipiltfslge pettpsmats hgteagsavp
 10981 tvlpevpqmv tsolvassrav tsttlptltl spgepettps matshgaeas stvptvapev
 11041 pgvvtslvts ssgvnatsip tllilspgele ttpsmatshg aeassavptp tvspgvsqvv
 11101 tplvtssrav tsttipiltl ssepettps matshgveas savltvapev pgmvtslvt
 10 11161 sravtsttip tltissdepe ttstlvthse akmisaiptl avspvtqglv tslytssgse
 11221 tsafsnltva ssgpetidsw vahpgteass vvpiltvtstg epftnlsvt hpaessstlp
 11281 rttstrfshse ldtmptvts peaeassais ttispgipgv tsvltssagr disatfptvp
 11341 espheaseata swvthpavts ttvprttpty shsepdtts iatpagaat sdfptitvsp
 11401 dvpdmvtsqv tssgtdtsit iptltlssge petttsfity sethtssaip tlpvsggask
 15 11461 mltalvissg tdstttfptl tetpyepett aiqlibpaet ntmvpkttpk fshkskdtl
 11521 pvaitspgpe assavsttti spdmsdlvts lvpssgtdts ttfptlsetp yepettvtwl
 11581 thpaetsttv egtipnfshr gsdtpasmvt spgvdrsgv ptttippsip gvvtsqvtss
 11641 atdtstaip ltpspgepet tassathpqt qtgftvpipt vpssepdtma swvthppqts
 20 11701 tpvrttssf shsspdtpv matsprteas savlttispg apemvtsqit ssgaatsttv
 11761 ptlthspgmp ettallsthp rtgtsktfpa stvfpgvset tasltirpga etstaltptqt
 11821 tsslftllvt gtsrvdlst aspghsakta plsthpgtet stmiptstls lglltettgll
 11881 atsssaetst stltltvspa vglssasit tdkpqtvtsw ntetspsvts vgppefartv
 11941 tggtmtlips emptppktsh gegvspttil rttmveatnl attgssptva kttttfntla
 25 12001 gslftpltt gmstlaseev tsrtsynhrs wistssynr rywtpatstp vstsfpgis
 12061 tssipsstaa tvpfmvpftl nftitnlqye edmrhpgsrk fnaterelqg llkplfrnss
 12121 leylysgcrl aslrpekds amavdaicth rdpedlglr rerlywelsn ltngigelgp
 12181 ytlrnslyv ngfthrsmp ttstpgtstv dvgtsgtpps spsptaagpl lmpftlnfti
 12241 tnlqeedmr rtgsrkfntm esvlqgllk lfkntsvgpl ysgcrltlr pekdgatgv
 30 12301 daicthrlp kspglnreq ywelsklnd ieelgpytld rnslyvngf hgsavsttst
 12361 pgtstvdlt sgtpsalssp timaagpllv pftlnftitn lqygdmghp gsrkfntter
 12421 vlqgllgpif kntsvgplye gcrllsrse kdgaatgvda icihhldpks pglrnrlyw
 12481 elsqtlngik elgpytldrn slyvngfthr tsvpttstpg tstvdltsg tpfslpspat
 12541 agpllvftl nftitnlkye edmrhpgsrk fnttervlt llgpmfknts vgllysgcrl
 35 12601 tllrsekda atgvdaicth rldpkspgld reqlywelsq ltngikelgp ytlrnslyv
 12661 ngfthwlpvp tsstpgtstv dlsgtspss psptaagpl vpftlnftit nlqeedmhh
 12721 pgsrkfntte rvlqgllgpm fknsvglly sgcrlllrs ekdgaatgv aicthrlp
 12781 spgvdrqly welsqltngi kelgpytldr nslvngfth qtsapntstp gtsvdltgs
 12841 gtpsslpst sagpllvft lntitnlqy eedmrhpgsr kfnttervlt gllkplfkst
 12901 svgplysgcr ltlrsekdg aatgvdaic hrlpdkspgv dreqlywels qltngikelg
 40 12961 pytlrnsly vngfthqtsa pntstpgtst vdlgtsgtps slpsptsagg llvpftlnft
 13021 itnlqeedm hhpgrkfn tervlqgllg pmfkntsvgl lysgcrltl rpekngaag
 13081 mdaicshrl pkspglnreq lywelsqlth gikelgpytl drnslyvngf thrssvapt
 13141 ptgstvdlt sgtpsslp pttavpllv ftlnftitn qygdmrhp gsrkfntterv
 13201 lqgllgplfk nssvplyeg crllsrsek dgaatgvda cthhlnpqp gldreqlwq
 45 13261 lqmtngike lgytldrn lyvngfthrs sglttstpw stvdltsgt pspvpstta
 13321 gppllvftln ftitnlqye dmhrpgsrkf nttervltg lspifknssv gplysgcrlt
 13381 slrpekdgaa tgmavclyh pnpkrpgldr eqlywelsq thnitelgpy slrdalslyv
 13441 gfthqnsvpt ttpgtstvy wattgtpsf pghtepgpl ipftfnftit nlhyeenmqh
 50 13501 pgsrkfntte rvlqgllkpl fknsvgply sgcrllsrp ekdgaatgmd avclyhpnk
 13561 rpgldreql welsqlthni telgpyldr dslyvngfth qnsvptstp gtsvwtatt
 13621 gtpssfpght epgpilipft fntitnlhy eenmqhpgsr kfnttervlt gllkplfknt
 13681 svgplysgcr ltlrpekhe aatgvdtict hrvdpgpgl drerlywels qltnsitelg
 13741 pytlrdsly vngfnprssv pttstpgtst vhlatsgtps slpghtapvp llipftlnft
 55 13801 itnlhyeenm qhpgsrkfnt tervlqgllk plfkntsvgp lysgcrltl rpekheaag
 13861 vdticthrvd pigpglxxex lywelsxlt xixelgpytl drxslvngf thxaxptts
 13921 tpgtstvxsg tsptsspxp xtsagpllv ftlnftitn qyeedmhhpg srkfntterv
 13981 lqgllgpmfk ntsvglllye crllrpek ngaatgmadi cshrlpdkp gldreqlwe
 14041 lsqthgike lgytldrn lyvngfthrs svaptstpg stvdltsgt psslpstta
 60 14101 vpllvftln ftitnlqye dmhrpgsrkf nttervltg lgpplknssv gplysgcrl
 14161 slrsekdgaa tgvdaicthh lnpqspgldr eqlywelsqm tngikelgpy tldrnslyv
 14221 gfthrsaglt ttpwtstvd lgtsgtspv pspttagpl vpftlnftit nlqeedmhr

14281 pgsrkfnate rvlqgllspi fknssvgply sgcrltslrp ekdgaatgmd avclyhpnkp
 14341 rpgldreqly welsqlthni telgpysldr dslyvngfth qssmtttrtp dtstmlhats
 14401 rtpaslsqpt tasp1lvft inctitnlqy eedmrtrgsr kfntmesvlq gllkplfknt
 14461 svqplysgcr ltllrpkkdg aatgvdaict hrldpkspgl nreqlywels klndieelg
 5 14521 pytlrnsly vngfthqssv sttstpgtst vdlrtsgtps slssptimxx xp1lxpftxn
 14581 xtitnlxxxx xmxpgsrkf nttervlggl lrplfkntsv sslysgcrlt llrpekdgaa
 14641 trvdaactyr pdpkspgl dr eqlywelsql thsitelgpy tldrvslyvn gfnprssvpt
 14701 tstpgtstvh latsgtpsal pghtxxqpl xpftxnxtit nlxxxxmxx pgsrkfntte
 14761 rvlqgllkpl fnssleyly sgcrilaslrp ekdssamavd aicthrpdp d1gldrerly
 10 14821 welsnltngi qelgpytl dr nslyvngfth xssglttstp wstsvdlgts gtpspvpspt
 14881 tagpllvpt lnftitnlqy eedmhrgpsr rfnttervlg glltplfknt svqplysgcr
 14941 ltllrpekqe aatgvdtict hrvdpiqpgl drerlywels qltnsitelg pytlrdrslly
 15001 vngfnpwssv pttstpgtst vhlatsgtps slpghtapvp llipftlnft itdlhyeenm
 15061 qhpgsrkfnt tervlgllk plfkstsvgp lysgcrltll rpekhaatg vdaictlrl d
 15121 ptgpgldrer lywelsqltn svtelgpytl drdslyvngf thrssvptts ipgtsavhle
 15181 tsqtpas1pg htapggllvp ftlnftitnl qyeedmrhpg srkfstterv lqgllkplfk
 15241 ntsvsslysg crltllrpek dgaatrvdav cthrpdpksp gl drerlywk lsqlthgite
 15301 lgpytl drhs lyvngfthqs smtttrtpdt stmlhatsrt paslsqptta spllvftin
 15361 ftitnlryee nmhpgsrkf nttervlggl lrpvfkntsv gplysgcrlt tlrpkkdga
 20 15421 tkvdaictyr pdpkspgl dr eqlywelsql thsitelgpy tqdrdslyvn gfthrsvpt
 15481 tsipgtsavh letsqtpas1 pghtapggll vpftlnftit nlqyeedmrh pgsrkfntte
 15541 rvlqgllkpl fkstsvgply sgcrltllrp ekrgaatgvd ticthrl dpl npgldreqly
 15601 welskltrgi ielgpyll dr gslyvngfth rtsvpttstp gtstvd1gts gtpfslpspa
 25 15661 xxxp1lxpft xnxtitnlxx xxxmxxpgsr kfnttervlg tllgpmfknt svgllysgcr
 15721 ltllrsekdg aatgvdaict hrldpkspgv dreqlywels qltngike1g pytlrdrslly
 15781 vngfthwipv pttstpgtst vdlsgtpps lpspttagpl lvpftlnfti tnlkyeedmh
 15841 cpgsrkfntt ervlgallgp mfkntsvgpl ysgcrltllr sekdgatgv daicthrl d
 15901 kspgvdreql ywelsqltn ielgpytl dr rnslyvngft hqtsapntst pgtstvd1gt
 15961 sgtpsalpsp txxp1lxpft txnxtitnlx xxxmxxpgs rkfnttexvl qgllxpxfk
 30 16021 xsvgxlysgc rltxlrxekx gaatgxdaic xhxxpxkxpg lxxexlywel sxltxxixel
 16081 gpytl drxsl yvngfthwip vptstpgts tvdlsgtpps slpspttagp llvpftlnft
 16141 itnlkyeedm hcpgsrkfnt tervlgallgp pmfkntsvgp lysgcrlt1s rsekdgatg
 16201 vdaicthrvd pkspgvdr eq lywelsqltn gikelgpytl drnslyvngf thqtsapnts
 16261 tpgtstvxq tsqtpssxpx xtsagpllv ftlnftitnl qyeedmhpg srkfntterv
 35 16321 lqgllgpmfk ntsvgllysg crltllrpek ngattgmdai cthrl dpksp glxxexlywe
 16381 lsxltxxixe lgpytl drxs lyvngfthxx xpttstpgt stvxxtsgt psxpxxtxx
 16441 xp1lxpftxn xtitnlxxxx xmxpgsrkf nttervlggl lkplfrnsl eylysgcrla
 16501 slrpekdsaa mavdaicthr dpdldgl dr erlywelsnl tngiqelgpy tldrnslyvn
 16561 gfthrsmpt tstpgtstvd vgtsgtpss pspttagpl ipftlnftit nlqygedmgh
 40 16621 pgsrkfntte rvlqgllgpi fkntsvgply sgcrltslrs ekdgaatgvd aic1hhl dpk
 16681 spgl nrerly welsqltn gi kelgpytl dr nslyvngfth rtsvpttstp gtstvd1gts
 16741 gtpfslpspa tagpllvft lnftitnlky eedmhrgpsr kfnttervlg tllgpmfknt
 16801 svgllysgcr ltllrsekdg aatgvdaict hrldpkspgl xxexlywels xltxxixelg
 16861 pytl drxsly vngfthxxsx pttstpgtst vxxtsgtpps sxpxxtxxx llxpftxnx
 45 16921 itnlxxxxm xxpgsrkfnt tervlgllr pvfkntsvgp lysgcrltll rpkkdgaatk
 16981 vdaictrypd pkspgl dr eq lywelsqltn sitelgpytq drdslyvngf thrssvptts
 17041 ipgtsavhle ttqtpssfpg htepgpllip ftfnftitnl ryeenmqhpg srkfntterv
 17101 lqglltplfk ntsvgplysg crltllrpek qeaatgvdti cthrvdpigg gl drerlywe
 17161 lsqltnsite lgpytl drds lyvdgfnpws svpttstpgt stvhlatsgt psplpghtap
 50 17221 vp1lipftln ftitdlhyee nmqhpgrkf nttervlggl lkplfkstsv gplysgcrlt
 17281 llrpekhaa tgvdai ctlr ldtpggldr erlywelsql tnsitelgpy tldrdslyvn
 17341 gfnpwssvpt tstpgtstvh latsgtpsal pghttagpl vpftlnftit nlkyeedmhc
 17401 pgsrkfntte rvlqslhpgm fkntsvgply sgcrltllrs ekdgaatgvd aicthrl d
 17461 spglxxexly welsxltxxi xelgpytl dr xslyvngfth xsxpttstp gtstvxxts
 55 17521 gtpasxpxt xxxp1lxpft xnxtitnlxx xxxmxxpgsr kfnttexvlq glxpxfkx
 17581 svgxlysgcr ltxlrxekx aatgxdaicx hxxpxkxpgl xxexlywels xltnsitelg
 17641 pytl drdsly vngfthrxsm pttstpgtsa vhlatsgtpa slpghtapgp llvpftlnft
 17701 itnlqyeedm rhpgsrkfnt tervlgllk plfkstsvgp lysgcrltll rpekrgaatg
 17761 vdticthrl plnpglxxex lywelsltx xixelgpytl drxslyvngf thxxsxptts
 60 17821 tpgtstvxq tsqtpssxpx xtxxp1lxp ftxnxtitnl xxxmxxpgs rkfnttexv
 17881 lqgllxpxfk nxsvgxlysg crltxlrxek xgaatgx dai cxhxxpxkx glxxexlywe

17941 lsxltxxixe lgpytldrxx lyvngfhprs svpttstpgt stvhlatsgt psslpghtap
 18001 vpllipftln ftitnlhyee nmqhpgerkf nttervlggl lgpmmfntsv gllysgcrlt
 18061 llrpekngaa tgmdaicshr ldpkspglxx exlywelsxl txxixelgpy tldrxxslyvn
 18121 gfthxxsxpt tstpgtstvx xgtsgtpssx pxxtxxxppl xpftxnxtit nlxxxxmxmxx
 5 18181 pgsrkfntte xvlqgllxpx fknxsvgxly sgcrltxlrx ekxgaatgxd aicxhxxpxk
 18241 xpglxxexly welsxltxxi xelgpytldr xslyvngfth qnsvpttstp gtstvywatt
 18301 gtpssfpght epgppllpft fnftitnlhy eenmqhpgsr kfnttervlg glltplfknt
 18361 svgplysgcr ltllrpekqe aatgvdtict hrvdpgpgl xxexlywels xltxxixelg
 18421 pytldrxxsly vngfthxxsx ptstpgtst vxxgtsgtps sxpxttxxxp lxxpftxnx
 10 18481 itnlxxxxxm xpgsrkfnt texvlqgllx pxfknxsvgx lysgcrltxl rxekxgaatg
 18541 xdaicxhxxx pxxpglxxex lywelsxltx xixelgpytl drxslyvngf thrssvptts
 18601 spgtstvhla tsqtpsslp htapvpplip ftlnftitnl hyeenmqhpg srkfntterv
 18661 lqgllkplfk stsvgplysg crltllrpek hgaatgvda ctlrldptgp glxxexlywe
 18721 lsxltxxixe lgpytldrxx lyvngfthxx sxpttstpgt stvxxgtsgt psspxxtxxx
 15 18781 xpllxpftxn xtitnlxxx xmxpgsrkf nttervlggl lxxpfxknxv gxlsgcrlt
 18841 xlrkekxgaa tgxdaicxh xpxkxpglxx exlywelsxl txxixelgpy tldrxxslyvn
 18901 gfthrtsvpt tstpgtstvh latsgtpssl pghtapvppl ipftlnftit nlqeedmhr
 18961 pgsrkfntte rvlqgllspi fknxsvgply sgcrltslrp ekdgaatgmd avclyhpnk
 19021 rpgldreqly celsqlthni telgpyaldr dslyvngfth qnsvpttstp gtstvywatt
 20 19081 gtpssfpght xxxpplxpft xxtitnlxxx xxxmxpgsr kfnttervlg gllxpxfkx
 19141 svxlysgcr ltxlrkekxg aatgxdaicx hxxpxkxpgl xxexlywels xltxxixelg
 19201 pytldrxxsly vngfthwssg lttstptwt vdlgtsgtps pvpspttagp llvpftlnft
 19261 itnlqeedm hrpgsrkfna tervlglls pifkntsvgp lysgcrltll rpekqeaatg
 19321 vdticthrvd pigpglxxex lywelsxltx xixelgpytl drxslyvngf thxxsxptts
 25 19381 tpgtstvxsg tsqtpssxpx txxpplxp ftxnxtitnl xxxmxpxg srkfnttexv
 19441 lqgllxpfxk nxsvgxlysg crltxlrxek xgaatgxdai cxhxxpxkx glxxexlywe
 19501 lsxltxxixe lgpytldrxx lyvngfthrs fglttstpw stvdlgtsgt pepvpptta
 19561 gpplvpftln ftitnlqyee dmhrpgsrkf nttervlggl ltpfmxntsv sslysgcrlt
 19621 llrpekdgaa trvdavcthr pdpkspglxx exlywelsxl txxixelgpy tldrxxslyvn
 30 19681 gfthxxsxpt tstpgtstvx xgtsgtpssx pxxtxxxppl xpftxnxtit nlxxxxmxmxx
 19741 pgsrkfntte xvlqgllxpx fknxsvgxly sgcrltxlrx ekxgaatgxd aicxhxxpxk
 19801 xpglxxexly welsxltxxi xelgpytldr xslyvngfth wipvptstsp gtstvdlgsg
 19861 tpsslpeptt agpllvpftl nftitnlqy edmghpgsrkf fnttervlg llgpfknts
 19921 vgpysgcr ltlrsekda atgvdaicx hldpkspglx xexlywelsx ltxixelgp
 35 19981 ytlrxxslyv ngfthxxsxpt tstpgtstvx xgtsgtpss pxxtxxxppl lxxpftxnx
 20041 tnlxxxxmx xpgsrkfntt exvlqgllxp xfkxsvgxly ysgcrltxlrx xekxgaatg
 20101 daicxhxxpx kxpglxxex lywelsxltx xixelgpytl xslyvngfth xgtfapntst
 20161 pgtstvdltg sgtpsslp tsagpllvpf tlnftitnlq yeedmhhpgs rkfntterv
 20221 qgllgpmfkn tsvgllysgc rltllrpek gaatrxdavc thrpdpkspg lxxexlywel
 40 20281 sxltxxixel gpytldrxxsly yvngfthxxsx xpttstpgts vxxgtsagtp sxxpxxtapv
 20341 pllipftlnf titnlhyeen mqhpgsrkf nttervlggl kplfkstsvg plysgcrltl
 20401 lrpekhaat gvdaictlrl dptgpgldre rlywelsqlt nsvtelgpyt ldrdslyvng
 20461 ftqrssvptt sipgtsavhl etsgtpaslp ghtapgpplv pftlnftitn lqyevdmrhp
 20521 gsrkfntter vlgllkplf kstsvgplys gcrltllrpe krgaatgvdt icthrldpln
 45 20581 pglrdreqlyw elskltrgi elgpylldrg slyvngfthr nfvpitstpg tstvhlgtse
 20641 tpsslprpiv pgpllvpftl nftitnlqy eamrhpgrkf fnttervlg llrplfknts
 20701 igplysscr ltlrpekda atrvdaicth hpdpgspgln reqlywelsq lthgitelgp
 20761 ytlrdslyv dgfthwspip ttstpgtsiv nlgtsgipps lpettxxxpl lxxpftxnx
 50 20821 tnlxxxxmx xpgsrkfntt ervlgllkp lfkstsvgpl ysgcrltllr pekdgvatrv
 20881 daicthrpdp kipgldrqql ywelsqlths itelgpytld rdslyvngf qrrsvpttst
 20941 pgtftvqpet setpsslp tatgvpplp tlnftitnlq yeedmhhpgs rkfntterv
 21001 qgllmplfk tsvslysgc rltllrpek gaatrxdavc thrpdpkspg ldrerlywk
 21061 sqlthgitel gpytldrxxsly yvngfthqss mtttrtpdts tmhlatsrt aslsgpttas
 55 21121 pllvftlnf titnlryeen mhhpgsrkf nttervlggl rpvfkntsvg plysgcrltl
 21181 lrpkkdgaat kvdaictyrp dpkspgldre qlywelsqlt hsitegpyt ldrdslyvng
 21241 ftqrssvptt sipgtptvdl gtsgtpvskp gpsaaspplv lftlnftitn lryeenmqh
 21301 gsrkfntter vlgllrslf kstsvgplys gcrltllrpe kdgtatgvda ictthpdpks
 21361 prldreqlyw elsqldnith elghyaldnd slfvngfthr ssvststpg tptvylgask
 21421 tpsifgpps ashllilftl nftitnlrye enmwpgrkf nttervlggl lrpplfknts
 60 21481 gplysgsr ltlrpekdgaa tgvdacithr pdptgpgldr eqlylelsq lthsitegpy
 21541 tldrdslyvn gftthrsvpt tstgvvseep ftlnftinnl rymadmqqg slkfntitdnv

```

21601 mkhlslplfq rslgarytg crvialrsvk ngaetrvdll ctylqplsgp glpikqvfhc
21661 lsqqtghitr lgpysldkds lylnygnepg ldeppptpkp attflpplse attamgyhik
21721 tltlnftian lqyspdmkgk satfnstegv lghllrplfq kssmgyfylg cqlislrpek
21781 dgaatgvdtc ctyhdpdvpg gldiqglywe lsqllthgvtq lgfyvldrds lfingyapqn
5 21841 lsirgeyqin fhivnwnlsn pdptsseyit llrdiqdkvt tlykgsqldh tfrfclvtnl
21901 tmdsvlvtvk alfssnldps lveqvfdkt lnasfhwlg tyqlvdihvt emessvyqpt
21961 sssstqhfyl nftitnlpye qdkaqpgttn yqrnkknied alnqlfrns ikysfscqv
22021 stfrsvpnrh htgvdslnfn splarrvdrv aiyeeflrmr rngtqlqnt ldrssvldvg
22081 yspnrnepln gnsdlpfwav iliglagllg litcliegvl vttrrrkkee eynvqqcpg
10 22141 yyqshldled lq

```

SEQ ID NO. 2

15 CA125 nucleic acid Genbank No. AF414442

CDS 205..66663

```

1 aagcgttgca caattccccc aacctccata catacggcag ctcttctaga cacaggtttt
61 ccaggtgcaa atgcggggac ccagcccata tctcccacc tgagaaattt tggagtttca
121 gggagctcag aagctctgca gaggccaccc tctctgagg gattcttctt agacctccat
20 181 ccagaggcaa atgttgacct gtccatgctg aaaccctcag gccttcctgg gtcattctct
241 cccacccgct ccttgatgac agggagcagg agcactaaag ccacaccaga aatggattca
301 ggactgacag gagccacctt gtcacctaa acatctacag gtgcaatcgt ggtgacagaa
361 catactctgc cctttacttc cccagataag acctggcca gtcctacatc ttcggttggtg
421 ggaagaacca cccagtcttt gggggtgatg tcctctgctc tccttgagtc aacctctaga
25 481 ggaatgacac actccgagca aagaaccagc ccatcgctga gtcccagggt caatggaact
541 ccctctagga actacctgct tacaagcatg gtttcaggat tgagtcccc aaggaccagg
601 ccaggttcca cagaaggaaa ttttaccaaa gaagcatcta catacacact cactgtagag
661 accacaagtg gccagtcac tgagaagtac acagtcccca ctgagacctc aacaactgaa
721 ggtgacagca cagagacccc ctgggacaca agatatattc ctgtaaaaat cacatctcca
30 781 atgaaaacat ttgcagattc aactgcatcc aaggaaaaatg cccagtgctc tatgactcca
841 gctgagacca cagttactga ctcacatact ccaggaagga caaacccatc atttgggaca
901 ctttattctt ccttccttga cctatcacct aaagggaccc caaattccag aggtgaaaca
961 agcctggaac tgattctatc aaccactgga tatccctctt cctctcctga acctggctct
1021 gcaggacaca gcagaataag taccagtgcg cctttgtcat catctgcttc agttctcgat
35 1081 aataaaatat cagagaccag catattctca ggccagagtc tcacctcccc tctgtctcct
1141 ggggtgcccg aggccagagc cagcacaaatg cccaactcag ctatcccttt ttccatgaca
1201 ctaagcaatg cagaaacaag tgccgaaagg gtcagaagca caatttctc tctggggact
1261 ccatcaatat ccacaaagca gacagcagag actatcctta ccttccatgc cttcgctgag
1321 accatggata taccagcac ccacatagcc aagactttgg cttcagaatg gttgggaagt
40 1381 ccaggtaccc ttggtggcac cagcacttca gcgctgacaa ccacatctcc atctaccact
1441 ttagtctcag aggagacca caccatcac tccacgagtg gaaaggaaac agaaggaaact
1501 ttgaatacat ctatgactcc acttgagacc tctgctcctg gagaagagtc cgaatgact
1561 gccaccttgg tccccactct aggttttaca actcttgaca gcaagatcag aagtcactct
1621 caggtctctt catcccacc aacaagagag ctcagaacca caggcagcac cctctggagg
45 1681 cagagttcca gcacagctgc ccacgggagc tctgacatcc tgaggggcaac cacttccagc
1741 acctcaaaag catcatcatg gaccagtga agcacagctc agcaatttag tgaacccag
1801 cacacacagt ggggtggagc aagtcctagc atgaaaacag agagaccccc agcatcaacc
1861 agtgtggcag cccctatcac cactctgtt cctcagtggt tctctggctt caccacctg
1921 aagaccagct ccacaaaagg gatttggctt gaagaaacat ctgcagacac actcatcgga
50 1981 gaatccacag ctggcccaac caccatcag tttgtgttc ccactgggat ttcaatgaca
2041 ggaggcagca gcaccagggg aagccagggc acaacccacc tactcaccag agccacagca
2101 tcacttgaga catccgcaga tttgactctg gccacgaacg gtgtcccagt ctcggtgtct
2161 ccagcagtgga caaagacggc tgctggctca agtccctcag gagggacaaa gtcactatat
2221 acaatgggtt cttctgtcat ccctgagaca tcatctctac agtccctcagc ttccagggaa
55 2281 ggaaccagcc tgggactgac tccattaaac actagacatc ccttctcttc cctgaaacca
2341 gactctgcag gacacaccaa gataagcacc agcattcctc tgttgtcatc tgcttcagtt
2401 cttgaggata aagtgtcagc gaccagcaca ttctcacacc acaaaagccc gctcagccgt cctctctatt
2461 accacagggg ctctgaaat ctcaacaaag acaaaagccc gctcagccgt tcttctctcc
2521 atgaccctaa gcaatgcagc aacaagtcct gaaagagtca gaaatgcaac tccccctctg

```

2581 actcatccat ctccatcagg ggaagagaca gcagggagtg tcctcactct cagcacctct
 2641 gctgagacta cagactcacc taacatccac ccaactggga cactgacttc agaatcgtca
 2701 gagagtccta gcactctcag cctcccaagt gtctctggag tcaaaaccac attttcttca
 2761 tctactcctt ccactcatct atttactagt ggagaagaaa cagaggaaac ttcgaatcca
 5 2821 tctgtgtctc aacctgagac ttctgtttcc agagtaagga ccaccttggc cagcacctct
 2881 gtccctaccc cagtattccc caccatggac acctggccta caggttcagc tcagttctct
 2941 tcatcccacc tagtgagtga gctcagagct acgagcagta cctcagttac aaactcaact
 3001 ggttcagctc ttctctaaat atctcacctc actgggacgg caacaatgtc acagaccaat
 3061 agagacacgt ttaatgactc tgcgtgaccc caaagcacaa cttggccaga gactagtccc
 10 3121 agattcaaga cagggttacc ttccagcaaca accactgttt caacctctgc cacttctctc
 3181 tctgtactcg taatggtctc taaattcact totccagcaa ctagtcccat ggaagcaact
 3241 tctatcaggg aacctcaac aacctcctc acaacagaga ccacgaatgg ccaggtctct
 3301 atggctgtgg cttctaccaa catcccatt ggaaagggct acattactga aggaagattg
 3361 gacacaagcc atctgccc atggaccaca gcttctctg agacatctat ggattttacc
 15 3421 atggccaaag aaagtgtctc aatgtcagta totccatctc agtccatgga tgcgtctggc
 3481 tcaagcactc caggaaggac aagccaattc gttgacacat tttctgatga tgtctatcat
 3541 ttaacatcca gagaattac aatacctaga gatggaacaa gctcagctct gactccacaa
 3601 atgactgcaa ctcacctccc atctcctgat cctggctctg ctagaagcac ctggcttggc
 3661 atcttgcct catctcctt tctcctact ccaaagtca caatgagctc cacattttca
 20 3721 actcagagag tcaccacaag catgataatg gacacagttg aaactagtgc gtggaacatg
 3781 ccaacttac cttccacgac ttccctgaca ccaagtaata ttccaacaag tgggtccata
 3841 gaaaaaagca ccctggttcc cttggacact ccatctccag ccacatcatt ggaggcatca
 3901 gaagggggac ttccaacctc cagcacctac cctgaatcaa caaacacacc cagcatccac
 3961 ctggagcac acgctagtcc agaaaagtcga agcaccatca aacttaccat ggcttcagta
 25 4021 gtaaaacctg gctcttacac acctctcacc ttccctcaa tagagacca cattcatgta
 4081 tcaacagcca gaatggctta ctcttctggg tcttcacctg agatgacagc tcctggagag
 4141 actaacactg gtagtacctg ggaccccc accctacatca ccactacgga tcctaaagga
 4201 acaagttcag ctcaggtctc tacaccccac tcagttagga cactcagaac cacagaaaac
 4261 catccaaaga cagagtccgc caccctcagc gcttactctg gaagtccata aatctcaagt
 30 4321 tcacccaatc tcaccagtc ccgccacaaa gcatggacca tcacagacac aactgaacac
 4381 tccactcaat tacattacac aaaattggca gaaaaatcat ctggatttga gacacagtca
 4441 gctccaggac ctgtctctgt agtaatccct acctccccta ccattggaag cagcacattg
 4501 gaactaactt ctgatgtccc aggggaaccc ctggctcctg ctcccagtgga gcagaccaca
 4561 atcactctcc ccattggcaac atggctgagt accagtttga cagaggaaat ggcttcaaca
 35 4621 gaccttgata tttcaagtcc aagttcacc atgagtacat ttgctatttt tccacctatg
 4681 tccacacett ctcattgaact ttcaaagtca gaggcagata ccagtgccat tagaaatata
 4741 gattcaacaa cgttggatca gcacctagga atcaggagtt tgggcagaaac tggggactta
 4801 acaactgttc ctatcacccc actgacaacc acgtggacca gttgtattga acactcaaca
 4861 caagcacagg acaccttctc tgcaacgatg agtcctactc acgtgacaca gtcactcaaa
 40 4921 gatcaaacat ctataccagc ctcagcatcc ccttcccato ttactgaagt ctacctgag
 4981 ctggggacac aagggagaag ctctctgag gcaaccactt ttggaaac atctacagac
 5041 acactgtcca gagagattga gactggccca acaaacattc aatccactcc acccatggac
 5101 aacacaacaa cagggagcag tagtagtgga gtcaccctgg gcatagccca ccttcccata
 5161 ggaacatcct cccagctga gacatccaca aacatggcac tggaaagaag aagttctaca
 45 5221 gccactgtct ctatggctgg gacaatggga ctcttgtta ctagtgtctc aggaagaagc
 5281 atcagccagt cattaggaag agtttctctc gtccttctg agtcaactac tgaaggagtc
 5341 acagattcta gtaagggaag cagcccaagg ctgaacacac agggaaatac agctctctcc
 5401 tcctctcttg aacctcagta tgcgtgaagg agccagatga gcacaagcat ccctctaacc
 5461 tcatctccta caactcctga tgtggaattc atagggggca gcacattttg gaccaaggag
 50 5521 gtcaccacag ttatgacctc agacatctcc aagtcttcag caaggacaga gtcacgtca
 5581 gctaccctta tgtccacagc ttgggaagc actgaaaata caggaaaaga aaaactcaga
 5641 actgctctca tggatcttcc atctccaact ccatcaatgg aggtgacacc atggatttct
 5701 ctcactctca gtaatgcccc caataccaca gattcacttg acctcagcca tggggtgcac
 5761 accagctctg cagggacttt ggccactgac aggtcattga atactggtgt cactagagcc
 55 5821 tccagattgg aaaacggctc tgatacctct tctaagtcct tgtctatggg aaacagact
 5881 cacacttcca tgactgacac agagaagagt gaagtgtctt ctccaatcca tccccgacct
 5941 gagacctcag ctcttgagc agagaccact ttgacttcca ctctggaaa cagggccata
 6001 agcttaacat tgccttttcc atccattcca gtggaagaag tcattttotc aggcataacc
 6061 tcaggaccag acatcaactc agcaccatg acacattctc ccatcaccac accaacaatt
 60 6121 gtatggacca gtacaggcac aattgaacag tccactcaac cactacatgc agtttcttca
 6181 gaaaaagttt ctgtgcagac acagtcaact ccatatgtca actctgtggc agtgcctgct

5 6241 tccccctacc atgagaattc agtctctctt ggaagcagca catcctctcc atattcctca
6301 gcctcacttg aatccttgga ttccacaatc agtaggagga atgcaatcac ttccctggcta
6361 tgggacctca ctacatctct cccactaca acttggccaa gtactagttt atctgaggca
6421 ctgtcctcag gccattcttg ggtttcaaac ccaagttaa ctacgactga atttccactc
6481 ttttcagctg catccacatc tgcctgtaag caaagaaatc cagaacaga gacccatggt
6541 cccagaata cagccgcag tactttgaac actgatgcat cctcggtcac aggtctttct
6601 gagactcctg tgggggcaag tatcagctct gaagtccctc ttccaatggc cataacttct
6661 agatcagatg tttctggcct tacatctgag agtactgcta acccgagttt aggcacagcc
6721 tcttcagcag ggaccaaatt aactaggaca atatccctgc ccacttcaga gtctttggtt
10 6781 tcctttagaa tgaacaagga tccatggaca gtgtcaatcc ctttggggtc ccatccaact
6841 actaatcacg aaacaagcat cccagtaaag agcgaggtc cacttggtt gtccacagta
6901 gcatcagatg taattgacac accttcagat ggggctgaga gtattccac tgtctcctt
6961 tccccctccc ctgatactga agtgacaact atctcacatt tcccagaaaa gacaactcat
7021 tcatttagaa ccatttcac tctcactcat gaggtagctt caagagtgc acctattcct
15 7081 ggggattgga tgagttcagc tatgtctaca aagcccacag gagccagtc cccattaca
7141 ctgggagaga gaaggacaat cactctgct gctccaacca cttccctcat agttctcact
7201 gctagtttca cagagaccag cacagtttca ctggataatg aaactacagt aaaaacctca
7261 gatatccttg acgcacggaa acaaatgag ctccctcag atagcagttc ttctctgat
7321 ctgatcaaca cctccatagc ttctcaact atggatgtca ctaaacacgc tccatcagt
20 7381 cccactagca tctcaggaat gacagcaagt tctccctcat ctctcttctc tccagataga
7441 cccaggttc ccacatctac aacagagaca aatacagcca cctctccatc tgtttccagt
7501 aacacctatt ctcttgatgg gggtccaat gtgggtggca ctccatccac ttaccaccc
7561 tttacaatca cccacctgt cgagacaagc tcggccctat tagcctggtc tagaccagta
7621 agaactttca gcacatggt cagcactgac actgcctccg gagaaaatcc tactctagc
25 7681 aattctgtgg tgacttctgt tccagcacca ggtacatggg ccagtgtagg cagtactact
7741 gacttacctg ccattgggct tctcaagaca agtccctgcag gagaggcaca ctacttcta
7801 gcatcaacta ttgaaccagc cactgccttc actccctatc tctcagcagc agtggtcact
7861 ggatccagtg ctacatcaga agccagtctt ctactacga gtgaaagcaa agccattcat
7921 tcttcaccac agaccccaac tacaccacc tctggagcaa actgggaaac ttcagctact
30 7981 cctgagagcc ttttggtagt cactgagact tcagacacaa cacttacctc aaagattttg
8041 gtcacagata ccattctgtt ttcaactgtg tccacgccac cttctaaatt tccaagtacg
8101 gggactctgt ctggagcttc ctccctact ttactcccgg acactccagc catccctctc
8161 actgccactg agccaacaag ttacttagct acatcctttg attccaccgc actggtgact
35 8221 atagcttcgg atagctcttg cacagtccca gagactaccc tgaccatgtc agagacctca
8281 aatggtgatg cactggttct taagacagta agtaaccacag ataggagcat ccctggaatc
8341 actatccaag gagtaacaga aagtccactc catccttctt ccacttcccc ctctaagatt
8401 gttgctccac ggaatacaac ctatgaaggt tcgatcacag tggcacttct tactttgcct
8461 gcgggaacta ctgggttccct tgtattcagt cagagtcttg aaaactcaga gacaacggct
40 8521 ttggtagact catcagctgg gcttgagagg gcatctgtga tgccactaac cacaggaagc
8581 cagggtatgg ctagctctgg aggaatcaga agtgggtcca ctactcaac tggaaacaaa
8641 acattttctt ctctccctct gaccatgaac ccaggtgagg ttacagccat gtctgaaatc
8701 accacgaaca gactgacagc tactcaatca acagcaccca aagggatacc tgtgaagccc
8761 accagtgtg agtcaggcct cctaaccct gtctctgcct cctcaagccc atcaaaggcc
8821 tttgcctcac tgactacagc tccccatca acttggggga tcccacagtc taccttgaca
45 8881 tttgagtttt ctgaggtccc aagtttggat actaagtccg ctctttacc aactcctgga
8941 cagtccctga acaccattcc agactcagat gcaagcacag catcttctcc actgtccaag
9001 tctccagaaa aaaacccaag ggcaaggatg atgacttcca caaaggccat aagtgcaagc
9061 tcatttcaat caacaggttt tactgaaacc cctgagggat ctgcctcccc ttctatggca
50 9121 gggcatgaac ccagagtcct cacttcagga acaggggacc ctgatatgc ctccagagac
9181 atgtcttatc cagacccaag caaggcatca tcagctatga catcgacctc tcttgcatca
9241 aaactcacia ctctcttcag cacaggtcaa gcagcaaggt ctgggtctag ttctctccc
9301 ataagcctat ccactgagaa agaaacaagc ttctttccc ccactgcac cactccaga
9361 aagacttcac tatttcttgg gccttccatg gcaaggcagc ccaacatatt ggtgcatctt
9421 cagacttcag ctctgacact ttctccaaca tccactctaa atatgtccca ggaggagcct
55 9481 cctgagttaa cctcaagcca gaccattgca gaagaagagg gaacaacagc tgaaacacag
9541 acgttaacct tcacaccatc tgagacccca acatccttgt tacctgtctc ttctcccaca
9601 gaaccacacag ccagaagaaa gaggttctcca gaaacatggg caagctctat ttcatgtcct
9661 gccagacct ccttgggtga aacaactgat ggaacgctag tgaccacct aaagatgtca
9721 agccaggcag cacaaggaaa ttccacgtgg cctgccccag cagaggagac ggggaccagt
60 9781 ccagcaggca catccccagg aagcccagaa gtgtctacca ctctcaaat catgagctcc
9841 aaggaaccca gcatcagccc agagatcagg tccactgtgc gaaattctcc ttggaagact

9901 ccagaaacaa ctgttcccat ggagaccaca gtggaaccag tcacccttca gtccacagcc
 9961 ctaggaagtg gcagcaccag catctctcac ctgcccacag gaaccacatc accaaccgaag
 10021 tcaccaacag aaaatatgtt ggctacagaa aggggtctccc tctccccatc cccacctgag
 10081 gcttggacca acctttattc tggaaactcca ggagggacca ggcagtcact ggccacaatg
 5 10141 tcctctgtct ccctagagtc accaactgct agaagcatca caggggactgg tcagcaaaagc
 10201 agtccagaac tgggtttcaaa gacaactgga atggaattct ctatgtggca tggctctact
 10261 ggagggacca caggggacac acatgtctct ctgagcacat cttccaatat ccttgaagac
 10321 cctgtaacca gcccacactc tgtgagctca ttgacagata aatccaaaca taaaaccgag
 10381 acatgggtaa gcaccacagc cattccctcc actgtcctga ataataagat aatggcagct
 10 10441 gaacaacaga caagtgcgac tgtggatgag gcttattcat caactagtcc ttggtcagat
 10501 cagacatctg ggagtgcacat cacccttggg gcattctcctg atgtcacaaa cacattatac
 10561 atcacctcca cagcacaaac cactcacta gtgtctctgc cctctggaga ccaaggcatt
 10621 acaagcctca ccaatccctc agggagaaaa acaagctctg cgtcatctgt cacatctcct
 10681 tcaatagggc ttgagactct gagggccaat gtaagtgcag tgaaaagtga cattgccctt
 15 10741 actgctgggc atctatctca gacttcatct cctgcggaag tgagcatcct ggacgtaacc
 10801 acagctccta ctccaggat ctccaccacc atcaccacca tgggaaccaa ctcaatctca
 10861 actaccacac ccaaccacaga agtgggtatg agtaccatgg acagcaccac ggccacagag
 10921 aggcgcacaa cttctacaga acacccttcc acctgggtctt ccacagctgc atcagattcc
 10981 tggactgtca cagacatgac ttcaaaacttg aaagtgtcaa gatctcctgg aacaatttcc
 20 11041 acaatgcata caacttcatt cttagcctca agcactgaat tagactccat gtctactccc
 11101 catggccgta taactgtcat tggaaaccagc ctggtcactc catcctctga tgcctcagct
 11161 gtaaaagacag agaccagtac aagtgaaga acattgagtc cttcagacac aactgcattct
 11221 actcccatct caactttttc tctgtccag aggatgagca tctcagttcc tgacatttta
 25 11281 agtacaagtt ggactcccag tagtacagaa gcagaagatg tgcoctgttc aatggtttct
 11341 acagatcatg ctagtacaaa gactgaccca aatacgcccc tgtccacttt tctgtttgat
 11401 tctctgtcca ctcttgactg ggacactggg agatctctgt catcagccac agccactacc
 11461 tcagctcctc agggggccac aactccccag gaactcactt tggaaaccat gatcagccca
 11521 gctacctcac agttgccctt ctctataggg cacattacaa gtgcagtcac accagctgca
 11581 atggcaagga gctctggagt tactttttca agaccagatc ccacaagcaa aaaggcagag
 30 11641 cagacttcca ctacagcttc caccaccact tctgcacatc cagggcaggt gccagatca
 11701 gcagcaacaa ctctggatgt gatccacac acagcaaaaa ctccagatgc aacttttcag
 11761 agacaagggc agacagctct tacaacagag gcaagagcta catctgactc ttggaatgag
 11821 aaagaaaaat caaccccaag tgcaccttgg atcactgaga tgaatgaatc tgtctcagaa
 11881 gataccatca aggagggtac cagctcctcc agtgtattaa aggaccctga atacgctgga
 35 11941 cataaacttg gaatctggga cgacttcac cccaagtttg gaaaagcagc ccatatgaga
 12001 gagttgcccc ttctgagtc accacaggac aaagaggcaa ttcacccttc tacaacaca
 12061 gtagagacca caggctgggt cacaagttcc gaacatgctt ctcatccac tatccagcc
 12121 cactcagcgt catccaaact cacatctcca gtggttaca cctccaccag ggaacaagca
 12181 atagtttcta tgtcaacaac cacatggcca gactctacaa gggctagaac agagccta
 40 12241 tccttcttga ctattgaact gagggacgtc agcccttaca tggacaccag ctcaaccaca
 12301 caaacaagta ttatctcttc cccagggttc actgcatca ccaaggggcc tgaacagaa
 12361 attacctct ctaagagaat atccagctca ttcttggccc agtctatgag gtcgtcagac
 12421 agccctcag aagccatcac caggctgtct aactttctct ccatgacaga atctggagga
 12481 atgaccttg ctatgcaaac aagtccacct ggcgctacat cactaagtgc acctactttg
 45 12541 gatacatcag ccacagcctc ctggacaggg actccactgg ctacgactca gagatttaca
 12601 tactcagaga agaccactct ctttagcaaa ggtcctgagg atacatcaca gccaagccct
 12661 ccctctgtgg aagaaaccag ctcttctctt tccctggtac ctatccatgc tacaacctcg
 12721 ccttccaata ttttgttgac atcacaaggg cacagtcctt cctctactcc acctgtgacc
 12781 tcagttttct tgtctgagac ctctggcctg gggaagacca cagacatgtc gaggataagc
 50 12841 ttggaacctg gcacaagttt acctcccaat ttgagcagta cagcaggtga ggcgttatcc
 12901 acttatgaag cctccagaga tacaaggca attcatcatt ctgcagacac agcagtgacg
 12961 aatatggagg caaccagtct tgaatattct cctatcccag gccatacaaa gccatccaaa
 13021 gccacatctc cattggttac ctccacatc atgggggaca tcaacttcttc cacatcagta
 13081 tttggctcct ccgagaccac agagattgag acagtgtcct ctgtgaacca gggacttcag
 55 13141 gagagaagca catcccaggt ggcagctct gctacagaga caagcactgt cattaccat
 13201 gtgtctagtg gtgatgttac tactcatgtc accaagacac aagccacttt ctctagcgga
 13261 acatccatct caagccctca tcagtttata acttctacca acacatttac agatgtgagc
 13321 accaaccctt ccacctctct gataatgaca gaatcttcag gagtgaacct caccacccaa
 13381 acaggtccta ctggagctgc aacacagggt ccatatctct tggacacatc aacctgcct
 60 13441 tacttgacag agactccatt agctgtgact ccagatttta tgcaatcaga gaagaccact
 13501 ctcataagca aaggtcccaa ggtgtgacc tggacaagcc ctccctctgt ggacagaacc

	13561	agctatccct	cttccctgac	acctttcttg	gtcacaacca	tacctcctgc	cacttccacg
	13621	ttacaagggc	aacatacatc	ctctcctgtt	tctgcgactt	cagttctttac	ctctggactg
	13681	gtgaagacca	cagatatgtt	gaacacaagc	atggaacctg	tgaccaattc	acctcaaaat
	13741	ttgaacaatc	catcaaatga	gatactggcc	acttttggcag	ccaccacaga	tatagagact
5	13801	attcatcctt	ccataaacia	agcagtgaac	aatatgggga	ctgccagttc	agcacatgta
	13861	ctgcattcca	ctctcccagt	cagctcagaa	ccatctacag	ccacatctcc	aatggttcct
	13921	gcctccagca	tgggggacgc	tcttgcttct	atatcaatac	ctggttctga	gaccacagac
	13981	attgagggag	agccaacatc	ctccctgact	gctggacgaa	aagagaacag	caccctccag
	14041	gagatgaact	caactacaga	gtcaaacatc	atcctctcca	atgtgtctgt	gggggctatt
10	14101	actgaagcca	caaaaatgga	agtccccctc	tttgatgcaa	cattcatacc	aactcctgct
	14161	cagtcaacaa	agttcccaga	tattttctca	gtagccagca	gtagacttcc	aaactctcct
	14221	cccatacaca	tatctaccca	catgaccacc	acccagacag	gggtcttctg	agctacatca
	14281	aagattccac	ttgccttaga	cacatcaacc	ttggaaacct	cagcagggac	tccatcagtg
	14341	gtgactgagg	ggtttgccca	ctcaaaaata	accactgcaa	tgaacaatga	tgtcaaggac
15	14401	gtgtcacaga	caaaccctcc	ctttcaggat	gaagccagct	ctccctcttc	taagcacctc
	14461	gtccttgta	caaccttacc	ttcttctgtt	gctttcacac	cgcaatggca	cagtacctcc
	14521	tctcctgttt	ctatgtcctc	agttcttact	tcttcaactg	taaagaccgc	aggcaagggtg
	14581	gatacaagct	tagaaacagt	gaccagttca	cctcaaagta	tgagcaacac	tttggatgac
	14641	atatcggtca	cttcagcagc	caccacagat	atagagacaa	cgcctccttc	cataaacaca
20	14701	gtagttacca	atgtggggag	caccgggtca	gcatttgaat	cacattctac	tgtctcagct
	14761	taccagagc	catctaaagt	cacatctcca	aatgttacca	cctccaccat	ggaagacacc
	14821	acaatttccc	gatcaatacc	taaatcctct	aagactacaa	gaactgagac	tgagacaact
	14881	tcctccctga	ctcctaaact	gaggagagac	agcatctccc	aggagatcac	ctcgtccaca
	14941	gagacaagca	ctgttccctt	caaagagctc	actggtgcca	ctaccgaggt	atccaggaca
25	15001	gatgtcactt	cctctagcag	tacatccttc	cctggccctg	atcagtcac	agtgtcacta
	15061	gacatctcca	cagaaaccaa	caccaggctg	tctacctccc	caataatgac	agaatctgca
	15121	gaaataacca	tcaccaccca	aacaggctct	catgggggcta	catcacagga	tacttttacc
	15181	atggaccat	caaatacaac	ccccaggcca	gggatccact	cagctatgac	tcattggattt
	15241	tcacaattgg	atgtgaccac	tcttatgagc	agaattccac	aggatgtatc	atggacaagt
30	15301	cctccctctg	tggataaaac	cagctccccc	tcttcttctc	tgtcctcacc	tgcaatgacc
	15361	acaccttccc	tgatttcttc	taccttacca	gaggataagc	tctcctctcc	tatgacttca
	15421	cttctcacct	ctggcctagt	gaagattaca	gacatattac	gtacacgctt	ggaacctgtg
	15481	accagctcac	ttccaaattt	cagcagcacc	tcagataaga	tactggccac	ttctaaagac
	15541	agtaaagaca	caaaggaaat	ttttccttct	ataaacacag	aagagaccaa	tgtgaaagcc
35	15601	acaactcaga	gacatgaatc	ccattcccct	gcactggctg	actcagagac	acccaaagcc
	15661	acaactcaaa	tgggttatcac	caccactgtg	ggagatccag	ctccttccac	atcaatgcca
	15721	gtgcatgggt	cctctgagac	tacaaacatt	aagagagagc	caacatattt	cttgactcct
	15781	agactgagag	agaccagtac	ctctcaggag	tccagcttct	ccacggacac	aagttttcta
	15841	ctttccaaag	tccccactgg	tactattact	gaggctctca	gtacaggggt	caactcttct
40	15901	agcaaaattt	ccaccccaga	ccatgataag	tccacagtgc	cacctgacac	cttcacagga
	15961	gagatcccca	gggtcttcac	ctcctctatt	aagacaaaat	ctgcagaaat	gacgatcacc
	16021	acccaagcaa	gtcctcctga	gtctgcatcg	cacagtaccc	ttcccttgga	cacatcaacc
	16081	acactttccc	agggagggac	tcattcaact	gtgactcagg	gattcccata	ctcagaggtg
	16141	accactctca	tgggcatggg	tcttggggat	gtgtcatgga	tgacaactcc	ccctgtggaa
45	16201	gaaaccagct	ctgtgtcttc	cctgatgtct	tcacctgcca	tgacatcccc	ttctcctggt
	16261	tcctccacat	caccacagag	catcccctcc	tctcctcttc	ctgtgactgc	acttccactt
	16321	tctgttctgg	tgacaaccac	agatgtgttg	ggcacaacaa	gcccagagtc	tgtaaccagt
	16381	tcacctccaa	atttgagcag	catcactcat	gagagaccgg	ccacttacaa	agacactgca
	16441	cacacagaag	ccgcatgca	tcattccaca	aacaccgcag	tgaccaatgt	agggacttcc
50	16501	gggtctggac	ataaatcaca	atcctctgtc	ctagctgact	cagagacatc	gaaagccaca
	16561	cctctgatga	gtaccacctc	caccctgggg	gacacaagtg	tttccacatc	aactcctaata
	16621	atctctcaga	ctaaccaaat	tcaaacagag	ccaacagcat	ccctgagccc	tagactgagg
	16681	gagagcagca	cgtctgagaa	gaccagctca	acaacagaga	caaatactgc	cttttcttat
	16741	gtgcccacag	gtgctattac	tcaggcctcc	agaacagaaa	tctcctctag	cagaacatcc
55	16801	atctcagacc	ttgatcggtc	cacaatagca	cccgacatct	ccacagggaat	gatccaccag
	16861	ctcttcacct	cccccatcat	gacaaaatct	gcagaaatga	cgtcaccac	tcaaacact
	16921	actcctgggg	ctacatcaca	gggtatcctt	ccttggggaca	catcaaccac	acttttccag
	16981	ggagggactc	attcaaccgt	gtctcaggga	ttcccacact	cagagataac	cactctctcg
	17041	agcagaaccc	ctggagatgt	gtcatggatg	acaactcccc	ctgtggaaga	aaccagctct
60	17101	gggttttccc	tgatgtcacc	ttccatgaca	tccccttctc	ctgtttctctc	cacatcacca
	17161	gagagcatcc	cctcctctcc	tctcctctgt	actgcacttc	ttacttctgt	tctggtgaca

5 17221 accaccaatg tattggggac aacaagccca gagaccgtaa cgagttcacc tccaaattta
17281 agcagcccca cacaggagag actgaccact tacaaagaca ctgcgcacac agaagccatg
17341 catgcttcca tgcatacaaa cactgcagtg gccaacgtcg ggacctccat ttctggacat
17401 gaatcacaaat cttctgtccc agctgattca cacacatcca aagccacatc tccaatgggt
17461 atcaccttcg ccattggggga tacaagtgtt tctacatcaa ctctgcctt ctttgagact
17521 agaattcaga ctgaatcaac atcctctttg attcctggat taaggagacac caggagctct
17581 gaggagatca acactgtgac agagaccagc actgtccttt cagaagtgc cactactact
17641 actactgagg tctccaggac agaagttatc acttccagca gaacaacatc ctcagggcct
17701 gatcattcca aaatgtcacc ctacatctcc acagaaacca tcaccaggct ctccactttt
10 17761 ccttttgtaa caggatccac agaatgggc atcaccaacc aaacaggtcc tatagggact
17821 atctcacagg ctacccttac cctggacaca tcaagcacag ctctctggga agggactcac
17881 tcacctgtga ctacagagatt tccacactca gaggagacca ctactatgag cagaagtact
17941 aagggcggtg catggcaaaag cctccctct gtggaagaaa ccagttctcc ttcttcccca
18001 gtgcctttac ctgcaataac ctcacattca tctctttatt ccgcagtatc aggaagttagc
15 18061 cccactttctg ctctcctgt gacttccctt ctcacctctg gcaggaggaa gaccatagac
18121 atgttggtgaca cacactcaga acttgtgacc agtcccttac caagtgcagg tagcttctca
18181 ggtgagatac tcaacttctga agcctccaca aatacagaga caattcactt ttcagagaac
18241 acagcagaaa ccaatatggg gaccaccaat tctatgcata aactacattc ctctgtctca
18301 atccactccc agccatccgg acacacacct ccaaagggtta ctggatctat gatggaggac
20 18361 gctattgttt ccacatcaac acctgggttct cctgagacta aaaatgttga cagagactca
18421 acatcccttc tgactcctga actgaaagag gacagcaccg ccttggtgat gaactcaact
18481 acagagtcaa acactgtttt ctccagtgtg tccctggatg ctgctactga ggtctccagg
18541 gcagaagtca cctactatga tctacattc atgcccagtt ctgctcagtc aacaaagtcc
18601 ccagacattt caccctgaagc cagcagcagt cattctaact ctctccctt gacaatatct
25 18661 acacacaaga ccatcgccac acaaacaggt ccttctgggg tgacatctct tggccaactg
18721 accctggaca catcaaccat agccacctca gcaggaactc catcagccag aactcaggat
18781 tttgttagatt cagaacaac cagtgtcatg aacaatgatc tcaatgatgt gttgaagaca
18841 agccctttct ctgcagaaga agccaaactc ctctcttctc aggcacctct ccttgtgaca
18901 acctcacctt ctctgtgata tccacattg caagagcaca gtacctctc tcttgtttct
30 18961 gtgacctcag taccacccc tactctggcg aagatcacag acatggacac aaacttagaa
19021 cctgtgactc gttcacctca aaatttaagg aacacctgg ccacttcaga agccaccaca
19081 gatacacaca caatgcatcc ttctataaac acagcaatgg ccaatgtggg gaccaccagt
19141 tcaccaaatg aattctatct tactgtctca cctgactcag acccatataa agcccaactc
35 19201 gcagtagtta tcaactccac ctggtgggac tcaatagttt ccacatcaat gcctagatcc
19261 tctgcgatga aaaagattga gtctgagaca actttctccc tgatathtag actgaggag
19321 actagcacct cccagaaaat tggctcatcc tcagacacaa gcacggtctt tgacaaagca
19381 ttcactgctg ctactactga ggtctccaga acagaaactc cctctctag cagaacatcc
19441 atccaaggca ctgaaaagcc cacaatgtca ccggacacct ccacaagatc tgtcaccatg
40 19501 ctttctactt ttgctggcct gacaaaatcc gaagaaagga ccattgccac ccaaacaggt
19561 cctcataggg cgacatcaca gggtaacctt acctgggaca catcaatcac aacctcacag
19621 gcagggaccc actcagctat gactcatgga ttttcacaa tagatttgc cactcttagc
19681 agtagagttc ctgagtacat atcaggggaca agccacctc ctgtggaaaa aaccagctct
19741 tctcttctcc ttctgtcttt accagcaata acctcacctg cccctgtacc tactacatta
45 19801 ccagaaagta ggcctgtctc tctgtttcat ctgacttcac tccccacctc tggcctagt
19861 aagaccacag atatgtggc atctgtggcc agtttacctc caaacttggg cagcacctca
19921 cataagatac cgactacttc agaagacatt aaagatcac agaaaatgta tcttccaca
19981 aacatagcag taaccaatgt ggggaccacc acttctgaaa aggaatctta ttctgtgtc
20041 ccagcctact cagaaccacc caaagtcacc tctccaatgg ttacctctt caacataagg
50 20101 gacaccattg tttccacatc catgctggc tctctgaga ttacaaggat tgagatggag
20161 tcaacattct cgttggtcca tgggctgaag ggaaccagca cctcccagga ccccatcgta
20221 tccacagaga aaagtgtgt ttgcacaaag ttgaacctg gtgctactga gaccttagg
20281 acagaagtgt cctcttctag aagaacatcc attccaggcc ctgatcttc cacagagtca
20341 ccagacatct ccaactgaat gatccccagc ctgacctatc cccttggcat tacagaatct
20401 tcaaatatga ccatcatcac tccaacaggt cctctctgt gctctacatc acagggcaca
55 20461 tttaccttgg acacaccaac tacatctcc agggcaggaa cacactcag ggcactcag
20521 gaatttccac actcagaaat gacctgtgc atgaacaagg acctgagat tctatcatg
20581 acaatccctc cttctataga gaaaaccagc ttctctctt ccctgatgac ttccaccagc
20641 atgacttcac ctctgtttc ctcaacatta ccaaagacca ttccaccac tcttctctc
20701 atgacctcac tgcctacccc tagcctagt atgaccacag acacattggg cacaagccca
60 20761 gaacctacaa ccagttcacc tccaaatttg agcagtacct cacatgtgat actgacaaca
20821 gatgaagaca ccacagctat agaagccatg catccttcca caagcacagc agcgactaat

20881 gtggaaacca cctgttctgg acatgggtca caatcctctg tcttaactga ctcagaaaaa
20941 accaaggcca cagctccaat ggataccacc tccaccatgg ggcatacaac tgtttccaca
21001 tcaatgtctg tttcctctga gactacaaaa attaagagag agtcaacata ttccttgact
21061 cctgggactga gagagaccag cattiecccaa aatgccagct tttccactga cacaagtatt
5 21121 gttctttcag aagtcctccac tgggtactact gctgaggtct ccaggacaga agtcacctcc
21181 tctggtagaa catccatccc tggcccttct cagtccacag ttttgccaga aatatccaca
21241 agaacaatga caaggctctt tgctcgccc accatgacag aatcagcaga aatgaccatc
21301 cccactcaaa caggctcctt tgggtctacc tcacaggata cccttacctt ggacacatcc
21361 accacaaagt cccaggcaaa gactcattca actttgactc agagatttcc aactcagag
10 21421 atgaccactc tcatgagcag aggtcctgga gatatgtcat ggcaaagctc tccctctctg
21481 gaaaaatcca gctctctccc ttcctctctg tctttacctg ccacaacctc acctcctccc
21541 atttccctcca cattaccagt gactatctcc tccctctctc ttcctgtgac ttcacttctc
21601 acctctagcc cggtaacgac cacagacatg ttacacacaa gcccagaact tgtaaccagt
21661 tcacctccaa agctgagcca cacttcagat gagagactga ccactggcaa ggacaccaca
15 21721 aatacagaag ctgtgcattc ttccacaaac acagcagcgt ccaatgtgga gattcccagc
21781 tttggacatg aatccctctc ctctgcctta gctgactcag agacatccaa agccacatca
21841 ccaatgttta ttacctccac ccaggaggat acaactgttg ccatatcaac ccctcacttc
21901 ttggagacta gcagaattca gaaagagtca atttccctcc tgagccctaa attgaggagg
21961 acaggcagtt ctgtggagac aagctcagcc atagagacaa gtgctgtcct tcttgaagtg
20 22021 tccattgggtg ctactactga gatctccagg acagaagtca cctcctctag cagaacatcc
22081 atctctgggt ctgtgagtc cacaatgttg ccagaaatat ccaccacaag aaaaatcatt
22141 aagttcccta cttcccccat cctggcagaa tcatcagaaa tgaccatcaa gaccacaaca
22201 agtccctctg ggtctacatc agagagtacc tttacattag acacatcaac cactccctcc
22261 ttggtaataa cccattcgac tatgactcag agattgcoac actcagagat aaccactctt
25 22321 gtgagtagag gtgctgggga tgtgccacgg ccagctctc tccctgtgga agaaacaagc
22381 cctccatctt cccagctgtc tttatctgcc atgatctcac cttctcctgt tcttccaca
22441 ttaccagcaa gtaggcactc ctcttctgtc tctgtgactt cactctcac accaggccaa
22501 gtgaagacta ctgaggtgtt ggacgcaagt gcagaacctg aaaccagttc acctccaagt
22561 ttgagcagca cctcagttga aatactggcc acctctgaag tcaccacaga tacggagaaa
30 22621 attcatctt tcccaaacac gccagtaacc aaagttggaa cttccagttc tggacatgaa
22681 tccctctct ctgtcctacc tgactcagag acaaccaaaag ccacatcggc aatgggtacc
22741 atctccatta tgggggatac aagtgtttct acattaactc ctgccttacc taacactagg
22801 aaaattcagt cagagccagc ttcctcactg accaccagat tgaggagagac cagcacctct
22861 gaagagacca gcttagccac agaagcaaac actgttcttt ctaaaagtgc cactggtgct
35 22921 actactgagg tctccaggac agaagccatc tcccttagca gaacatccat gtcaggccct
22981 gagcagttca caatgtcaca agacatctcc ataggaacca tccccaggat tctctgctcc
23041 tctgtcctga cagaatctgc aaaaatgacc atcacaaacc aaacaggtcc tctggagtct
23101 aactagaaa gtacccttaa tttgaacaca gcaaccacac cctcttgggt ggaaccacac
23161 tctatagtaa ttcagggatt tccacacca gagatgacca cttccatggg cagaggtcct
40 23221 ggaggtgtgt catggcctag cctccctttt gtgaaagaaa ccagccctcc atcctcccg
23281 ctgtctttac ctgocgtgac ctcacctcat cctgtttcca ccacattcct agcacatatc
23341 cccctctct ccttctctgt gacttcactt ctcacctctg gcccgcgac aaccacagat
23401 atcttgggta caagcacaga acctggaacc agttcatctt caagtttgag caccacctcc
23461 catgagagac tgaccactta caaagacact gcacatacag aagccgtgca tcttccaca
45 23521 aacacaggag ggaccaatgt ggcaaccacc agctctggat ataaatcaca gtcctctgtc
23581 ctactgact catctccaat gtgtaccacc tccaccatgg gggatacaag tgttctcaca
23641 tcaactcctg ccttcttga gactaggagg attcagacag agctagcttc ctcctgacc
23701 cctggattga gggagtccag tggctctgaa gggaccagct caggcaccac gatgagcaat
23761 gtcctctcta aagtgtccac tgggtctact actgagatct ccaaggaga cgtcacctcc
50 23821 atcccaggtc ccgctcaatc cacaatatca ccagacatct ccacaagaac cgtcagctgg
23881 ttctctacat cccctgtcat gacagaatca gcagaaataa ccatgaacac ccatacaagt
23941 ccttttaggg ccacaacaca aggcaccagt actttggcca cgtcaagcac aacctctttg
24001 acaatgacac actcaactat atctcaagga ttttcacact cacagatgag cactcttatg
24061 aggaggggtc ctgaggatgt atctggatg agccctcccc tcttgaaaaa aactagacct
55 24121 tctttttctc tgatgtcttc accagccaca acttcacctt ctoctgtttc ctcacattta
24181 ccagagagca tctcttctc tctcttctct gtgacttca cctcactgct tggcttggea
24241 aaaactacag atagtgtgca caaaagtca gaacctgtaa ccaactcacc tgcaaatgtg
24301 agcagcacct cagttgaaat actggccacc tctgaagtca ccacagatac agagaaaaact
24361 catccttctt caaacagaa agtgaccgat gtggggacct ccagttctgg acatgattcc
60 24421 acttcttttg tctagctga ctcacagaca tccaaagtca catctccaat ggttattacc
24481 tccaccatgg aggatacagag tgtctccaca tcaactcctg gcttttttga gactagcaga

	24541	attcagacag	aaccaacatc	ctccctgacc	cttggactga	gaaagaccag	cagctctgag
	24601	gggaccagct	tagccacaga	gatgagcact	gtcctttctg	gagtgccac	tgggtgccact
	24661	gctgaagtct	ccaggacaga	agtacacctc	tctagcagaa	catccatctc	aggctttgct
5	24721	cagctcacag	tgtcaccaga	gacttccaca	gaaaccatca	ccagactccc	tacctccagc
	24781	ataatgacag	aatcagcaga	aatgatgato	aagacacaaa	cagatocctc	tgggtctaca
	24841	ccagagagta	ctcatactgt	ggacatatca	acaacaccca	actgggtaga	aacccactcg
	24901	actgtgactc	agagattttc	acactcagag	atgaccactc	ttgtgagcag	aagccctggg
	24961	gatatgttat	ggcctagtca	atcctctgtg	gaagaaacca	gctctgcctc	ttccctgctg
	25021	tctctgcctg	ccacgacctc	accttctcct	gtttcctcta	cattagtaga	ggatttccct
10	25081	tccgcttctc	ttcctgtgac	ttctcttctc	acccctggcc	tggtgataac	cacagacagg
	25141	atggggcataa	gcagagaacc	tggaaccagt	tccacttcaa	atttgagcag	cacctcccat
	25201	gagagactga	ccacttttga	agacactgta	gatacagaag	acatgcagcc	ttccacacac
	25261	acagcagtg	ccaacgtgag	gacctccatt	tctggacatg	aatcacatc	ttctgtccta
	25321	tctgactcag	agacacccaa	agccacatct	ccaatgggta	ccacctacac	catgggggaa
15	25381	acgagtgttt	ccatatccac	ttctgacttc	tttgagacca	gcagaattca	gatagaacca
	25441	acatcctccc	tgacttctgg	attgagggag	accagcagct	ctgagaggat	cagctcagcc
	25501	acagagggaa	gcactgtcct	ttctgaagtg	cccagtggtg	ctaccactga	ggtctccagg
	25561	acagaagtga	tatcctctag	gggaacatcc	atgtcagggc	ctgatcagtt	caccatatac
	25621	ccagacatct	ctactgaagc	gatcaccagg	ctttctactt	ccccattat	gacagaatca
20	25681	gcagaaagtg	ccatcactat	tgagacaggt	tctcctgggg	ctacatcaga	gggtaccctc
	25741	accttggaca	cctcaacaac	aaccttttgg	tcagggaccc	actcaactgc	atctccagga
	25801	ttttcacact	cagagatgac	cactcttatg	agtagaactc	ctggagatgt	gccatggccg
	25861	agccttccct	ctgtggaaga	agccagctct	gtctcttctc	cactgtcttc	acctgccatg
	25921	acctcaactt	cttttttctc	cgattatcca	gagagcatct	cctcctctcc	tcactctgtg
25	25981	actgcacttc	tcacccttgg	cccagtgaag	accacagaca	tgttgccgac	aagctcagaa
	26041	cctgaaacca	gttcacctcc	aaatttgagc	agcacctcag	ctgaaatatt	agccacgtct
	26101	gaagtcacca	aagatagaga	gaaaattcat	ccctcctcaa	acacacctgt	agtcaatgta
	26161	gggactgtga	tttataaaca	tctatccctc	tctctgtttt	tggctgactt	agtgacaaca
	26221	aaacccacat	ctccaatggc	taccacctcc	actctgggga	atacaagtgt	ttccacatca
30	26281	actcctgcct	tcccagaaac	tatgatgaca	cagccaactt	cctccctgac	ttctggatta
	26341	agggagatca	gtacctctca	agagaccagc	tcagcaacag	agagaagtgc	ttctctttct
	26401	ggaatgccca	ctgggtgctac	tactaagggtc	tccagaacag	aagccctctc	cttaggcaga
	26461	acatccaccc	caggctcctgc	tcaatccaca	atatcaccag	aaatctccac	ggaaacacatc
	26521	actagaatth	ctactcccct	caccacgaca	ggatcagcag	aaatgaccat	cacccccaaa
35	26581	acaggtcatt	ctggggcatc	ctcacaaggt	acctttacct	tggacacatc	aagcagagcc
	26641	tcttggccag	gaactcactc	agctgcaact	cacagatctc	cacactcagg	gatgaccact
	26701	cctatgagca	gaggctcctga	ggatgtgtca	tggccaagcc	gcccatcagt	ggaaaaaact
	26761	agccctccat	cttccctggg	gtctttatct	gcagtaacct	cacctctgcc	actttattcc
	26821	acaccatctg	agagttagcca	ctcatctcct	ctccgggtga	cttctctttt	cacccctgtc
40	26881	atgatgaaga	ccacagacat	gttgagacaca	agcttggaaac	ctgtgaccac	ttcacctccc
	26941	agtatgaata	tcacctcaga	tgagagtctg	gocacttcta	aagccaccat	ggagacagag
	27001	gcaattcagc	tttcagaaaa	cacagctgtg	actcagatgg	gcacctcag	cgctagacaa
	27061	gaattctatt	cctcttatcc	aggcctccca	gagccatcca	aagtgcacac	tccagtgggtc
	27121	acctcttcca	ccataaaaaga	cattgtttct	acaaccatac	ctgcttctc	tgagataaca
45	27181	agaattgaga	tggagtcaac	atccaccctg	acccccacac	caagggagac	cagcacctcc
	27241	caggagatcc	actcagccac	aaagccaagc	actgttccct	acaaggcact	cactagtgcc
	27301	acgattgagg	actccatgac	acaagtcagt	tcctctagca	gaggacctag	ccctgatcag
	27361	tccacaatgt	cacaagacat	atccagtga	gtgatcacca	ggctctctac	ctcccccatc
	27421	aaggcagaat	ctacagaaat	gaccattacc	acccaaacag	gttctcctgg	ggctacatca
50	27481	aggggtaccc	ttaccttgg	cacttcaaca	acttttatgt	cagggaccoca	ctcaactgca
	27541	tctcaaggat	tttcacactc	acagatgacc	gctcttatga	gtagaactcc	tggagatgtg
	27601	ccatggctaa	gccatccctc	tgtggaagaa	gccagctctg	cctctttctc	actgtcttca
	27661	cctgtcatga	cctcatcttc	tccggtttct	tccacattac	cagacagcat	ccactcttct
	27721	tgccttccctg	tgacatcact	tctcacctca	gggctgggtga	agaccacaga	gctgttgggc
55	27781	acaagctcag	aacctgaaac	cagttcaccc	ccaaatttga	gcagcacctc	agctgaaata
	27841	ctggccacca	ctgaagtcac	tacagataca	gagaaactgg	agatgaccaa	tgtggtaacc
	27901	tcaggttata	cacatgaatc	tccttctctc	gtcctagctg	actcagtgac	aacaaaggcc
	27961	acatcttcaa	tgggtatcac	ctacccccca	ggagatacaa	atgttctcac	atcaacccct
	28021	gccttctctg	acaccagtag	gattcaaaaca	aagtcaaagc	tctcactgac	tctcgggttg
60	28081	atggagacca	gcactctctga	agagaccagc	tctgccacag	aaaaaagcac	tgtcctttct
	28141	agtgtgcccc	ctgggtgctac	tactgaggtc	tccaggacag	aagccatctc	ttctagcaga

	28201	acatccatcc	caggccctgc	tcaatccaca	atgtcatcag	acacctccat	ggaaccatc
	28261	actagaatth	ctacccccct	cacaaggaaa	gaatcaacag	acatggccat	cacccccaaa
	28321	acaggtcctt	ctggggctac	ctcgcagggt	acctttacct	tggactcatc	aagcacagcc
	28381	tcctggccag	gaactcactc	agctacaact	cagagatttc	cacagtcagt	ggtgacaact
5	28441	cctatgagca	gaggtcctga	ggatgtgtca	tggccaagcc	cgctgtctgt	ggaaaaaaac
	28501	agccctccat	cttccctggg	atcttcatct	tcagtaacct	caccttcgcc	actttattcc
	28561	acaccatctg	ggagtageca	ctcctctcct	gtccctgtca	cttctctttt	caoctctatc
	28621	atgatgaagg	ccacagacat	gttggatgca	agtttggaa	ctgagaccac	ttcagctccc
	28681	aatatgaata	tcacctcaga	tgagagtctg	gccacttcta	aagccaccac	ggagacagag
10	28741	gcaattcacg	tttttgaaaa	tacagcagcg	tcccatgtgg	aaaccaccag	tgctacagag
	28801	gaactctatt	cctcttcccc	aggcttctca	gagccaacaa	aagtgatatc	tccagtggtc
	28861	acctcttctc	ctataagaga	caacatgggt	tccacaacaa	tgctgggtc	ctctggcatt
	28921	acaaggattg	agatagagtc	aatgtcatct	ctgaccctcg	gactgaggga	gaccagaacc
	28981	tcccaggaca	tcacctcatc	cacagagaca	agcactgtcc	tttacaagat	gtcctctggg
15	29041	gccactcctg	aggctctccag	gacagaagtt	atgccctcta	gcagaacatc	cattcctggc
	29101	cctgctcagt	ccacaatgtc	actagacatc	tccgatgaag	ttgtcaccag	gctgtctacc
	29161	tctcccatca	tgacagaatc	tgacagaaata	accatcacca	cccaaacagg	ttattctctg
	29221	gctacatccc	aggttaccct	tcccttgggc	acctcaatga	cctttttgtc	agggaccacc
	29281	tcaactatgt	ctcaaggact	ttcacactca	gagatgacca	atcttatgag	caggggtcct
20	29341	gaaagtctgt	catggacgag	cctctcgctt	gtggaaacaa	ctagatcttc	ctcttctctg
	29401	acatcattac	ctctcacgac	ctcactttct	cctgtgtcct	ccacattact	agacagtagc
	29461	ccctcctctc	ctcttctctg	gacttcactt	atcctcccag	gcctgggtga	gactacagaa
	29521	gtgttgata	caagctcaga	gcctaaaacc	agttcatctc	caaatttgag	cagcacctca
	29581	gttgaaatac	cgcccaacct	tgaattcatg	acagatacac	agaaaattca	tccttctca
25	29641	aacacagcgg	tggccaaagt	gaggacctcc	agttctgttc	atgaatctca	ttcctctgtc
	29701	ctagctgact	cagaaacaac	cataaaccata	ccttcaatgg	gtatcacctc	cgctgtggac
	29761	gataccactg	ttttcacatc	aaatcctgcc	ttctctgaga	ctaggaggat	tccgacagag
	29821	ccaacattct	cattgactcc	tggattcagg	gagactagca	cctctgaaga	gaccacctca
	29881	atcacagaaa	caagtgcagt	cctttatgga	gtgcccacta	gtgctactac	tgaagtctcc
30	29941	atgacagaaa	tcatgtcctc	taatagaaca	cacatccctg	actctgatca	gtccacgatg
	30001	tctccagaca	tcatcactga	agtgtatcac	aggctctctt	cctcatccat	gatgtcagaa
	30061	tcaacacaaa	tgaccatcac	cacccaaaaa	agttctcctg	gggctacagc	acagagtact
	30121	cttaccttgg	ccacaacaac	agcccccctg	gcaaggaccc	actcaactgt	tcctcctaga
	30181	tttttacct	cagagatgac	aactcttatg	agtaggagtc	ctgaaaatcc	atcatggaag
35	30241	agctctccct	ttgttgaaaa	aaactagctc	tcactttctc	tggtgtcctt	acctgtcacg
	30301	acctcacctt	ctgtttcttc	cacattaccg	cagagtatcc	cttctctctc	tttttctgtg
	30361	acttcactcc	tcaccccagg	catgggtgaag	actacagaca	caagcacaga	acctggaaac
	30421	agtttatctc	caaattctgag	tggcacctca	gttgaataac	tggctgcctc	tgaagtccac
	30481	acagatacac	agaaaattca	tccttcttca	agcatggcag	tgaccaatgt	gggaaccacc
40	30541	agttctggac	atgaactata	ttcctctgtt	tcaatccact	cggagccatc	caaggctaca
	30601	tacccagtgg	gtactccctc	ttccatgggt	gaaacctcta	tttccacatc	aatgctgtct
	30661	aattttgaga	ccacaggatt	tgggctgag	ccattttctc	atttgacttc	tggatttagg
	30721	aagacaaaac	tgtccctgga	caccagctca	gtcacaccaa	caaatacacc	ttcttctcct
	30781	gggtccactc	accttttaca	gagttccaag	actgatttca	cctcttctgc	aaaaacatca
45	30841	tccccagact	ggcctccagc	ctcacagtat	actgaaattc	cagtggacat	aatcaccccc
	30901	tttaatgctt	ctccatctat	tacggagtcc	actgggataa	cctccttccc	agaaatccagg
	30961	tttactatgt	ctgtaacaga	aagtactcat	catctgagta	cagatttgct	gccttcagct
	31021	gagactatth	ccactggcac	agtgtatgct	tctctatcag	aggccatgac	ttcatttgcc
	31081	accactggag	ttccacgagc	catctcaggt	tcaggtagtc	cattctctag	gacagagtca
50	31141	ggccctgggg	atgctactct	gtccaccatt	gcagagagcc	tgccctcatc	cactctgtg
	31201	ccattctcct	cttcaacctt	cactaccact	gattcttcaa	ccatcccagc	cctccatgag
	31261	ataacttctc	cttcagctac	cccatataga	gtggacacca	gtcttgggac	agagagcagc
	31321	actactgaag	gacgcttggg	tatggctcagt	actttggaca	cttcaagcca	accaggcagg
	31381	acatcttcaa	cacccattht	ggataccaga	atgacagaga	gcgttgagct	gggaacagtg
55	31441	acaagtgtct	atcaagttcc	ttcactctca	acacgggtga	caagaactga	tggcattatg
	31501	gaacacatca	caaaaatacc	caatgaagca	gcacacagag	gtaccataag	accagtcaaa
	31561	ggccctcaga	catccacttc	gcctgocagt	cctaaaggac	tacacacagg	agggacaaaa
	31621	agaatggaga	ccaccaccac	agctttgaag	accaccacca	cagctttgaa	gaccacttcc
	31681	agagccacct	tgaccaccag	tgtctatact	cccactttgg	gaacactgac	tcccctcaat
60	31741	gcatcaaggc	aatggccag	cacaatcctc	acagaaatga	tgatcacaa	cccataatgt
	31801	ttcctgatg	ttccagaaac	gacatcctca	ttggctacca	gcctgggagc	agaaaccagc

	31861	acagctcttc	ccaggacaac	cccatctgtt	ctcaatagag	aatcagagac	cacagcctca
	31921	ctgggtcttc	gttctggggc	agagagaagt	cgggttattc	aaactctaga	tgtttcttct
	31981	agtgagccag	atacaacagc	ttcatgggtt	atccatcctg	cagagacccat	cccaactgtt
	32041	tccaagacaa	cccccaattt	ttccacagt	gaattagaca	ctgtatcttc	cacagccacc
5	32101	agtcattggg	cagacgtcag	ctcagccatt	ccaacaaata	tctcacctag	tgaactagat
	32161	gcaactgacc	cactgggtcac	tatttcgggg	acagatacta	gtacaacatt	cccaactggt
	32221	actaagtccc	cacatgaaac	agagacaaga	accacatggc	tcactcatcc	tcagagagacc
	32281	agctcaacta	ttcccagaac	aatccccaat	ttttctcatc	atgaatcaga	tgccacacct
	32341	tcaatagcca	ccagtccctg	ggcagaaacc	agttcagcta	ttccaattat	gactgtctca
10	32401	cctgggtgag	aagatctggt	gacctcacag	gtcactagtt	ctgggacaga	cagaaatatg
	32461	actattccaa	ctttgactct	ttctcctggt	gaaccaaaga	cgatagcctc	attagtcacc
	32521	catcctgaag	cacagacaag	ttcggccatt	ccaacttcaa	ctatctcgcc	tgctgtatca
	32581	cgggttggtg	cctcaatggt	caccagtttg	gcggcaaaga	caagtacaac	taatcgagct
	32641	ctgacaaact	cccctgggtg	accagctaca	acagtttcat	tggtcacgca	tcctgcacag
15	32701	accagcccaa	cagttccctg	gacaaacttc	atTTTTttcc	atagtaaatc	agacaccaca
	32761	ccttcaatga	ccaccagtca	tggggcagaa	tcaggttcag	ctgttccaac	ttcaactgtt
	32821	tcaactgagg	taccaggagt	agtgacccct	ttggtcacca	gttctagggc	agtgatcagt
	32881	acaactattc	caattctgac	tctttctcct	ggtagaaccc	agaccacacc	ttcaatggcc
	32941	accagtcag	gggaagaagc	cagttctgct	attccaactc	caactgtttc	acctggggta
20	33001	ccaggagtgg	tgacctctct	ggtcactagt	tctagggcag	tgactagtac	aactattcca
	33061	attctgactt	tttctcttgg	tgaaccagag	accacacctt	caatggccac	cagtcattgg
	33121	acagaagctg	gctcagctgt	ttcaactggt	ttacctgagg	taccaggagt	ggtagctctt
	33181	ctgggttgct	gttctagggc	agtaaccagt	acaactcttc	caactctgac	tctttctcct
	33241	ggtagaacag	agaccacacc	ttcaatggcc	accagtcag	gggcagaagc	cagctcaact
25	33301	gttccaactg	tttcaactga	ggtaccagga	gtggtgacct	ctctgggtcac	tagttctagt
	33361	ggagtaaaac	gtacaagtat	ttcaactctg	attctttctc	ctggtgaact	agaaaccaca
	33421	ccttcaatgg	ccaccagtca	tggggcagaa	gccagctcag	ctgttccaac	ttcaactggt
	33481	tcacctgggg	tatcaggagt	ggtgacccct	ctggtcacta	gttccagggc	agtgaccagt
	33541	acaactattc	caattctaac	tctttcttct	agtgagccag	agaccacacc	ttcaatggcc
30	33601	accagtcag	gggtagaagc	cagctcagct	gttctaactg	tttcaactga	ggtaccagga
	33661	atgggtgacct	ctctgggtcac	tagttctaga	gcagtaacca	gtacaactat	ttcaactctg
	33721	actatttctt	ctgatgaacc	agagaccaca	acttcattgg	tcacccattc	tgaggcaaat
	33781	atgatttcag	ccattccaac	tttagctgtc	tcccctactg	tacaagggtc	ggtgacttca
	33841	ctgggtcacta	gttctgggtc	agagaccagt	gcgttttcaa	atctaactgt	tgctcaagt
35	33901	caaccagaga	ccatagactc	atgggtcgct	catcctggga	cagaagcaag	ttctgtgtgt
	33961	ccaactttga	ctgtctccac	tggtgagccg	tttcaaaata	tctcattggt	cacctatcct
	34021	gcagagagta	gctcaactct	tcaccaggaca	acctcaaggt	tttcccacag	tgaattagac
	34081	actatgcctt	ctacagtcac	cagtcctgag	gcagaatcca	gctcagccat	ttcaactact
	34141	attttcacctg	gtataccagg	tgtagctgaca	tcactgggtca	ctagctctgg	gagagacatc
40	34201	agtgaacttt	ttccaacagt	gcctgagtc	ccacatgaat	cagaggccaac	agcctcatgg
	34261	gttactcatc	ctgcagtcac	cagcacaaca	gttcccaggga	caacccttaa	ttattctcat
	34321	agtgaaccag	acaccacacc	atcaatagcc	accagtcctg	gggcagaagc	caacttcagt
	34381	tttccaacaa	taactgtctc	acctgatgta	ccagatatgg	taacctcaca	ggtcactagt
	34441	tctgggacag	acaccagtat	aactattcca	actctgactc	tttcttctgg	tgagccagag
45	34501	accacaacct	catttatcac	ctattctgag	acacacacaa	gttcagccat	ttcaactctc
	34561	cctgtctccc	ctgggtgcac	aaagatgctg	acctcactgg	tcactcagttc	tgggacagac
	34621	agcactacaa	ctttcccaac	actgacggag	accccatatg	aaccagagac	aacagccata
	34681	cagctcattc	atcctgcaga	gaccaacaca	atgggtccca	agacaactcc	caagttttcc
	34741	catagtaagt	cagacaccac	actcccagta	gccatcacca	gtcctggggc	agaagccagt
50	34801	tcagctgttt	caacgacaac	tatctcacct	gatagtgcag	atctggtgac	ctcactgggtc
	34861	cctagtctctg	ggacagacac	cagtacaacc	ttcccaacat	tgagtgcagc	cccatatgaa
	34921	ccagagacta	cagtcacgtg	gctcactcat	cctgcagaaa	ccagcacaac	ggtttctggg
	34981	acaattccca	acttttccca	taggggatca	gacactgcac	cctcaatggt	caccagtcct
	35041	ggagtagaca	cgagggtcagg	tgttccaact	acaacctatc	caccagtagt	accaggggta
55	35101	gtgacctcac	aggtoactag	ttctgcaaca	gacactagta	cagctattcc	aactttgact
	35161	ccttctcctg	gtgaaccaga	gaccacagcc	tcactcagcta	cccatcctgg	gacacagact
	35221	ggcttcactg	ttccaattcg	gactgttccc	tctagtgcag	cagatcaaat	ggcttctcgg
	35281	gtcactcatc	ctccacagac	cagcacacct	gtttccagaa	caacctccag	tttttcccat
	35341	agtagtccag	atgcccaccc	tgtaattggc	accagtccta	ggacagaagc	cagttcagct
60	35401	gtactgacaa	caatctcacc	tggtgcacca	gagatggtga	cttcacagat	cactagtctc
	35461	ggggcagcaa	ccagtcacaac	tgtttccaact	ttgactcatt	ctcctgggtat	gccagagacc

	35521	acagccttat	tgagcaccca	tcccagaaca	gggacaagta	aaacatttcc	tgcttcaact
	35581	gtgtttcctc	aagtatcaga	gaccacagcc	tcactcacca	ttagacctgg	tgacagagact
	35641	agcacagctc	tcccactca	gacaacatcc	tctctcttca	ccctacttgt	aactgggaacc
	35701	agcagagtgg	atctaagtcc	aactgcttca	cctggtggtt	ctgcaaaaac	agccccactt
5	35761	tccacccatc	cagggacaga	gaccagcaca	atgattccaa	cttcaactct	ttcccttggt
	35821	ttactagaga	ctacaggctt	actggccacc	agctcttcag	cagagaccag	cacgagtact
	35881	ctaactctga	ctgtttcccc	tgctgtctct	gggctttcca	gtgcctctat	aacaactgat
	35941	aagcccaaaa	ctgtgacctc	ctggaacaca	gaaacctcac	catctgtaac	ttcagttgga
	36001	cccccagaat	tttccaggac	tgtcacaggc	accactatga	ccttgatacc	atcagagatg
10	36061	ccaacaccac	ctaaaaccag	tcattggaga	ggagtgaagc	caaccactat	cttgagaact
	36121	acaatggttg	aagccactaa	tttagctacc	acaggttcca	gtccactgtg	ggccaagaca
	36181	acaaccacct	tcaatacact	ggctggaagc	ctctttactc	ctctgaccac	acctgggatg
	36241	tccaccttgg	cctctgagag	tgtgacctca	agaacaagtt	ataaccatcg	gtcctggatc
	36301	tccaccacca	gcagttataa	ccgtcggtac	tggacccctg	ccaccagcac	tccagtgaat
15	36361	tctacattct	ccccaggat	tccacatcc	tccatcccca	gctccacagc	agccacagtc
	36421	ccattcatgg	tgccattcac	cctcaacttc	accatcacca	acctgagta	cgaggaggac
	36481	atgcggcacc	ctggttccag	gaagttcaac	gccacagaga	gagaactgca	gggtctgctc
	36541	aaaccttctg	tcaggaatag	cagtcctgga	tacctctatt	caggctgcag	actagcctca
	36601	ctcaggccag	agaaggatag	ctcagccatg	gcagtggatg	ccatctgcac	acatcgccct
20	36661	gacctgaag	acctcggaat	ggacagagag	cgactgtact	gggagctgag	caatctgaca
	36721	aatggcatcc	aggagctggg	ccccacacc	ctggaccgga	acagtcctca	tgtcaatggt
	36781	ttcaccatcc	gaagctctat	gcccaccacc	agcactcctg	ggacctccac	agtggatgtg
	36841	ggaacctcag	ggactccatc	ctccagcccc	agccccacgg	ctgctggccc	tctctgtatg
	36901	ccgtttcccc	tcaacttcac	catcaccaac	ctgcagtacg	aggaggacat	gcgtcgcatg
25	36961	ggctccagga	agttcaacac	catggagagt	gtcctgcagg	gtctgtctaa	gcccttggtc
	37021	aagaacacca	gtgttggccc	tctgtactct	ggctgcagat	tgaccttgtc	caggcccgag
	37081	aaagatgggg	cagccactgg	agtggatgcc	atctgcaccc	accgccttga	ccccaaaagc
	37141	cctggactca	acagggagca	gctgtactgg	gagctaagca	aactgacca	tgacattgaa
	37201	gagctggggc	cctacacctc	ggacaggaac	agtctctatg	tcaatgggtt	caccatcag
30	37261	agctctgtgt	ccaccaccag	cactcctggg	acctccacag	tggatctcag	aacctcaggg
	37321	actccatcct	ccctctccag	ccccacaatt	atggctgctg	gccctctcct	ggtaccattc
	37381	acctcaact	tcaccatcac	caacctgcag	tatggggagg	acatgggtca	ccctggctcc
	37441	aggaagtcca	acaccacaga	gagggtcctg	cagggtctgc	ttggtcccat	attcaagaac
	37501	accagtgttg	gccctctgta	ctctggctgc	agactgacct	ctctcaggtc	tgagaaggat
35	37561	ggagcagcca	ctggagtggg	tgccatctgc	atccatcatc	ttgaccccaa	aagccctgga
	37621	ctcaacagag	agcggctgta	ctgggagctg	agccaactga	ccaatggcat	caaagagctg
	37681	ggcccctaca	ccctggacag	gaacagtctc	tatgtcaatg	gtttcaccca	ctggacctct
	37741	tgccccacca	ccagcactcc	tgggacctcc	acagtggacc	ttggaacctc	agggactcca
	37801	ttctccctcc	caagccccgc	aactgctggc	cctctcctgg	tgctgttcac	cctcaacttc
40	37861	accatcacca	acctgaagta	tgaggaggac	atgcatcgcc	ctggctccag	gaagtccaac
	37921	accactgaga	gggtcctgca	gactctgctt	ggctcctatg	tcaagaacac	cagtggtggc
	37981	cttctgtact	ctggctgcag	actgaccttg	ctcagggtccg	agaaggatgg	agcagccact
	38041	ggagtggatg	ccatctgcac	ccacctcttt	gaccccaaaa	gccctggact	ggacagagag
	38101	cagctatact	gggagctgag	ccagctgacc	aatggcatca	aagagctggg	cccctacacc
45	38161	ctggacagga	acagtctcta	tgtcaatggt	ttcaccattt	ggatccctgt	gcccaccagc
	38221	agcactcctg	ggacctccac	agtggaacctt	gggtcaggga	ctccatccct	cctccccage
	38281	cccacagctg	ctggccctct	cctggtgcca	ttcaccctca	acttcacctc	caccaacctg
	38341	cagtacgagg	aggacatgca	tcaccaggcc	tccaggaagt	tcaacaccac	ggagcgggtc
	38401	ctgcagggtc	tgcttgggtc	catgttcaag	aacaccagtg	tcggccttct	gtactctggc
50	38461	tgccagactga	ccttgctcag	gtccgagaag	gatggagcag	ccactggagt	ggatgccatc
	38521	tgacccacc	gtcttgaccc	caaaagccct	ggagtggaca	gggagcagct	atactgggag
	38581	ctgagccagc	tgaccaatgg	catcaaagag	ctgggtccct	acacctgga	cagaacagct
	38641	ctctatgtca	atggtttcac	ccatcagacc	tctgcgcccc	acaccagcac	tcctgggacc
	38701	tccacagtgg	accttgggac	ctcagggact	ccatcctccc	tccccagccc	tacatcngct
55	38761	ggccctctcc	tggtnccttt	cacctccaac	ttcaccatca	ccaacctgca	gtaccgaggag
	38821	gacatgcggc	accnngntc	caggaaagttc	aacaccacng	agagggtnct	gcagggtctg
	38881	ctnaagcccc	tnttcaagag	caccagtgtt	ggccctctgt	actctggctg	cagactgacc
	38941	ttgctcaggt	ccgagaagga	tggagcagcc	actggagtgg	atgccatctg	caccacacct
	39001	cttgacccca	aaagccctgg	agtggacagg	gagcagctat	actgggagct	gagccagctg
60	39061	accaatggca	tcaaagagct	gggtccctac	acctgggaca	gaaacagctc	ctatgtcaat
	39121	ggttttcccc	atcagacctc	tgccgccaac	accagcactc	ctgggacctc	cacagtggac

5 39181 cttgggacct caggggactcc atcctccctc cccagcccta catctgctgg ccctctcctg
39241 gtgccattca ccctcaactt caccatcacc aacctgcagt acgaggagga catgcatcac
39301 ccaggctcca ggaagttcaa caccacggag cgggtcctgc agggctctgct tgggtcccatg
39361 ttcaagaaca ccagtgtcgg ccttctgtac tctggctgca gactgacctt gctcaggcct
39421 gagaagaatg gggcagccac tgggaatggat gccatctgca gccaccgtct tgaccccaaa
39481 agccctggac tcaacagaga gcagctgtac tgggagctga gccagctgac ccattggcatc
39541 aaagagctgg gcccctacac cctggacagg aacagtctct atgtcaatgg tttcaccat
39601 cggagctctg tggcccccac cagcactcct gggacctcca cagtggacct tgggacctca
39661 gggactccat cctccctccc cagcccccaca acagctgttc ctctcctggt gccgttcacc
10 39721 ctcaacttta ccataccaa tctgcagtat ggggaggaca tgcgtcacc tggctccagg
39781 aagttcaaca ccacagagag ggtcctgcag ggtctgcttg gtccctgtt caagaactcc
39841 agtgtcggcc ctctgtactc tggctgcaga ctgatctctc tcaggctctga gaaggatggg
39901 gcagccactg gagtggatgc catctgcacc caccacctta accctcaaag ccttggactg
39961 gacagggagc agctgtactg gcagctgagc cagatgacca atggcatcaa agagctgggc
15 40021 ccctacaccc tggaccggaa cagttctctac gtcaatggtt tccccatcg gagctctggg
40081 ctcaccacca gcactccttg gacttccaca gttgaccttg gaacctcagg gactccatcc
40141 cccgtcccca gcccccacaac tgetggccct ctctggtgc cattcaccct caacttcacc
40201 atcaccaacc tgcagtatga ggaggacatg catcgccctg gatctaggaa gttcaacacc
20 40261 acagagaggg tctgcaggg tctgcttagt cccattttca agaactccag tgggtggccct
40321 ctgtactctg gctgcagact gacctctctc agggcccgaga aggatggggc gactccatga
40381 atggatgctg tctgcctcta ccacctaat cccaaaagac ctggactgga cagagagcag
40441 ctgtactggg agctaagcca gctgaccac aacatcactg agctggggcc ctacagcctg
40501 gacagggaca gtctctatgt caatggtttc acccatcaga actctgtgcc caccaccagt
40561 actcctggga cctccacagt gtactgggca accactggga ctccatcctc cttccccggc
25 40621 cacacagagc ctggccctct cctgatacca ttacttttca actttaccat caccacactg
40681 cattatgagg aaaacatgca acaccctggt tccaggaaat tcaacaccac ggagagggtt
40741 ctgcaggggtc tgctcaagcc ctgttcaag aacaccagtg ttggccctct gtactctggc
40801 tgcagactga cctctctcag gcccgagaag gatggggcag caactggaat ggtatgctgc
30 40861 tgcctctacc accctaatac caaaagacct gggctggaca gagagcagct gtactgggag
40921 ctaagccagc tgaccacaa catcactgag ctgggcccct acagcctgga cagggacagt
40981 ctctatgtca atggtttcac ccatcagaac tctgtgccca ccaccagtac tctgggacc
41041 tccacagtgt actgggcaac cactgggact ccatcctcct tccccggcca cacagagcct
41101 ggccctctcc tgataccatt cactttcaac tttaccatca ccaacctgca ttatgaggaa
35 41161 aacatgcaac accctggttc cagggaagttc aacaccacgg agagggttct gcaagggtctg
41221 ctcaagccct tgttcaagaa caccagtgtt ggccctctgt actctggctg cagactgacc
41281 ttgctcagac ctgagaagca tgaggcagcc actggagtggt acaccatctg taccaccgc
41341 gttgatccca tgcgacctgg actggacagg gagcggctat actgggagct gagccagctg
41401 accaacagca ttaccgaact gggacctac accctggaca gggacagctc ctatgtcaat
41461 ggcttcaacc ctgcggagctc tgtgccaacc accagcactc ctgggacctc cacagtgcac
40 41521 ctggcaacct ctgggactcc atcctccctg cctggccaca cagccctgt cctctctctg
41581 ataccattca ccctcaactt taccatcacc aacctgcatt atgaggaaaa catgcaacac
41641 cctggttcca ggaagttcaa caccacggag agggttctgc agggctctg caagcccttg
41701 ttcaagaaca ccagtgttg ccctctgtac tctggctgca gactgacctt gctcagacct
41761 gagaagcatg aggcagccac tggagtggac accatctgta cccaccgctg tgatcccatc
45 41821 ggacctggac tgnacagnga gcngctntac tgggagctna gccanctgac caannncatc
41881 nnnagactgg gmcctacac cctggacagg nacagtctct atgtcaatgg tttcaccat
41941 cnganctctg ngcccaccac cagcactcct gggacctcca cagtgnacnt nggnacctcn
42001 gggactccat cctccntccc cngccncaca tctgctggcc ctctcctggt gccattcacc
42061 ctcaacttca ccataccaa cctgcagtac gaggaggaca tgcatacccc aggtccagg
50 42121 aagttcaaca ccacggagcg ggtcctgcag ggtctgcttg gtcccatggt caagaacacc
42181 agtgtcggcc ttctgtactc tggctgcaga ctgaccttgc tcaggcctga gaagaatggg
42241 gcagccactg gaatggatgc catctgcagc cacogtcttg accccaaaag ccttggactc
42301 gacagagagc agctgtactg ggagctgagc cagctgacct atggcatcaa agagctgggc
42361 ccctacaccc tggacaggaa cagtctctat gtcaatggtt tccccatcg gagctctgtg
55 42421 gccccacca gactcctgg gactccaca gtggaccttg ggacctcagg gactccatcc
42481 tccctcccca gccccacaac agctgttctt ctctggtgc cgttaccct caactttacc
42541 atcaccaatc tgcagtatgg ggaggacatg cgtcacctg gctccaggaa gttcaacacc
42601 acagagaggg tctgcaggg tctgcttggt ccttgttca agaactccag tgtcggccct
42661 ctgtactctg gctgcagact gatctctc aggtctgaga aggatggggc agccactgga
60 42721 gtggatgcca tctgcaccca ccacctaac cctcaaagcc ctggactgga cagggagcag
42781 ctgtactggc agctgagcca gatgaccaat ggcataaag agctggggcc ctacaccctg

	42841	gaccggaaca	gtctctacgt	caatgggttc	acccatcgga	gctctgggct	caccaccagc
	42901	actccttgga	cttccacagt	tgaccttgga	acctcagggg	ctccatcccc	cgtccccagc
	42961	cccacaactg	ctggccctct	cctgggtgcca	ttcacccctaa	acttcacccat	caccaacctg
	43021	cagtatgagg	aggacatgca	tcgccctgga	tctaggaagt	tcaacgccac	agagagggtc
5	43081	ctgcagggtc	tgcttagtcc	catattcaag	aactccagtg	ttggccctct	gtactctggc
	43141	tgccagactga	cctctctcag	gcccggagaag	gatggggcag	caactggaat	ggatgctgtc
	43201	tgccctctacc	accctaatcc	caaaagacct	ggactggaca	gagagcagct	gtactgggag
	43261	ctaagccagc	tgaccaccaa	catcactgag	ctggggccct	acagcctgga	cagggacagt
	43321	ctctatgtca	atgggtttcac	ccatcagagc	tctatgacga	ccaccagaac	tctgtatacc
10	43381	tccacaatgc	acctggcaac	ctcgagaact	ccagcctccc	tgtctggacc	tacgacggcc
	43441	agccctctcc	tggtgctatt	cacaatcaac	tgacccatca	ccaacctgca	gtacgaggag
	43501	gacatgctc	gcactggctc	caggaagtcc	aacacccatgg	agagtgtcct	gcagggtctg
	43561	ctcaagccct	tggttcaaga	caccagtgtt	ggccctctgt	actctggctg	cagattgacc
	43621	ttgctcaggc	ccaagaaaga	tggggcagcc	actggagtg	atgccatctg	cacccaccgc
15	43681	cttgacccca	aaagccctgg	actcaacagg	gagcagctgt	actgggagct	aagcaaaactg
	43741	accaatgaca	ttgaagagct	gggcccctac	acctgggaca	ggaacagctc	ctatgtcaat
	43801	ggtttcaccc	atcagagctc	tgtgtccacc	accagcactc	ctgggacctc	cacagtggat
	43861	ctcagaacct	cagggactcc	atcctccctc	tccagcccca	caattatgnc	nnctgnccct
	43921	ctcctgntnc	cnttccacct	caacttnacc	atcaccaacc	tgcantangn	ggannacatg
20	43981	cnncnccng	gntccaggaa	gttcaacacc	acngagagg	tcctacaggg	tctgtctcagg
	44041	cccttggtca	agaacaccag	tgtcagctct	ctgtactctg	gttgccagct	gaccttgctc
	44101	aggcctgaga	aggatggggc	agccaccaga	gtggatgctg	cctgcaccta	ccgccttgat
	44161	cccaaaagcc	ctggactgga	cagagagcaa	ctatactggg	agctgagcca	gctaaccac
	44221	agcatcactg	agctgggacc	ctacaccctg	gacaggggtca	gtctctatgt	caatggcttc
25	44281	aacctctgga	gctctgtgcc	aaccaccagc	actcctggga	cctccacagt	gcactgggca
	44341	acctctggga	ctccatcctc	cctgcctggc	cacacancnn	ctgnccctct	cctgntnccn
	44401	ttcacentca	acttnaccat	caccaacctg	cantangngg	annacatgcn	nncccnnggn
	44461	tccaggaagt	tcaacaccac	ngagagggtt	ctgcagggtc	tgctcaaacc	cttgttcagg
	44521	aatagcagtc	tggaataacct	ctattcaggc	tgccagactag	cctcaactcag	gccagagaag
30	44581	gatagctcag	ccatggcagc	ggatgccatc	tgccacacac	gccctgaccc	tgaagacctc
	44641	ggactggaca	gagagcgact	gtactgggag	ctgagcaatc	tgcaaaatgg	catccaggag
	44701	ctggggccct	acaccctgga	ccggaacagt	ctctacgtca	atgggtttcac	ccatcggagc
	44761	tctgggctca	ccaccagcac	tccttggtct	tccacagttg	accttggaac	ctcagggact
	44821	ccatcccccg	tccccagccc	cacaactgct	ggccctctcc	tggtgccatt	cacctcaac
35	44881	ttcacatca	ccaacctgca	gtatgaggag	gacatgcac	gccctggttc	caggagggtc
	44941	aacaccacgg	agagggttct	gcagggtctg	ctcacgccct	tggtcaagaa	caccagtgtt
	45001	ggccctctgt	actctggctg	cagactgacc	tgctcagac	ctgagaagca	agaggcagcc
	45061	actggagtg	acaccatctg	taccacccgc	gttgatccca	tcggacctgg	actggacaga
	45121	gagcggctat	actgggagct	gagccagctg	accaacagca	tcacagagct	gggaccttac
40	45181	acctgggata	gggacagtct	ctatgtcaat	ggcttcaacc	cttgagctc	tgtgcccaacc
	45241	accagcactc	ctgggacctc	cacagtgcac	ctggcaacct	ctgggactcc	atcctccctg
	45301	cctggccaca	cagccctgtg	ccctctcttg	ataccattca	ccctcaactt	taccatcacc
	45361	gacctgcatt	atgaagaaaa	catgcaaac	cctgggtcca	ggaagttcaa	caccacggag
	45421	agggttctgc	agggtctgct	caagcccttg	ttcaagagca	ccagcgttgg	ccctctgtac
45	45481	tctggctgca	gactgacctt	gctcagacct	gagaaacatg	gggcagccac	tggagtggac
	45541	gccatctgca	ccctccgctc	tgatcccact	ggctctggac	tggaacagaga	gcggctatac
	45601	tgggagctga	gccagctgac	caacagcgtt	acagagctgg	gccccctacac	cctggacagg
	45661	gacagtctct	atgtcaatgg	cttcacccat	cggagctctg	tgccaaccac	cagtattcct
	45721	gggacctctg	cagtgcacct	ggaaacctct	gggactccag	cctccctccc	tggccacaca
50	45781	gccccctggc	ctctcctggt	gcatttcacc	ctcaacttca	ctatcaccaa	cctgcagtat
	45841	gaggaggaca	tgctgcaccc	tggttccagg	aagttcagca	ccacggagag	agtccctgag
	45901	ggtctgctca	agcccttggt	caagaacacc	agtgtcagct	ctctgtactc	tggttgacga
	45961	ctgaccttgc	tcaggccctga	gaaggatggg	gcagccacca	gagtggatgc	tgtctgcacc
	46021	catcgctctg	accccaaaaag	ccctggactg	gacagagagc	ggctgtactg	gaagctgagc
55	46081	cagctgaccc	acggcatcac	tgagctgggc	ccctacaccc	tggaacaggca	cagctctcat
	46141	gtcaatgggt	tcacccatca	gagctctatg	acgaccacca	gaactcctga	tacctccaca
	46201	atgcacctgg	caacctcgag	aactccagcc	tcctgtctg	gacctacgac	cgccagccct
	46261	ctcctgggtg	tattcacaat	taacttcacc	atcactaac	tgcggtatga	ggagaacatg
	46321	catcacccctg	gctctagaaa	gtttaacacc	acggagagag	tccttcagg	tctgtcagg
60	46381	cctgtgttca	agaacaccag	tggtggccct	ctgtactctg	gctgcagact	gaccacgctc
	46441	aggcccaaga	aggatggggc	agccacaaaa	gtggatgcca	tctgcaccta	ccgccttgat

	46501	cccaaaagcc	ctggactgga	cagagagcag	ctatactggg	agctgagcca	gctaaccacc
	46561	agcatcactg	agctggggccc	ctacaccag	gacaggagaca	gtctctatgt	caatggcttc
	46621	acccatcgga	gctctgtgcc	aaccaccagt	attcctggga	cctctgcagt	gcacctggaa
	46681	acctctggga	ctccagcctc	cctccctggc	cacacagccc	ctggccctct	cctgggtgcca
5	46741	ttcaccctca	acttcaactat	caccaacctg	cagtatgagg	aggacatgcg	tcaccctggt
	46801	tccaggaagt	tcaacaccac	ggagagagtc	ctgcagggtc	tgctcaagcc	cttggtcaag
	46861	agcaccagt	ttggccctct	gtactctggc	tgcagactga	ccttgctcag	gcctgaaaaa
	46921	cgtggggcag	ccaccggcgt	ggacaccatc	tgcactcacc	gccttgacc	tcctaaaccca
	46981	ggactggaca	gagagcagct	atactgggag	ctgagcaaac	tgaccctggt	catcatcgag
10	47041	ctggggccct	acctcctgga	cagaggcagt	ctctatgtca	atggtttcac	ccatcgagcc
	47101	tctgtgccc	ccaccagcac	tcctggggacc	tccacagtgg	accttggaac	ctcagggact
	47161	ccattctccc	tcccaagccc	cgancnnct	gnccctctcc	tgntnccntt	caccntcaac
	47221	ttnacatca	ccaacctgca	ntangnggan	nacatgcnnc	nccnnggntc	cagggaagttc
	47281	aacaccacng	agagggtcct	gcagactctg	cttgggtccta	tggtcaagaa	caccagtgtt
15	47341	ggccttctgt	actctggctg	cagactgacc	ttgctcaggt	ccgagaagga	tggaagagcc
	47401	actggagtgg	atgccatctg	cacccaccgt	cttgacccca	aaagccctgg	agtggacagg
	47461	gagcaactat	actgggagct	gagccagctg	accaatggca	ttaaagaact	gggcccctac
	47521	accctggaca	ggaacagtct	ctatgtcaat	gggttcaccc	attggatccc	tggtcccacc
	47581	agcagcactc	ctgggacctc	cacagtggac	cttgggtcag	ggactccatc	ctccctcccc
20	47641	agccccacaa	ctgctggccc	tctcctgggt	ccgttcaccc	tcaacttcac	catcaccaac
	47701	ctgaagtacg	aggaggacat	gcattgccct	ggctccagga	agttcaacac	cacagagaga
	47761	gtcctgcaga	gtctgcttgg	tccatgttcc	aagaacacca	gtgttggtccc	tctgtactct
	47821	ggctgcagac	tgaccttgct	caggtccgag	aaggatggag	cagccactgg	agtggatgcc
	47881	atctgcaccc	acogtcttga	cccacaaagc	cctggagtgg	acagggagca	gctatactgg
25	47941	gagctgagcc	agctgaccaa	tggtcatcaa	gagctgggtc	cctacaccct	ggacagaaac
	48001	agtctctatg	tcaatgggtt	caccatcag	acctctgcgc	ccaacaccag	cactcctggg
	48061	acctccacag	tggaacctgg	gacctcaggg	actccatcct	ccctccccag	ccctacancn
	48121	nctgncccto	tctgntncc	nttcaacctc	aacttnacca	tcaccaacct	gcantangng
	48181	gannacatgc	nncncccnng	ntccaggaag	ttcaacacca	cngagnngt	nctgcagggt
30	48241	ctgctnnnnc	ccntnttcaa	gaacnccagt	gtnggcnctc	tgactctggt	ctgcagactg
	48301	acctnnctca	ggncngagaa	gnatggngca	gccactggan	tggtatgccat	ctgcancac
	48361	cnnctnnanc	ccaaaagnc	tggaactgnac	agnagcngc	tnactggga	gctnagccan
	48421	ctgaccaann	ncatcnnga	gctgggnccc	tacacctgg	acaggnacag	tctctatgtc
	48481	aatgggttca	ccattgggat	ccctgtgccc	accagcagca	ctcctgggac	ctccacagtg
35	48541	gaccttgggt	cagggactcc	atcctccctc	cccagcccca	caactgctgg	ccctctcctg
	48601	gtgccgttca	ccctcaactt	caccatcacc	aaactgaagt	acgaggagga	catgcatgac
	48661	cctgggtcca	ggaagtcca	caccacagag	agagtctgc	agagtctgct	tttcacctatg
	48721	ttcaagaaca	ccagtgttgg	ccctctgtac	tctgggtgca	gactgaacctc	gctcagggtc
	48781	gagaaggatg	gagcagccac	tggaagtggat	gccatctgca	cccacctgtg	tgaccccaaa
40	48841	agccctggag	tggaacagga	gcagctatac	tggaagctga	gccagctgac	caatggcatc
	48901	aaagagctgg	gtccctacac	cctggacaga	aacagtctct	atgtcaatgg	tttcacctat
	48961	cagacctctg	cgcccaacac	cagcactcct	gggacctcca	cagtgnacnt	nggnacctcn
	49021	gggactccat	cctccntccc	cngccncaca	tctgctggcc	ctcctcctgt	gccattcacc
	49081	ctcaacttca	ccatcaccaa	cctgcagtac	gaggaggaca	tgcatcacc	aggctccagg
45	49141	aagttcaaca	ccacggagcg	ggtctgctg	ggtctgctg	gtcccatgtt	caagaacacc
	49201	agtgtcggtc	ttctgtactc	tggtgtcaga	ctgaccttgc	tcaggcctga	gaagaatggg
	49261	gcaaccactg	gaatggatgc	catctgcacc	caccgtcttg	accccaaaag	ccctggactg
	49321	nacagngagc	ngctntactg	ggagctnagc	canctgacca	annncatcnn	ngagctgggn
	49381	ccctacaccc	tggaacagga	cagtctctat	gtcaatggtt	tcaccatcnn	ganctctgng
50	49441	cccaccacca	gcactcctgg	gacctccaca	gtgnacntng	gnacctcngg	gactccatcc
	49501	tcctccccc	gccncacanc	nnctgnccct	ctcctgntnc	cnttcaacnt	caacttnacc
	49561	atcaccaacc	tgcantangn	ggannacatg	cnncccccng	gntccaggaa	gttcaacacc
	49621	acngagaggg	ttctgcaggg	tctgctcaaa	cccttggtca	ggaatagcag	tctggaatac
55	49681	ctctattcag	gctgcagact	agcctcactc	aggccagaga	aggatagctc	agccatggca
	49741	gtggatgcca	tctgcacaca	tcgcccgtgac	cctgaagacc	tcggactgga	cagagagcga
	49801	ctgtactggg	agctgagcaa	tctgacaaat	ggcatccagg	agctggggccc	ctacaccttg
	49861	gaccggaaaca	gtctctatgt	caatgggtttc	acccatcgaa	gctctatgcc	caccaccagc
	49921	actcctggga	cctccacagt	ggatgtggga	acctcagggg	ctccatcctc	cagccccagc
	49981	cccacgactg	ctggccctct	ctcgatacca	ttcaccctca	acttccacct	cacccaacctg
60	50041	cagtatgggg	aggacatggg	tcacctgggc	tccaggaagt	tcaacaccac	agagagggtc
	50101	ctgcagggtc	tgcttgggtc	catattcaag	aacaccagtg	ttggccctct	gtactctggc

50161 tgcagactga cctctctcag gtctgagaag gatggagcag ccactggagt ggatgccatc
 50221 tgcattccatc atcttgaccc caaaagccct ggactcaaca gagagcggct gtactgggag
 50281 ctgagccaac tgaccaatgg catcaaagag ctgggcccct acaccctgga caggaaacagt
 50341 ctctatgtca atggtttcac ccacgggacc tctgtgcccc ccaccagcac tcctggggacc
 50401 tccacagtgg accttggaac ctgagggact ccattctccc tcccaagccc cgcaactgct
 50461 ggccctctcc tgggtctgtt caccctcaac ttcaccatca ccaacctgaa gtatgaggag
 50521 gacatgcac gccctggctc caggaaagttc aacaccactg agaggggtct ctatgtcaat
 50581 cttgggtccta tgttcaagaa caccagtgtt ggccctctgt actctggctg cagactgacc
 50641 ttgctcaggt ccgagaagga tggagcagcc actggagtggt atgccatctg caccaccctg
 50701 cttgacccca aaagccctgg actgnacagn gagcngctnt actgggagct nagccanctg
 50761 accaannnca tcnnngagct gggnccctac accctggaca ggnacagtct ctatgtcaat
 50821 ggtttcaccc atcnganctc tnggccacc accagcactc ctgggacctc cacagtgnac
 50881 ntnggnacct cngggactcc atcctcctc cccngccnca caccnnctgn ccctctcctg
 50941 ntncctntca ccntcaactt naccatcacc aacctgcant annggganna catgcnncnc
 51001 ccnggntcca ggaagttaa caccacngag agagtctctc agggctctgt caggcctgtg
 51061 ttcaagaaca ccagtgttgg cctctgttac tctggctgca gactgacctt gctcaggccc
 51121 aagaaggatg gggcagccac caaagtggat gccatctgca cctaccgccc tgatcccaaa
 51181 agccctggac tggacagaga gcagctatac tgggagctga gccagctaac ccacagcatc
 51241 actgagctgg gcccctacac ccaggacagg gacagtctct atgtcaatgg cttcaccact
 51301 cggagctctg tgcccaaccac cagtattcct gggacctctg cagtgcacct ggaaaccact
 51361 gggactccat cctccttccc cgccacaca gagcctggcc ctctcctgat accattcact
 51421 ttcaacttta ccacaccaa cctgcgttat gaggaaaaca tgcaacaccc tgggtccagg
 51481 aagttcaaca ccacggagag ggttctgcag ggtctgtcga cgcccttgtt caagaacacc
 51541 agtgttggcc ctctgtactc tggctgcaga ctgacctgca tcagacctga gaagcaggag
 51601 gcagccactg gactggacac catctgtacc caccgctgtg atcccatcgg acctggactg
 51661 gacagagagc ggctatactg ggagctgagc cagctgacca acagcatcac agagctggga
 51721 ccctacaccc tggataggga cagtctctat gtogattggct tcaacccttg gagctctgtg
 51781 ccaaccacca gactcctgg gacctccaca gtgcacctgg caacctcttg cactccatcc
 51841 ccctgctctg gccacacagc cctgtctcct ctcttgatac cattcaccct caactttacc
 51901 atcaccgacc tgcattatga agaaaacatg caacacctg gttccaggaa gttcaacacc
 51961 acggagaggg ttctgcaggg tctgtcgaag cccttgttca agagcaccag cgttggccct
 52021 ctgtactctg gctgcagact gaccttgctc agacctgaga aacatggggc agccactgga
 52081 gtggagccca tctgcacctt ccgcttgat cccactgggt ctggactgga cagagagcgg
 52141 ctatactggg agctgagcca gctgaccaac agcatcacag agctgggacc ctacacctg
 52201 gatagggaca gtctctatgt caatggcttc aaccttgga gctctgtgcc aaccaccagc
 52261 actcctggga cctccacagt gcacctggca acctctggga ctccatctc cctgctggc
 52321 cacacaactg ctggccctct cctgggtgcg ttcacctca acttcacct caccacactg
 52381 aagtaggagg aggacatgca ttgcccctggc tccaggaaagt tcaacaccac agagagagtc
 52441 ctgcagagtc tgcattggtc catgttcaag aacaccagtg ttggccctct gtactctggc
 52501 tgcagactga ccttgctcag gtccgagaag gatggagcag ccactggagt ggatgccatc
 52561 tgcaccaccc gtcttgacc caaaagccct ggactgnaca gngagcngct ntactgggag
 52621 ctnagccanc tgaccaannn catcnnngag ctgggncctt acacctgga caggnacagt
 52681 ctctatgtca atggtttcac ccacnganc tctgngccca ccaccagcac tcctggggacc
 52741 tccacagtgn acntnggnac ctnggggact ccactcctcn tccccngcn caccannct
 52801 gncctctccc tgnntnctt caccntcaac ttnaccatca ccaacctgca ntangnggan
 52861 nacatgcnnn ncccnggntc caggaaagtcc aacaccacng agngngtntc gcagggtctg
 52921 ctnnnncccn tnttcaagaa cncagtgtn ggccntctgt actctggctg cagactgacc
 52981 tnnctcaggn cngagaagna tggngcagcc actggantgg atgccatctg caccaccnn
 53041 cntnanccca aaagncctgg actgnacagn gagcngctnt actgggagct nagccanctg
 53101 accaacagca tcacagagct gggaccttac accctggata gggacagtct ctatgtcaat
 53161 ggtttcaccc atcgaagctc tatgcccacc accagtattc ctgggacctc tgcagtgcac
 53221 ctggaaacct ctgggactcc agcctccctc cctggccaca cagccctgg ccctctcctg
 53281 gtgcaattca ccctcaactt cactatcacc aacctgcagt atgaggagga catgctgac
 53341 cctgggtcca ggaagttaa caccacggag agagtctgtc agggctctgt caagcccttg
 53401 ttcaagagca ccagtgttgg cctctgttac tctggctgca gactgacctt gctcaggcct
 53461 gaaaaacgtg gggcagccac cggcgtggac accatctgca ctacccgct tgaccctcta
 53521 aacctggac tgnacagnga gncgctntac tgggagctna gccanctgac caannncatc
 53581 nnnagctgg gncctacac cctggacagg nacagtctct atgtcaatgg tttcaccat
 53641 cnganctctg ngcccaccac cagcactcct gggacctcca cagtgnacnt nggnacctcn
 53701 gggactccat cctcctccc cngccncaca cennctgncc ctctcctgnt nccnttcacc
 53761 ntcaacttna ccacaccaa cctgcantn gnggannaca tgcnnccccc nggntccagg

	53821	aagttcaaca	ccacngagng	ngtntctgcag	ggctctgetnn	nncccntntt	caagaacncc
	53881	agtgtnggcc	ntctgtactc	tggctgcaga	ctgacctnnc	tcaggncnga	gaagnatgg
	53941	gcagccactg	gantggatgc	catctgcanc	caccnnontn	ancccaaaag	ncctggactg
	54001	nacagngagc	ngctntactg	ggagctnagc	canctgacca	annncatcnn	ngagctgggn
5	54061	ccctacaccc	tggacaggna	cagtctctat	gtcaatgggt	ttcaccctcg	gagctctgtg
	54121	ccaaccacca	gcactcctgg	gacctccaca	gtgcacctgg	caacctctgg	gactccatcc
	54181	tccttgccctg	gccacacagc	ccctgtccct	ctcttgatac	cattcacctc	caactttacc
	54241	atcaccaacc	tgcattatga	agaaaacatg	caacaccctg	gttccaggaa	gttcaacacc
	54301	acggagcggg	tcctgcaggg	tctgtctggg	cccattgttca	agaacacaa	gttcggcctt
10	54361	ctgtactctg	gctgcagact	gaccttgctc	aggcctgaga	agaatggggc	agccactgga
	54421	atggatgcca	tctgcagcca	ccgtcttgac	cccaaaagcc	ctggactgna	cagnagcng
	54481	ctntactggg	agctnagcca	nctgaccaan	nncatcnng	agctgggncc	ctacaccctg
	54541	gacaggnaca	gtctctatgt	caatgggttc	acccatcnga	nctctgngcc	caccaccagc
	54601	actcctggga	cctccacagt	gnacntnggn	acctcnggga	ctccatcctc	ontccccngc
15	54661	cncacancnn	ctgnccctct	ctgntnccn	ttcacntca	acttnaccat	caccaacctg
	54721	cantangngg	annacatgcn	ncncccnngn	tccaggaaagt	tcaacaccac	ngagnngtn
	54781	ctgcagggtc	tgtctnnncc	cntnttcaag	aacnccagt	tnggcntct	gtactctggc
	54841	tgcagactga	cctnnctcag	gncngagaag	natggngcag	ccactggant	ggatgccatc
	54901	tgcancaccc	nnentnancc	caaaagncct	ggactgnaca	gngagcngct	ntactgggag
20	54961	ctnagccanc	tgaccaannn	catcnngag	ctgggnccct	acaccctgga	caggnacagt
	55021	ctctatgtca	atggtttcac	ccatcagaac	tctgtgcccc	ccaccagtac	tcctgggacc
	55081	tccacagtgt	actgggcaac	cactgggact	ccatcctcct	tccccggcca	cacagagcct
	55141	ggccctctcc	tgataccatt	cactttcaac	tttaccatca	ccaacctgca	ttatgaggaa
	55201	aacatgcaac	accctgttcc	caggaaagttc	aacaccacgg	agagggttct	gcagggtctg
25	55261	ctcacgccct	tgttcaagaa	caccagtgtt	ggccctctgt	actctggctg	cagactgacc
	55321	ttgctcagac	ctgagaagca	ggagggcagcc	actggagtgg	acaccatctg	taccaccgac
	55381	ggtgatccca	tgggacctgg	actgnacagn	gagcngctnt	actgggagct	nagccanctg
	55441	accaannnca	ctnnngagct	gggnccctac	accctggaca	ggnacagctc	ctatgtcaat
	55501	ggttttaccc	atcngancct	tngnccccc	accagcactc	ctgggacctc	cacagtgnac
30	55561	ntnggnacct	cngggactcc	atcctccntc	cccngccnca	cancnctgn	ccctctcctg
	55621	ntnccnttca	ccntcaactt	naccatcacc	aacctgcant	angngganna	catgcnncnc
	55681	ccnggntcca	ggaagttcaa	caccacmgag	ngngtntctg	agggtctgct	nnnncccntn
	55741	ttcaagaacn	ccagtgtngg	ccntctgtac	tctggctgca	gactgacctn	ncacagncn
35	55801	gagaagnatg	gngcagccac	tggantggat	gccatctgca	nccaccnncn	tnancccaaa
	55861	agncttgga	tnacagnga	gngctntac	tgggagctna	gccanctgac	caannncatc
	55921	nnngagctgg	gnccctacac	cctggacagg	nacagtctct	atgtcaatgg	tttaccatct
	55981	cggagctctg	tgccaaccac	cagcagtcct	gggacctcca	cagtgcacct	ggcaacctct
	56041	gggactccat	cctccctgcc	tggccacaca	gcccctgtcc	ctctcttgat	accattcacc
40	56101	ctcaacttta	ccatcaccaa	cctgcattat	gaagaaacaa	tgcaacaccc	tggttccagg
	56161	aagttcaaca	ccacggagag	ggttctgcag	ggctctgetca	agccctgtgt	caagagcacc
	56221	agtgttgcc	ctctgtactc	tggctgcaga	ctgaccttgc	tcagacatgg	gaaacatggg
	56281	gcagccactg	gagtggacgc	catctgcacc	ctccgccttg	atccacttgg	tcctggactg
	56341	nacagngagc	ngctntactg	ggagctnagc	canctgacca	annncatcnn	ngagctgggn
	56401	ccctacaccc	tggacaggna	cagtctctat	gtcaatgggt	tcaccatcnn	ganctctgng
45	56461	cccaccacca	gcactcctgg	gacctccaca	gtgnacntng	gnacctcngg	gactccatcc
	56521	tccttccccc	gccnccacnc	nnctgnccct	ctcctgntnc	cnttaccnt	caacttnacc
	56581	atcaccaacc	tgcantangn	ggannacatg	cnncccccng	gntccaggaa	gttcaacacc
	56641	acngagngng	tnctgcaggg	tctgctnnnn	cccntnttca	agaacnccag	tgtnggcnt
	56701	ctgtactctg	gctgcagact	gacctnnctc	aggncngaga	agnatggngc	agccactgga
50	56761	ntggatgcca	tctgcancca	ccnccntnan	cccaaaagnc	ctggactgna	cagnagcng
	56821	ctntactggg	agctnagcca	nctgaccaan	nncatcnng	agctgggncc	ctacaccctg
	56881	gacaggnaca	gtctctatgt	caatgggttc	acccatcgga	cctctgtgcc	caccaccagc
	56941	actcctggga	cctccacagt	gcacctggca	acctctggga	ctccatcctc	cctgcctggc
	57001	cacacagccc	ctgtccctct	cttgatacca	ttcaccctca	actttaccat	caccaacctg
55	57061	cagtatgagg	aggacatgca	tcgcccctga	tctaggaaagt	tcaacaccac	agagagggtc
	57121	ctgcagggtc	tgttagtcc	cattttcaag	aactccagt	tggccctct	gtactctggc
	57181	tgcagactga	cctctctcag	gcccagagaag	gatggggcag	caactggaat	ggatgctgtc
	57241	tgccctctacc	accctaacc	caaaagacct	gggctggaca	gagagcagct	gtactgcag
	57301	ctaagccagc	tgaccacaaa	catcactgag	ctgggcccct	acagcctgga	cagggacagt
60	57361	ctctatgtca	atggtttcac	ccatcagaac	tctgtgcccc	ccaccagtac	tcctgggacc
	57421	tccacagtgt	actgggcaac	cactgggact	ccatcctcct	tccccggcca	cacancnct

57481 gncctctccc tgnntccntt caccntcaac ttnaccatca ccaacctgca ntangnggan
 57541 nacatgcnncc ncccnngntc caggaagtcc aacaccacmg agngngntct gcagggtctg
 57601 ctnnnncccn tnttcaagaa cncagtgtn ggcntctgt actctggctg cagactgacc
 57661 tnnctcaggc cngagaagna tggngcagcc actggantgg atgccatctg canccaccnn
 57721 cntnanccca aaagncctgg actgnacagn gagcngctnt actgggagct nagccanctg
 57781 accaanmnca tcnnngagct gggnccttac accctggaca ggnacagtct ctatgtcaat
 57841 ggttttcccc attggagctc tgggctcacc accagcactc ctgggacttc cacagttagc
 57901 ctgggaacct cagggactcc atccccctgc cccagcccca caactgctgg ccctctcctg
 57961 gtgccaattca ccctaaactt caccatcacc aacctgcagt atgaggagga catgcatcgc
 58021 cctggatcta ggaagttaa cgcacacag agggctcctg agggctctgt tagtcccata
 58081 ttcaagaaca ccagtgttg ccctctgtac tctggctgca gactgacct gctcagacct
 58141 gagaagcagg aggcagccac tggagtggac accatctgta cccaccctgt tgatcccatc
 58201 ggacctggac tgnacagnca gcngctntac tgggagctna gccanctgac caannncatc
 58261 nnnagctgg gncctacac cctggacagg nacagtctct atgtcaatgg ttccaccat
 58321 cnganctctg ngcccaccac cagcactcct gggacctcca cagtgnacnt nggnacctcn
 58381 gggactccat cctccntccc cngccnaca ncnctgncc ctctcctgnt nccnttcacc
 58441 ntcaacttna ccatcaccaa cctgcantan gnggannaca tgcnnccccc nggntccagg
 58501 aagttaacaa ccacngagng ngtntgcag ggtctgctnn nccccntntt caagaacncc
 58561 agtgtnggcc ntctgtactc tggctgcaga ctgacctnnc tcaggncnga gaagnatggn
 58621 gcagccactg gantggatgc catctgcanc caccnncntn ancccaaaag ncccttcacc
 58681 nacagnagc ngctntactg ggagctnagc canctgacca annncatcnn ngagctgggn
 58741 ccctacacccc tggacaggna cagtctctat gtcaatggtt tcacccatcg gagctttggg
 58801 ctcaccacca gcactccttg gacttcacca gttgaccttg gaacctcagg gactccatcc
 58861 cccgtcccca gcccacaaac tgcctggcct ctctggtgac cattcacct aaacttcacc
 58921 atcaccaacc tgcagtatga ggaggacatg catcgccctg gctccaggaa gttcaacacc
 58981 acggagaggg tccctcaggg tctgcttacg ccctgttca ggaacaccag tgtcagctct
 59041 ctgtactctg gttgcagact gaccttgctc aggcctgaga aggatggggc agccaccaga
 59101 gtggatgctg tctgcacca togtcctgac cccaaaagcc ctggactgna cagnagcng
 59161 ctntactggg agctnagcca nctgaccaan nncatcnng agctgggnc ctacacctg
 59221 gacaggnaca gtctctatgt caatggtttc accatcnaga nctctnggcc caccaccagc
 59281 actcctggga cctccacagt gnacntnggn acctcnggga ctccatcctc cntcccngc
 59341 cncacancnn ctgnccctct cctgntnccn ttcacctca acttnaccat caccaacctg
 59401 cantangngg annacatgcn ncnccnngn tcagggaagt tcaacaccac ngagnngtn
 59461 ctgcagggtc tgcnnnncc cntnttcaag aacnccagt tnggcmctct gtaactggg
 59521 tgcagactga cctnnctcag gncngagaag natggngcag ccaactggant ggaatgccatc
 59581 tgcancacc ncnntnanc caaaagncct ggactgnaca gngagcngct ntactgggag
 59641 ctgagccanc tgaccaann catcnngag ctgggncct acacctgga caggnacagt
 59701 ctctatgtca atgggttcc ccatggatc cctgtgccc ccagcagcac tctgggacc
 59761 tccacagtgg accttgggtc agggactcca tctcctcc ccagccccc aactgctggc
 59821 cctctcctgg taccattcac cctcaactc accatcacca acctgcagta tggggaggac
 59881 atgggtcacc ctggctccag gaagtcaac accacagaga gggtcctgca ggtctgctt
 59941 ggtcccatat tcaagaacac cagtgttggc cctctgtact ctggctgca actgacctct
 60001 ctcaggtccg agaaggatgg agcagccact ggagtggatg ccatctgcat ccatcatctt
 60061 gaccccaaaa gccctggact gnacagnag cngctntact gggagctnag ccanctgacc
 60121 aannncatcn nngagctggg nccctacacc ctggacaggn acagtctcta tgtcaatggg
 60181 ttcacccatc nganctctgn gccaccacc agcactcctg ggacctccac agtgnacntn
 60241 ggnacctcng ggactccatc ctcntcccc ngccnccan cnnctgnccc tctcctgntn
 60301 ccnttcaccn tcaacttnac catcaccaac ctgcantang nggannacat gcnnccccc
 60361 ggnccagga agttcaacac cacngagnn gtntcagagg gtctgctnnn nccntnttc
 60421 aagaacncca gtgtnggcn tctgtactct ggctgcagac tgacctnnt caggncngag
 60481 aagnatggng cagccactgg antggatgcc atctgcancc accnncntna ncccaaaagn
 60541 cctggactgn acagnagcn gctntactgg gagctnagcc anctgaccaa nnnccatcnn
 60601 gagctgggnc cctacacct ggacaggnac agtctctatg tcaatgggtt caccatcag
 60661 acctttgcgc ccaacaccag cactcctggg acctccacag tggaccttgg gacctcaggg
 60721 actccatcct cctcccccag cctacatct gctggcctc tctgggtgac tctcaccctc
 60781 aacttcacca tcaacaacct gcagtacgag gaggacatgc atcacccagg ctcagggaag
 60841 ttcaacacca cggagcgggt cctgcagggt ctgcttgggt ccatgttcaa gaacaccagt
 60901 gtcggccttc tgtactctgg ctgcagactg acctgtctca ggcttgagaa gaatggggca
 60961 gccaccagag tggatgctgt ctgcacccat cgtcctgacc ccaaaagccc tggactgnac
 61021 agngagcngc tntactggga gctnagccan ctgaccaann ncatcnnga gctgggnc
 61081 tacacctgg acaggnacag tctctatgtc aatggtttca ccatcnngan ctctgngccc

	61141	accaccagca	ctcctgggac	ctccacagtg	nacntnggna	cctcngggac	tccatcctcc
	61201	ntccccngcc	ncacagcccc	tgtccctctc	ttgataccat	tcaccctcaa	ctttaccatc
	61261	accaacctgc	attatgaaga	aaacatgcaa	cacctgggtt	ccaggaagtt	caacaccacg
	61321	gagagggttc	tgcagggtct	gtcraagccc	ttgttcaaga	gcaccagcgt	tggccctctg
5	61381	tactctggct	gcagactgac	cttgctcaga	cctgagaaac	atggggcagc	cactggagtg
	61441	gacgccatct	gcaccctccg	ccttgatccc	actggtcctg	gactggacag	agagcggtca
	61501	tactgggagc	tgagccagct	gaccaacagc	gttacagagc	tgggccccta	cacctgggac
	61561	agggacagtc	tctatgtcaa	tggcttcacc	cagcggagct	ctgtgccaac	caccagtatt
	61621	cctgggacct	ctgcagtgca	cctggaaaac	tctgggactc	cagcctccct	ccctggccac
10	61681	acagccccctg	gccctctcct	ggtgccattc	accctcaact	tcactatcac	caacctgcag
	61741	tatgaggtgg	acatgcgtca	ccctggttcc	aggaagttca	acaccacgga	gagagtctctg
	61801	caggggtctgc	tcaagccctt	gttcaagagc	accagtgttg	gccctctgta	ctctggctgc
	61861	agactgacct	tgtcagggcc	tgaaaaacgt	ggggcagcca	ccggcgtgga	caccatctgc
	61921	actcaccgcc	ttgacctctc	aaaccttgga	ctggacagag	agcagctata	ctgggagctg
15	61981	agcaaaactga	cccgtggcat	catcgagctg	ggcccctacc	tcctggacag	aggcagttctc
	62041	tatgtcaatg	gtttcaccca	tcggaaacttt	gtgcccatca	ccagcactcc	tgggacctcc
	62101	acagtaacac	taggaacctc	tgaaaactcca	tcctccctac	ctagaccctc	agtgccctggc
	62161	cctctccctgg	tgccattcac	cctcaacttc	accatcacca	acttgcatga	tgaggaggcc
	62221	atgcgacacc	ctgggtccag	gaagttcaat	accacggaga	gggtccctaca	gggtctgtctc
20	62281	aggcccttgt	tcaagaatac	cagtatcggc	cctctgtact	ccagctgcag	actgaccttg
	62341	ctcaggccag	tgaaggacaa	ggcagccacc	agagtggatg	ccatctgtac	ccaccacctc
	62401	gacctcctaaa	gccctggact	gaacagagag	cagctgtact	gggagctgag	ccagctgacc
	62461	cacggcatca	ctgagctggg	ccctacaccc	ctggacaggg	acagtctcta	tgtcgatggt
	62521	ttcactcatt	ggagccccat	accgaccacc	agcactcctg	ggacctccat	agtgaacctg
25	62581	ggaacctctg	ggatcccacc	ttccctccct	gaaactacan	cnctgncctc	ctcctgntn
	62641	cnnttcacn	tcaacttnac	catcaccaac	ctgcantang	nggannacat	gcnnccccn
	62701	ggntccagga	agttcaacac	cacngagagg	gttctgcagg	gtctgtctcaa	gcccttgttc
	62761	aagagcacca	gtgttggtcc	tctgtattct	ggctgcagac	tgacctgtct	caggcctgag
30	62821	aaggacggag	tagccaccag	agtggacgcc	atctgcaccc	accgccctga	ccccaaaatc
	62881	cctgggctag	acagacagca	gctatactgg	gagctgagcc	agctgaccca	cagcatcact
	62941	gagctgggac	cctacaccct	ggatagggac	agtctctatg	tcaatggttt	caccagcgg
	63001	agctctgtgc	ccaccaccag	cactcctggg	actttcacag	tacagccgga	aacctctgag
	63061	actccatcat	ccctccctgg	ccccacagcc	actggccctg	tcctgtctgcc	atccacctc
35	63121	aattttacca	tcactaacct	gcagtatgag	gaggacatgc	atcgccctgg	ctccagggaag
	63181	ttcaacacca	cggagaggggt	ccttcagggt	ctgcttatgc	ccttgttcaa	gaacaccagt
	63241	gtcagctctc	tgtactctgg	ttgcagactg	accttgcctc	ggcctgagaa	ggatggggca
	63301	gccaccagag	tggatgctgt	ctgcacccat	cgctctgacc	ccaaaagccc	tggactggac
	63361	agagagcggc	tgtactggaa	gtcgagccag	ctgacccacg	gcactactga	cctgggcccc
40	63421	tacaccttg	acaggcacag	tctctatgtc	aatgggtttca	cccatcagag	ctctatgacg
	63481	accaccagaa	ctcctgatac	ctccacaatg	cacctggcaa	cctcgagAAC	tcagacctcc
	63541	ctgtctggac	ctacgaccgc	cagccctctc	ctggtgctat	tcacaattaa	cttcaccatc
	63601	actaacctgc	ggtatgagga	gaacatgcat	cacctgggct	ctagaaagtt	taacaccacg
	63661	gagagagtcc	ttcagggtct	gtcaggccct	gtgttcaaga	acaccagtgt	tggccctctg
	63721	tactctggct	gcagactgac	cttgctcagg	cccaagaagg	atggggcagc	caccaaagtg
45	63781	gatgccatct	gcacctaccg	ccctgatccc	aaaagccctg	gactggacag	agagcagcta
	63841	tactgggagc	tgagccagct	aaccacagc	atcactgagc	tgggccccta	cacctgggac
	63901	agggacagtc	tctatgtcaa	tggtttcaca	cagcggagct	ctgtgccacc	cactagcatt
	63961	cctgggaccc	ccacagtgga	cctgggaaca	tctgggactc	cagtttctaa	acctggtccc
	64021	tcggctgcca	gccctctcct	ggtgctatcc	actctcaact	tcaccatcac	caacctgcgg
50	64081	tatgaggaga	acatgcagca	ccctggctcc	aggaagttca	acaccacgga	gagggtccct
	64141	cagggcctgc	tcaggtccct	gttcaagagc	accagtgttg	gccctctgta	ctctggctgc
	64201	agactgactt	tgtcagggcc	tgaaaaggat	gggacagcca	ctggagtgga	tgccatctgc
	64261	accaccacc	ctgaccccaa	aagccctagg	ctggacagag	agcagctgta	ttgggagctg
	64321	agccagctga	cccacaatat	cactgagctg	ggccactatg	ccctggacaa	cgacagcctc
55	64381	tttgtcaatg	gtttcactca	ctggagctct	gtgtccacca	ccagcactcc	tgggaccccc
	64441	acagtgtatc	tgggagcatc	taagactcca	gcctcgatat	ttggcccttc	agctgccagc
	64501	catctcctga	tactattcac	cctcaacttc	accatcacta	acctgcggtg	tgaggagAAC
	64561	atgtggcctg	gtccaggaa	gttcaacact	acagagaggg	tccttcaggg	cctgctaagg
	64621	cccttgttca	agaacaccag	tgttggccct	ctgtactctg	gctccaggct	gaccttgtctc
60	64681	agggcagaga	aagatgggga	agccaccgga	gtggatgcca	tctgcaccca	cgcctctgac
	64741	cccacaggcc	ctgggctgga	cagagagcag	ctgtatttgg	agctgagcca	gctgaccac

64801 agcatcactg agctggggccc ctacacactg gacaggggaca gtctctatgt caatgggtttc
 64861 acccatcggg gctctgtacc caccaccagc accgggggtg tcagcggagg gccattcaca
 64921 ctgaacttca ccatcaacaa cctgcgctac atggcgggaca tgggccaacc cggctccctc
 64981 aagttcaaca tcacagacaa cgtcatgaag cacctgctca gtccctttgtt ccagaggagc
 5 65041 agcctgggtg caggttacac aggtgcagg gtcacgcac taaggctctgt gaagaacggt
 65101 gctgagacac ggggtggacct cctctgcacc tacctgcagc ccctcagcgg ccaggtctgt
 65161 cctatcaagc aggtgttcca tgagctgagc cagcagaccc atggcatcac cggctgggc
 65221 ccctactctc tggacaaaga cagcctctac cttaacggtt acaatgaacc tggctctagat
 65281 gagcctccta caactcccaa gccagccacc acattcctgc ctctctctgtc agaagccaca
 10 65341 acagccatgg ggtaccacct gaagaccctc acactcaact tcaccatctc caatctccag
 65401 tattcaccag atatgggcaa gggtcagct acattcaact ccaccgaggg ggtccttcag
 65461 cacctgctca gaccttgtt ccagaagagc agcatggggc ccttctactt ggggtgccaa
 65521 ctgatctccc tcaggcctga gaaggatggg gcagccactg gtgtggacac cacctgcacc
 65581 taccaccctg accctgtggg cccgggctg gacatacagc agctttactg ggagctgagt
 15 65641 cagctgaccc atggtgtcac ccaactgggc ttctatgtcc tggacaggga tagcctcttc
 65701 atcaatggct atgcaccca gaatttatca atccggggcg agtaccagat aaatttcac
 65761 attgtcaact ggaacctcag taatccagac cccacatcct cagagtacat caccctgctg
 65821 agggacatcc aggacaaggt caccacactc tacaaggga gtcaactaca tgacacattc
 20 65881 cgcttctgcc tggtcaccaa ctgacgatg gactcogtgt tggctactgt caaggcattg
 65941 ttctcctcca atttggacc cagcctgggt gagcaagtct ttctagataa gacctgtaag
 66001 gcctcattcc attggtggg ctccacctac cagttgggtg acatccatgt gacagaaatg
 66061 gagtcatcag tttatcaacc aacaagcagc tccagcacc agcacttcta cctgaatttc
 66121 accatcacca acctaccata ttcccaggac aaagcccagc caggcaccac caattaccag
 66181 aggaacaaaa ggaatattga ggatgcgctc aaccaactct tccgaaacag cagcatcaag
 25 66241 agttattttt ctgactgtca agtttcaaca ttcaggctctg tccccaacag gcaccacacc
 66301 ggggtggact cctgtgttaa ctctcgcca ctggctcgga gagtagacag agttgccatc
 66361 tatgaggaat ttctgoggat gaccgggaat ggtaccagc tgcagaactt caccctggac
 66421 aggagcagtg tcttgtgga tgggtattct cccaacagaa atgagccctt aactgggaat
 66481 tctgaccttc ccttctgggc tgtcatcctc atcggtctgg caggactcct gggactcatc
 30 66541 acatgcctga tctgcggtgt cctgggtgacc acccgccggc ggaagaagga aggagaatac
 66601 aacgtccagc aacagtgcac aggtactac cagtcacacc tagacctgga ggatctgcaa
 66661 tgactggaac ttgcccgtgc ctgggggtgc tttccccag ccagggtcca aagaagcttg
 66721 gctggggcag aaataaacca tattgttcgg aaaaaaaaaa aaaaa

35 SEQ ID NO. 3

hk5 amino acid

MATARPPWMWVLCALITALLGVTEHVLANNVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGS
 40 CDMHTQPWQAALLRPNQLYCGAVLVHPQWLLTAHCRKKVFRVRLGHYSLSPVYESGQMQFGVKSIPHPG
 YSHPGHSNDLMLIKLNRIRPTKDVREINVSSHCPASGATKCLVSGWGTTKSPQVHFVKVLQCLNISVLSQKR
 CEDAYPRQIDDTMFCAGDKAGRSDSCQGDSSGPPVVCNGLSLQGLVSWGDPYCARPNRPGVYTNLCKFTKWIQET
 IQANS

45 SEQ ID NO. 4

KLK5 CDS

ggtgtctgtg cgtcctgcac ccacatcttt ctctgtcccc tccttgccct gtctggaggc
 tgctagactc ctatcttctg aattctatag tgcctgggtc tcagcgcagt gccgatggtg
 gcccgctcct gtggttccto tctacttggg gaaatcaggt gcagcggcca tggctacagc
 50 aagaccccc tggatgtggg tgctctgtgc tctgatcaca gccttgcttc tgggggtcac
 agagcatggt ctgcacaaca atgatgtttc ctgtgaccac ccctctaaca cctgcccctc
 tgggagcaac caggacctgg gagctggggc cggggaagac gcccggtcgg atgacagcag
 cagccgcata atcaatggat ccgactgcga tatgcacacc cagccgtggc aggcgcgct
 gttgctaagg cccaaccagc tctactgcgg ggcggtgttg gtgcatccac agtggctgct
 55 cagggccgcc cactgcagga agaaagtttt cagagtccgt ctgggccact actccctgtc
 accagtttat gaatctgggc agcagatggt ccaggggtgc aaatccatcc cccaccctgg
 ctactccac cctggccact ctaacgacct catgtcatc aaactgaaca gaagaattcg
 tccactaaa gatgtcagac ccatcaacgt ctctctcat tgtccctctg ctgggacaaa


```

gtgcttggtg tctggctggg ggacaaccaa gagcccccaa gtgcacttcc ctaaggtcct
ccagtgcctg aatatcagcg tgctaagtca gaaaagggtg gaggatgctt acccgagaca
gatagatgac accatgttct gcgcccgtga caaagcaggt agagactcct gccagggtga
ttctgggggg cctgtggtct gcaatggctc cctgcaggga ctctgtctct ggggagatta
5 ccttgtgccc cggcccaaca gaccgggtgt ctacacgaac ctctgcaagt tcaccaagtg
gatccaggaa accatccagg ccaactcctg agtcatccca ggactcagca caccggcatc
cccacctgct gcagggacag ccctgacact cctttcagac cctcattcct tcccagagat
gttgagaatg ttcatctctc cagccctga ccccatgtct cctggactca gggctgtgctt
ccccacatt gggctgaccg tgtctctcta gttgaaccct gggaacaatt tccaaaactg
10 tccagggcgg ggggtgcgtc tcaatctccc tggggcactt tcctcctcaa gctcagggcc
catcccttct ctgcagctct gacccaaatt tagtcccaga aataaactga gaagtggaaa
aaaaaaa

```

15 SEQ ID NO. 5

KLK5 nucleic acid

```

gggcccagag tgaaggcaag agaaggagtt gagagctccc tctgcaaagt ggcttgagtc
20 tcccctgcct aaaatgcagg gagagggagg cagaaagaca ggggaagaga aggggtgggg
aagaaaagaga gagacagaga gagacagaat aacacaacta cagaaacaca gagagaacac
acagagagcc tgggacacag ggacacacag agtcagagag aaaagagaag atagagaaaag
acacaaatgg agacacagag gtgtaaagaa agagagatta acagagtccc agatacacgc
aaaggggcag aagcacagtt ttcagggtgg tgtctatgat catctctctt tttttttttt
25 tttttttttt tttttgagac ggagtctcgc tctgtcgccc aggctggagt gcagtggcgg
gatctcggct cactgcaagc tccgcctccc gggttcacgc cattctctg cctcagcctc
ccaagtagct gggactacag gcgcccgcga ctacgccgg ctaatttttt tgtattttta
gtagagacgg ggtttcaccc ttttagccgg gatggcctcg atctcctgac ctctgtatcc
gcccgcctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccgag cccggccatg
30 atcatcttct tgactatgct gatgtgacaa gtacctaaag ccatcagact ctacccttta
aatatgcagt ttgggccagg caccgtggct catgcctgta attccagcac tttgggaggc
agaggtgggt gaatcacttg aggcaggag tttgagacca gcctggccaa catggtgaaa
ctctgtcttt actaaaaaaa aaaaaaaaaa aaaaaaaatc agccgggtgt cgtggggcac
acctgtaatc ccagctatgc tggaggctga ggcacgagag tcacttgaac cctggaggcg
35 gaggttgtag tgggccgaga tcacatcacc gccctccagc ctgggcgaca gagcaagact
ctgtctcaaa taaataaata aacaaacgaa caagcagttt gttgtacctt agttatatct
aaaaaaaaa ttgtgtcaac aaatagagca gaagtgaat aaaggaaaaat aaatgggcca
agaactctaa ggtatatttg acaaatcatt cagaaccttt aaaaaagaaa gaatcacaga
ggcatagaaa gacagggagg aacagggaga cagaaacacc tgtggcccaa ggagaacaaa
40 acaaggctcc taagacagac aggaggagag agagagagag tgagtggagag acagacagag
aaaaagacag agagagagag acagagacag agagacagag aggcgagagg gatagaaaaga
gagagagggg tggagagaga cagagatat tgagagagac tcagaaagat agccgaggga
gaaccacaga gagatggaag aagactctga gaaaaaacca gagacaaaaga tggaaaaggag
agtatcgagg gtgaacagac agtggtgga tgagcaaaat gcagagaaga aagcaagcaa
45 tccaggcgcc aagaatagtg acccagagtt ggtgagaagc cagatcctta aggctggggg
aggcagggaa ggggctggcc tggcttccgg agacctctcc ccattctccg ggccagggag
gtagggagtg acattccgga ctgggtgggg ggtgctctgg ggtggagat agggggagca
ggaggagcta ttgctaaggc ccgataggca cctcattgcc cgggaatgtg cccagggag
50 cagtgggtgg ttataactca ggcccgtgac ccagagccca ggaggaggca gtggccagga
aggcacaggc ctgagaagtc tgcggctgag ctgggagcaa atccccacc ccctacctgg
gggacagggc aagttagacc tggtaggggt ggctcagcag gcagggaagg agaggtgtct
gtcgtctctg cacccacatc tttctctgtc cctccttgc cctgtctgga ggctgtaga
ctcctatctt ctgaattcta tagtgcttgg gtctcagcgc agtgccgatg gtggcccgct
55 cttgtggttc ctctctacct ggggaaataa ggtaggggag ggaggggaag tgggttaagg
gtcccccgga tgcctgggc ctccaacccc totgacattc cccatccagg tgcagcgcc
atgggtacag caagaccccc ctggatgtgg gtgctctgtg ctctgatcac agccttgcct
ctgggggtca caggtaacca gaactctggg gtgggagggt tgtgggattg ggaggactgt
ctctcgggca ctagagcgcc tgtcccctgg ggaactgtgt gagcctgggc atgactcgg
gaccgggtga atgtgagtct ctgtctgtac ttgtggttgt gcgatcgtat gtggccctgt

```

	gactgccacg	gtgtgtgtcg	gggaggggga	tgccttttcc	catatcaggt	gactgtgcgg
	cagggtggcac	tgaccctttg	aggctgtgtg	tgtgggtttg	tgattgtgtg	tgcatttaag
	attgtgtgtg	gctccacagc	tgtgtgggtg	aatgcatgta	gcactggggg	tgttcactgt
	gtgtttggct	gtgtgtgggt	acttggcatt	gtatatgact	gcaggtatct	gcagttcctg
5	tccctgaggt	cccgggattg	cgtgcaacaa	aagtggcat	caccatggaa	agctgtgact
	gtgtgctgct	tgaggcgcat	tatgtgattg	tggctgagtg	tgacgttatg	gatgcccgta
	tttgtgacgg	tgtgactacc	tgaagctctg	tgtaggggtg	actgtatgtg	actgtgtgtg
	tctgtgtgag	gccgtgtaaa	tgctactgta	tgtgtgatgg	tgacgtgtg	tgtctggagt
	ttctgtctct	gcctggaggg	atagaggggtg	caggggtagc	tatctctggg	agatgggtgc
10	cagggtgactg	acttgcagtg	tgtgcctgtg	tgacagaagag	tatgtggcag	tctgaacatc
	tgtgcacaca	cggcatctgt	gcgtggcact	gagacactgt	ggatgagggg	gtgcgatccc
	gctaggctgc	ccgggagcgt	gtgtacctgg	agacagagct	gtatgttagc	tgacactgtg
	gaggcaacat	ggcggtgtct	gcagaactgc	gtgcgtgctt	ggctgttact	gctgttgtgc
	gcgtggttct	tggggtgagt	tcgtgaatga	tgggtgggtcc	agggccatca	gcaagggtaa
15	gaaccaggcc	ggcgcggtg	gctcacgcct	gtaatcccag	ccctttggga	ggccgaggca
	ggcggtatcac	ctgaggtcgg	gagatcgagg	ccagcctgac	caacatggag	aaccccgctc
	ctactaaaaa	tacaaaaaat	tagctgggtg	ggtggcgctg	gcctgtaatc	ccagctactc
	gggagactgg	ggcagaaaaa	tcgcttgaac	ccgggaggtg	gaggttgctg	tgagccgaga
	tcgcgccatt	gcactccagc	ctgggcaaca	agagcgaaac	tccgtctcga	aagaaaaaaa
20	gaaaaaaaaa	agggtaaaga	ccagtgaatg	ggcacgggag	gactgatgat	ggagtggggc
	atgcatgtag	tctgtaggtc	tgtgtgtgag	aggaggagat	tgacaggatt	gagaaggcat
	gttttcatct	gagaattcag	aaacctaggg	ctgctcttcc	cctccatgtg	gccccctaag
	ctgagccctt	ctttcctggt	cctgctttcg	gaaccctagc	tccgccccatg	agctctgacc
	ccacctcctt	tcctcaacca	cggccctagg	ccagactcta	gtggaccccg	cctaaggcca
25	caccctcttg	ggccaggctc	caccctctat	tctgtgggta	ccttctagaa	ccccctcaa
	agtacagact	tttttttttt	tttttttggg	gacagtcttg	ctctctctcc	caggctggag
	tgacgtggcg	tgatctcgcc	tcactgcaac	ctctgcctcc	caggttcaag	tgattctcgt
	gcctccacct	cctgagtagc	tgggattaca	ggtgcgcgcc	accacgcctg	gctaattttt
	tgtctcttag	tagagacagg	gtttcacctt	gttggccagg	ctggtctcaa	actcccaacc
30	tcagggtgatc	cgcccacctc	ggcctcccag	agtgtctggg	ttacaggcgt	gagccaccgc
	cccagaccca	aagtcagagc	tctttatagg	agactctaac	atgtaaccct	gaccctggcc
	ctaactaagt	caattccaaa	cccttccctg	cctccagccc	tgaccccaact	cactgaggcc
	tgaccccaact	tcttgagacc	agttccatcc	ctaaagccct	ggtctccctc	ccatccccag
	gtccacagcc	ccacagcttt	ggcactaccc	ctgagcttgt	ccaggaatcc	tgtacccaat
35	tttaccctca	catgtagtcc	tagccaattc	caggaatctg	tgaggtccag	ttagagtcca
	gtaaccctac	ctgagcctgg	gctctgtcct	tgagcttgag	cctgggcttg	agaggtgcca
	ctcttattct	ccaggccctg	ccctgcccc	ctcagcatgt	cagacaccca	ccctctagct
	ggtctggcct	cttgagtctg	aaaccacccc	ccagcccaag	ccccgcctct	gagccccgcc
	caaccatttt	tccgttccca	gagcatgttc	tcgccaacaa	tgatgtttcc	tgtgaccacc
40	cctctaacac	cgtgccctct	gggagcaacc	aggacctggg	agctggggcc	ggggaagacg
	ccgggtcgga	tgacagcagc	agccgcacat	tcaatggatc	cgactgcgat	atgcacaccc
	agccgtggca	ggccgcgctg	ttgctaaggc	ccaaccagct	ctactgcggg	gcgggtgttg
	tgcatccaca	gtggctgctc	acggccgccc	actgcaggaa	gaagtgtagt	ggagtcccaa
	gaggagggtt	ggtggggacg	gggaagtggg	ggtgggggtg	gggaagtggg	ggtgggggtg
45	tcattggaggt	gagggctggg	ggggacgggg	aagtgggggt	gggggtgtca	tggaagggtga
	gggttggtgg	ggatgggttg	gggatgtggg	agcaggagga	ggtcaggttg	gggataggac
	taaggatgga	gttttgcggg	ggagcaagg	gggaggtatg	ggttgagag	gggagagtgt
	tgtggttaggg	aatgggaagg	agccaaggat	gggttggtat	tgggggttagg	agcatatatt
	tggtgaatgg	tttgggatgg	aggtggaatt	gggattggct	ttagaattgg	gggtgggtga
50	aaatcgggct	gggggtgaaa	tgaagatagc	atggagatag	ggttgagatt	gggagcagat
	atagaatgaa	ggatggggat	tggagtgttg	ggtgggggtg	gagatggttg	gatttgggct
	tgagaatgca	tatgtgtgatg	gcttctgggt	agggaaagaa	ttagggttgg	gaatgggatg
	ggtttggaat	tgtgactggg	atggggacag	gcatgggatt	ggagaccaag	agggagttag
	ggatgggttg	gggaccgggg	gtggggatgg	gggtggggct	ggggctgggt	gtgggggttg
55	gattggcgtt	ggacgtggag	atagagatca	gggttggttg	tgacctgccc	catcttccct
	agagttttca	gagtcctgct	cggccactac	tcctgtctac	cagtttatga	atctggggcag
	cagatgttcc	agggggtcaa	atccatcccc	caccctggct	actccacccc	tggccactct
	aacgacctca	tgctcatcaa	actgaacaga	agaattcgct	ccactaaaga	tgacagaccc
	atcaacgtct	cctctcattg	tccctctgct	gggacaaagt	gcttggtgtc	tggctggggg

acaaccaaga gcccccaagg tgagtgtcca ggttcttctt gataccgacc catctctgcc
 gcctttccatc tttctccact tctcattgtg ttctgttttg acagtgcact tccctaaggt
 cctccagtg c ttgaatatca gcgtgctaag tcagaaaagg tgcgaggatg cttacccgag
 acagatagat gacaccatgt tctgcgcggg tgacaaagca ggtagagact cctgccaggt
 5 gaggacacct ctctttattc agcagataca cactgagtgc caactcggta acatggagcg
 ttgccaaatt ctgagaatcc agcaattgcc aagacagtca ggacccctgt tctcacagag
 ctcataccct agagtagtgg tgtttagtag aaataatgct gagctgttta tgtcatttcc
 agtttttttag tagccacatt aaaacaggta aaaaaggctg ggcgcagtgg ctcacacctg
 taatcccagc actttgggag gctgaggcag gcagatcacc tttggtcagg agtttgagac
 10 tagcctggcc aacatggcga aactctgtct ctaaaaaaa atacaaaaat tagcctggca
 tgggtggcggg cgctgttaat ctcagctgct caggaggccg agacacaaga atcacttaaa
 ccagggaggt ggaggttgca gtgagctgag atcgtgccac tcaactccaa cttgggagaca
 gagtgcacct tttgtctcaa aaagaaaaaa aaaaacaagt aaaaaagaaa caggtgaagt
 taactttaat aacccaatgt atcccaaata caatcatttc aaagtgaat taatataaaa
 15 caattatgaa tgagatactt tacattcttt tcttgttttc atattaagtc tttgaaagtg
 agtatatatg ttatgctgac agcacatctc aatttggact agctacattt caggtgctca
 gtaggccat gtggctagca gttactgtat tggatggcac ggatctagag ggaagatca
 gggctgtttt gtatggttgg gcaggttgtg cactgcataa agataccata tctaataagg
 gcaactccgtg ttacagatgt cagttttggc agttttcagg cgtgtggtag ttaagtgtct
 20 tgtttcaaca aaatctgtaa tatgacagtt ttctagcaag tgctggtaaa atatcttgag
 gaaggaaaag agaaatctgg taggtatttt tacaagagaa tatttaatac aggggattaa
 ttgcaaaagt gctggaagg gctggaggaa aaagttaaaa aataaaaaac tctgtggtca
 agaactctgca taaatagggc aatttcagag agtggtaaag gtttaaccca aaataaaa
 tggtttttagg atagtaaaaca ataaggcca atattcaaaa aggtggtcag gggagcctcc
 25 ttggagaggt ggcatttgag cagagaatgg atgacacaaa gaagctaaac tctgtaagtt
 taaggggaaa gaaaaggcac gtgcaaaagg cctgaggcag taaggaaattt ggctgattca
 aagaagaaga ggaaccaat gcaactggag acaaaaagt ggggcaacag tagaaagtga
 cgctggaggt gtaggcagg gcgaatgctc tgcaagtatt tcttggtcac caacacagag
 ctccctatg ttctaattga agctgtatct gttgaggaag acagaattta aatcaaaact
 30 gttacatcaa ccagcaccct tctctgtatt caggctccca agggatctag aaggacgtaa
 gttacaagc tctcattagc aggggtgtgtg tttcaacagt agttaggaag ctggggattc
 aggagtactc cagtcoccatg gctatgaaaa gctcccccca aattgtacaa acctgacaaa
 tgcaacacct cccagctct cccatttct tctctgtgcc ctgggtgtgg gggggtgggt
 35 tgcgaggggg aaaaactttta acagaagaaa gcacatctcg gccgggctgt gtggctcaca
 cctgtaatcc caacactttg ggaggccgag gcgggtggat cactaggtca ggagatggag
 accatcctgg ctgacacggt gaaaccctgt ctctactaaa aacacaaaaa attagccggg
 cgtggtggca ggcgcctgta gtcccagcta ctggggaggc tgaggcagga gaatggcctg
 aacccgggag gcggaacttg cagtgaagg aggttgacc actgcactcc agcctgggca
 acacagttag actcgtctc aaaaaaaa aaagaaaaga aaagaaatca catctattc
 40 aagtgtggc atttaaaact atttagcctt tctgtaggca aggttagtat cttgtttttc
 cagacctcaa ggtgtttttt tgtttgtttt ttcataccgg tgtgtggtct ggggtggcc
 actaaaagt acaagcaaga aataataaca actacaacaa tactaatacc aatagtataa
 aaataatagc atctggctaa ttgctggaca ctgttttaag tggtttgcat gcctcagctc
 45 attaaactcat ttacctgtta ttattggccc tattttacia acaaggagcc aaggctcaga
 gcagttaact aacagcctct caaaagaaac tctgcagaga tattaattt aaaaaataat
 gagagaaatt aaaccacaag aaagttgaaa tttagaggta caggcagcta agcttgtttg
 ctttgaacaa gtgtctgcta ctgggaaaaa ggcaagtctt ggctttccta ataattgata
 ccaggactct gtaattcata ttttgcatgc atgtaagtaa gaaatgaagc cgggtgcaat
 50 ggcacatgcc agtaatccca gcaactgagg agactgaagt ggaagatca cttgagctca
 ggagtccaag accagcctgg gcaactaaaa attaaaaaaa taaaaatact aattgttttt
 atttttagtag attttattca taccacttac atcattattg tagtatgtac atattttatt
 cttttctttt cttttctttt cttttttgag acggagtctc gctctgtcac ccaggctgga
 gtgcaatggc accatatcag ctactgcag catgcgcctc ctgggttcaa gcatttcttc
 55 caccctagcc tccaagtag ctgggataac aggcaccac caccatgcct tggctctgaa
 ttttttccgt agagatggg ttccaccatg ttggccaggc ttgctggtat tacaggtgtg
 ccagtgatct gcctgcctcg gcctcccaaa ttgctggtat ggtccactca agccaccgtg
 ccaggtggg agatagacat ttctctctac ctcaaacaga ggtccactca agctactttt
 cattttcttc ataatatta gccagtggtc tattttgcac caggaatggt tccaggtgct
 gtggatatgg catcaggcaa aacagaccaa aaacttctg ccgcgtggac ctcattgttc

ccaagtggaa gacaggcaat aaagagatag ataaatatgt agtaaattaa aaaaaaaaaa
 aattagccgg gtgtggtggc ttgcacctgt agttccagct acttgggagg ctgaggtggg
 agaattgctt gagcccaaac gtttgaggct gcggttaagcc atgactgcac tgctgcactc
 cagacagcag cctgggtgac aaagcaagac gtttttgtca gaaagaaaaa aaaaagagac
 5 gaagggagga aggagagaga aaggaaggaa ggaaggagaa agaaaggaag gaaggagaaa
 gaaagggaag aaggaaggag aaagaaagga agaaagagaa agaaagaaaa agaaagaaag
 aaagaagaaa gaaaagagag aggaagggaag gaaagaaggaa aaagaggga aaaaatgact
 gttgaagagc agtgagtatt attataggag ggtaattata gggaggtatg ggggaattgaa
 gacaggaaac acaaatagtg ccaagcgaat ggattttctat tgggagtgat tctgcccta
 10 gaagacactg gcaataccag gagacatttt tggttgtcac aactatatgg aggggcatta
 ctggcaacta atggatagat gccaaagtgtg ctgttcaaca tgctatgatg cacacggcag
 gctccacaa caaaccatta tccagcttca gatgccaca gtgccagat cgaggaaccc
 tcatccagg gctgagaacc gtatttttgc agaaggagag tataaggatg ggttgggtgga
 gaattgggaa ggaagggtgtg tgtccagtaa gagaaataag gcctgcacag gctggagggg
 15 agagtggag agaaaggag gcggagagat acacgatgag ggagacaggc tggaaacagaa
 agtagagacg aagattcgag atgtggagag gaagggtcac agacccccc gaaatgatgt
 gtggacaaca ggaatctgga agaggaagat ggagtggaga gtgacaaatg ggttctaaaag
 gttgaacttg gaggccaggc atgggtggctc acgcctgtaa tcccaacact ttggaggctg
 aggtggggcga atcacttgag gccaggagtt cgagaccagc ctggccaaca tggtgaaacc
 20 cgtctctac aaaaaaata caaaaaatta gccgggtgtg gtgatggaca cctgtagtca
 cagctacttg ggaggctgag gcaggagaat tgcttgaacc cgggagatgg aggtgcagt
 gagctgaggt caggccactg cgctcaacc tgggcaacag agtaagactc catctcaaaa
 aaaaaaaagc tggatttga gtgaaatatt aataacattc tccctctctc tccctttgcc
 tgtgtctoca tctctgtctt tttctgcatt tcttcatctc tgtactttcc atctctgtg
 25 gtctgttccc atctgtctct ccatctatgg gcatctctgg gtctctcatg tctctctg
 cccactttgc cacatctctg cctctctcat gcccccttt ctctcctgca gggtgattct
 ggggggcctg ttgtctgcaa tggctccctg cagggactcg tgtcctgggg agattaccct
 tgtgcccggc ccaacagacc ggggtgtctac acgaacctct gcaagttcac caagtggatc
 caggaaaacca tccaggccaa ctccctgagtc atccaggac tcagcacacc ggcatcccca
 30 cctgtcgag ggacagccct gacactcctt tcagacccto attccttccc agagatgttg
 agaatgttca tctctccagc ccctgacccc atgtctcctg gactcagggg ctgcttcccc
 cacattgggc tgaccgtgtc tctctagtgt aaccctggga acaatttcca aaactgtcca
 gggcgggggg tgcgtctcaa tctccctggg gcactttcat cctcaagctc agggcccatc
 35 ccttctctgc agctctgacc caaathtagt cccagaaata aactgagaag

SEQ ID NO. 6

hk6 amino acid

40

MKKLMVVLSLIAAAWAEQNKLVHGGPCDKTSHFYQAALYTSGLLLCGGVLIHPLWVLTAAHCKKPNLQVFL
 GKHNLQRRESSQEQQSSVVRVIAHPDYDAASHQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWG
 KTADGDFPDITQCAIYIHLVSREECEHAYPGQITQNMMLCAGDEKYGKDSQGGDGGPLVCGDHLRGLVSWGNI
 45 PC GSKEKPGVYTNVCRYTNWIQKTIQAK

SEQ ID NO. 7

KLK6 nucleic acid

CDS 147.. 881

gtcgacccac gcgtccggct ggctggctcg ctctctcctg gggacacaga ggtcggcagg
 50 cagcacacag agggacctac gggcagctgt tccttcccc gactcaagaa tccccggagg
 cccggaggcc tgcagcagga gcggccatga agaagctgat ggtggtgctg agtctgattg
 ctgcagcctg ggcagaggag cagaataagt tgggtgcatg cggaccctgc gacaagacat
 ctcaacccta ccaagctgcc ctctacacct cgggccactt gctctgtggt ggggtcctta
 tccatccact gtgggtctct acagctgccc actgcaaaaa accgaatctt caggctctcc
 55 tggggaagca taaccttcgg caaagggaga gttcccagga gcagagttct gttgtccggg
 ctgtgatcca ccctgactat gatgccgcca gccatgacca ggacatcatg ctgttgccgc
 tggcacgccc agccaaactc tctgaactca tccagccct tccctggag agggactgct

```

cagccaacac caccagctgc cacatcctgg gctggggcaa gacagcagat ggtgatttcc
ctgacacccat ccagtgtgca tacatccacc tgggtgtccc tgaggagtgt gagcatgcct
accctggcca gatcaccag aacatgttgt gtgctgggga tgagaagtac gggaaggatt
cctgccaggg tgattctggg ggtccgctgg tatgtggaga ccacctccga ggccttgtgt
5 catggggtaa catcccctgt ggatcaaagg agaagccagg agtctacacc aacgtctgca
gatacacgaa ctggatccaa aaaaccattc aggccaagtg accctgacat gtgacatcta
cctcccgacc taccacccca ctggctggtt ccagaacgtc tctcacctag accttgcctc
ccctcctctc ctgcccagct ctgaccctga tgcttaataa acgcagcgac gtgagggtcc
tgattctccc tggttttacc ccagctccat ccttgcatca ctggggagga cgtgatgagt
10 gaggacttgg gtocctcggtc ttacccccac cactaagaga atacagggaa atcccttcta
ggcatctcct ctccccaacc cttccacacg tttgatttct tcctgcagag gccagccac
gtgtctggaa tcccagctcc gctgcttact gtcgggtgcc ccttgggatg tacctttctt
cactgcagat ttctcacctg taagatgaag ataaggatga tacagtctcc ataaggcagt
ggctgttggg aagatttaag gtttcacacc tatgacatac atggaataag acctgggcca
15 ccattgcactc aataaagaat gaattttatt atgaaaaaaa aaaaaaaaaa aaaaaaaaaa
aggcgggccg c

```

SEQ ID NO. 8

KLK6 nucleic acid

20 mRNA join(2001..2185,3084..3135,3559..3606,4346..4502,
8122..8369,9791..9927,11805..12483)

CDS join (3567..3606,4346..4502,8122..8369,9791..9927, 11805..11957)

```

25 acacttaaaa aatcttctga cttaaaaaaa aaagtatggt gattggaaaa tgtaaatgtg
catgcgtgct tggcatcaca ttcatctggc caggacttcc ctggatgcta aaggctcctca
aatgccaggc tggggggctg ggacttggtc ccaagggaga tggggaccca gggcacgtct
gtgagaggag gggcaaggtc agcacaaggc acaggaaggt ctctctgggg caagggatac
agagaacaga gggatcctgg tccaggtggg agaggtgcag ctctgagttg gggttgaggg
30 tgtgggtaca gagaggaagg gacccccag agagaggagg cagagggata gggcctggtc
actgggttgt gcaacatcag acttgctgtc tgtgaagata gcacgtcctg agaagaagggt
gctgaggtca gtggggacca aatgtgagag ggagcaccgc gagagtatac tgaataccga
agtagtcttc atccctggag tgatgggggg tgcacaatgc aagatgacaa ttagattcaa
tgcaagacaa agaaaagggt tggctgggaa cagtggctca tgcttatggt ccagctcct
35 gggaagactg aggcgggagg gtcgcttgag cccaggaggg ttgaggctgc cagcagcaag
gatcgtgccg ctgcactcca gcctaggcga cagaacaaga ccttgtctca aaagaaaaaa
gaactttttt ttttaagtta cctgtagtgc ccagcccaag cagggtgctga gccagacttc
attcctatca ttgtccttat tacgcagtga cttccccctc ctcatctctc tccactctgc
cacgcacaca ccctcaccct ccagcccata ccaaccaccc caaccactgc ctgtggttct
40 ccatgtgcac ccaggccagg cattttcacg gcctttcctc ctgacctacg cctggctcag
ctttctaggg ccaagttaa agacacctcc ctaaaatctc ccagatccct ctgctactgc
ccagcaccac catcttatca cagccccacg tcgttcccaa gtgctctccg atttctgctt
aactccatgc ctctcgctgt gtgtccgcat ctcatcaata agtcctcaag tcctcttcca
tcctgctagc ttctcctatg ctcggggaatc atccccgcta ctctctgggg aaactgactc
45 ccttctgggc acacacagtg ctacccccgg ggaaatctaa gaagagaccc aggagaagat
aagcacggag agtcagagaa tcaaggggaa agaaaggag agaggccggg cacagtggct
cacacctgta atccagcact ttgggaggcc aagggtgggt gatcacctga ggtcaggagt
tgagaccag cctggccaac atggtgaaac ctcttcccta ctaaaaatac aaaaaacatt
tagccgggcg tgggtgtggg tgctgtaat ccagctact tgggaagctg aggcaggaga
50 actgcttgaa ctcaggaggc ggaggttgca gtgaactgag atcacaccac tgcactccag
cctgagtgac agagcaagac tccgtcaaaa aaaaagaaag aaagaaagaa aagaaggag
gaaagaaaga aggaaggag gaagggagga agggagagag gaagggagag aggaaggag
agagagaaaa aaagaggag agagacacaa atacagagac tgagatggga gagagagaga
gatggaagct ccctcccctc catggccagg gagacagatg gagcaagaga cctcaggggt
55 gggcagactt ggaggagaag gaccaggagg atgtggagtg ccgaaatctc cagtcagggc
caggtgggca gtcagagact gcaaaggagg actgtcagac agggacaaaa ggaagccatt
gatgtaaccg ccctcccgcc tgcccgccg aagagaggtt gaggccggag ctgctgggag
catggcactg ggggtgctggg aggcggacaa agcccagatt ttcttgggcc ctttccccat

```

5 cgcgcctggg cctgctcccc agccccgggc aggggcgggg gccagtgtgg tgacacacgc
tgtagctgtc tccccggctg gctggctcgc tctctcctgg ggacacagag gtcggcaggc
agcacacaga gggacctacg ggcagggtgt tgagtcaccc caaccgcact gaacctgggc
aggctgcttc ccagtgccgg agggctctag agcccgaggt gagggcctgc aggtccctgg
gtggcacaga gagtgtctgg ggtgcaggga ggcctggggc accatctgct tgccccagag
gccggaatth gtcttcagac actttctttc tccaaaaccc ggaggtctaa ggactgagcc
gactagaact tctctgtcct cagattcagg cccagccccc tcttccctca gaccagggag
tttaggtcct agcccccctc cctcagacc caggagtcca agttcccacc tcttccctca
gactcaggag tccaggcccc cagcccccctc tccctcagac ccaggagtcc aagttctcac
10 ctctctccctc agaccagga gtccaggccc caagcccctc ctccctcaga cgcaagggtc
caggccccca gcccccctc cctcagactc aggagtccag gcccccaagc ccttccctcc
tcagaccagc gagtccaggc cctcactgca ctccaggacc agtgctccct tccctggagg
cctgggtcagg ggtcaccag agcagagcgt gggggcggga ggaatgtgtg tgggaggcct
gggtaaggag gaaaagggtg tagccagctc cctggctcag ggacctgaga gacagggtt
15 aaaaggacgt tccagaagca tctggggaca gaaccagcct ctccaggga ggccctgggag
ctgggggtgt gtgtctggca gtccctgcag ccctgggctc tgcggccctc gcgtcctccg
cttggtctct ccactgcac tgagtgtctt ctctcctcac ggtccccgc atttctaact
cttctgcct cctcgtctca aagctgttcc tcccccgac tcaagaatcc ccggaggccc
ggaggcctgc agcaggtgag atcacagaca tcacagaacc tgcgggtgtg gcgggtgtgg
20 tggccattgc gcacagagcc aggtccgag gaaaactccc atacagagga agaacgtag
ggccccctat ggtaaccctc tctgtcgcag aggaaggcaa atcagtgcct aagaaagtag
aaagatctaa tcagaatctc accatgggtt actggaccag tggacgtagt tgaattctct
ttggcactgt tttcgtggat cctcttgaa gatgtgggt gaggaagaat aaatcaggag
gctagatggg aaggacagag gtcaaggcag gagaccatag caggccagga aggaaggaga
25 ggatgcagag ggagcagaca gagggtggg gggagggtcg aggcagtgc taatggacca
tgtggcttcc cctctcagga gcggccatga agaagctgat ggtggtgctg agtctgattg
ctgcagggtg ggaaaggcca tttggatggg ggaggcttg agacagggtt gggcttgttg
atggagaaga ggctggtatt ggggatggg atatgcacag ggttgggtg ggggagcttt
gaaatgagga agacgttggg gattaggcta aggttggga atacagatag ggagggtgtg
30 gggagggtgg tttgaagata tgagggtttt ggggtgggtt ggctttaggg atggggatct
aaacatagaa gaggtaggag gttaggttga aagttggaga gagcccgga ataggggata
cagttgggtt tgtaatggga atgggtaag tttgggagt gaaatacaga gaagcttttt
ttttttgaga cagggtctca ctctgtcacc caggctggag tgtagtgga tgatccatag
35 ttcaactgcag acttgaactc ttgggtctca agtgaccctc ccacctcagc ctcccaagta
gctgggacta caggcgtatg ccaccatacc ctgctaattt gtgtgtgtgt gtgtgtgtgt
gtgtgtgtgt gtgtgtgtgg agatgaggtc tctactgtgt accgaggctg gtctcaaaact
cctgggctca agcgtatcct ctgcctcagc tgggattaca ggcataagcc actgcacctg
accaatcttg actggagttc atgttgagg ggatgcgctt ggtttctcca gaactcctct
40 ctgactcaga tcttctctcc ctcagcctgg gcagaggagc agaataagtt ggtgcattgg
ggaccctgcg acaagacatc tcaccctac caagctgccc tctacacctc gggccacttg
ctctgtgggt gggctcctat ccatccactg tgggtcctca cagctgcccc ctgcaaaaaa
ccgtgagtct acactgtaaa tgaacagcag atgcgactga accctgaggg tgtcttatag
atgtcaggca ggaggtgaca taggcattccc ccccatccca gcacgaggcc atctgatagc
cagggtgcatt cggctgttg ttaattgagt acttaattgt tgccaggccc tgcgggcata
45 gcagtggaag agaaaataaa aaaaagaaaa caaaaaaaa caagcaaat tgctgttttc
ctgaacttac tttctaatgg gggaattgga tcatttggg acctgcaggc cgtgatgggc
atthggattt aattctgagc acagtaggaa gccactgggc agttttgttt ttgtgtttg
ttgtttttt gagacacagt ctgcctctgt caccaggct ggagtgtagt ggcattgatct
cagctcactg caacctctgc ctcccagggt ccagcgattc tctgcctca gcaccccaag
50 tagctgagat tacagggtgt caccaccttg cctggctaatt tttgtatgt ttggtagaga
cggggtttca ccatgttggc caggctggtc tcgaactcct gacctcaggt gatccgccc
cctcgccctc ccaaagagct gggattacag gcatgagcca ccaccacacc cagcctgatt
tacattttta caagcacctt ggctaccacg tggaaactgg tctgggcaag agagagggag
ggaggccac gtgggggctg ttgctttcat ccggcgacat aggagggtg cttgaacca
55 ggcgtgcga gtggggatgg agggatgtt aatatcttgg gatgtggaat tctgagactg
agccagcaga atctggcaac gaggaacagg agggagagga agaagcacgg ctggcttccg
tgtattttgt ctgaacaact ggtgtttt ccacgtctt ctctgagttg tgggagaggg
aaagagaac aggcgggtg taggcagggt agcatctgac attttgctt agccacgatg
agttggagat gccggggaga tgtcccagca gggaggccag ggaggactct ggagctcaga

	ggagagggtca	gggctggagg	ttaaaatgaa	ggcatcgtca	gcaaacaggt	gtattttaaag
	ccatgggact	agatgagatc	atccaaaaag	ctggcatagt	tggaggagct	ggaggggccca
	ggacaaaaac	cctgggcgct	gatcctcact	agtcagattc	acgacagctg	ccacttgttt
	gatgtctaat	accaatcagg	tgctgagtga	aacctatgtac	acacctttcc	tggaaatgcc
5	accacaagg	actcttggca	ccattttgca	aatgaggaaa	ctgaggtgca	gggaaatagc
	aagtgcacaa	ccctgggggtg	gttcccctga	ccccaaggag	accttggatg	actctcacca
	ccatcattca	ttcctttgat	gtacattgac	taagagcacc	tgctaagtgc	cacattcgag
	ttgggcagtg	gagattcagc	aatggatggg	acacacacgt	catccctgcc	ctcgggagca
	caaggacaga	aaggtgcaga	caagcaaaagt	gagggctggg	catggtggct	cacgcctgta
10	atcccagcac	tttgggaggg	cgaggtgggt	ggattacctg	agttcgagac	cagcttggcc
	aacatggctc	aaccctgtct	ctactgaaaa	tacaaaaaat	tagccaggcg	tgggtggtggg
	cttctgtaat	tccagcaact	tgaggagcta	aggcaggaga	attgcttgaa	cgtgggaggg
	ggaggttgca	gtgagccgag	atcgcgccac	tgactccag	cctgaaccac	agagcgagac
	tctgtctaaa	aaaaaaaaaa	ggaaagaaaag	aagcagcaaa	ttgggctggc	cgtggtggct
15	catgcctgta	atcccagcac	tttgggaggg	cgaggcgggt	ggatcactcg	agcccaggag
	tacaaagctg	cagtgcagctg	tgatctacag	aacaccactg	cagatccagc	ctgggtgaca
	gagcgagacc	ctgtctcaaa	aaaacaaaca	aacaaaagaa	gcaaaccctt	caaaacccca
	tataattaca	aattatgaag	gaaaagaata	cgggtaccta	ctttagatgg	aggagggtca
	ggaaggactt	tctaattgaga	taaaatccaa	gcggaggcat	gaagatggga	aaaggaatgt
20	tcagggcaga	ggaaaggctg	tgataacacc	cctgaggtga	gaaccgtctt	gagtattctc
	agaaaataaa	atttcccgtt	cactgggggg	cagaagggtgc	tgggagataa	ggttggaaag
	tgactacagc	cagatcacac	aggggctoca	gtgccaaagt	gaggagccca	ggctttattc
	ttaggacaa	ggggagccat	gggtgatgtc	tgagcaaggg	agtgactctc	tgtttcagga
	atatgtatca	aacacctatc	ctgtgcccag	tgctgatcaa	cgcactggag	atactatatc
25	tgaatagaac	aaaaatcccc	atcttgacat	cctagagctg	cactgtctaa	tatggtagcc
	atcagccaca	tatagcaaat	tacattgaaa	ttaatgaaat	ggaaaatcca	caagccacat
	ttcaagtact	cagcagccac	ctgtagcttg	tggttccccc	agccacctct	ggacagtga
	gatcgagatc	atggcatcgt	agcatttagt	ggacagcatt	gctctgcaag	gaggagaaat
	aacacaatga	gtaaataattt	aacaataaat	atatagoagg	tcggatgatt	gtgatagggt
30	ctctgttgga	acagaaagca	ggggaggggg	ataggaattg	cctactaaca	ggtatttgta
	tttttaattgg	gcaactaagg	aaggcttccc	tgagaggcga	cattttaaagg	aagtgaggga
	gtgagctatg	cagatacttg	gaggacagac	ttgctggcag	agggaaacagc	agtgcacagg
	ccctgaggtg	ggaagatcac	tattgtgttc	aaggcaagac	agggaaagcca	gcgtttggct
	ggagcagagg	gagagaagg	gagagtggga	ggagaagatg	tctgtgagat	gatggggcag
35	tgcttgcaag	gcctgggtgtg	ccacgttgag	aactttggct	ttgattctga	gtgagatggg
	agtcatagga	ggggctgagc	agaggaggca	caggaccaac	ttacattggt	aaaatatctc
	tgggtgcttt	gtggaggatg	gactgtgggg	gaccagagac	agagcaggga	gcccagttag
	gaggctactg	ctctagttca	ggtaggaagt	gaaaaggcag	ctcaaaccac	gatggttagc
	gtgggaaagg	tgagatgtgg	ccagattctg	gatatgcttc	agagaggcaa	aaggaattct
40	ggacagcttg	gatgtagggc	atgaaataaa	gagagtgaag	aatagccccc	aagattattc
	tgaaggatg	gaattgccat	ttaccagct	ggggaagact	gtgggaggag	caggccagcg
	attcatgact	tcccagccct	ctctgaagcc	tcaactgcag	cccaagggct	ccagggtgaga
	cccagccctc	ttccttccca	ggaatcttca	ggtcttcctg	gggaagcata	accttcggca
	aaggggagagt	tcccaggagc	agagttctgt	tgtccgggct	gtgatccacc	ctgactatga
45	tgccgcccagc	catgaccag	acatcatgct	gttgcgcctg	gcacgcccag	ccaaactctc
	tgaactcatc	cagcccttc	ccctggagag	ggactgctca	gccaacacca	ccagctgccca
	catcctgggc	tggggcaaga	cagcagatgg	tcagtagtgg	gaggctgggtg	gggagcaggg
	tactggtctac	ttgggggaagt	gtgccaaagg	atggggagtg	ggaaaattgg	tgagggggcca
	tgggaagatg	ggctaattggt	gaggaccaat	gggacagggt	ttcaatggga	gaaagggtcaa
50	gggggagggg	gagtgaattt	gggagctggg	ccagtgaagt	aacagccaat	ggaaaatgta
	gaccaatggg	tgaatagcat	gggagagatg	gaacataaga	tgaagggtca	ataagagagg
	aaggtcagtg	gggagatgct	aatcagggaag	gatgtcaaag	gtcaaagggg	actgatcagg
	attcattgaa	cagcaggaag	gaataatgga	gaaggaactg	atggaagaag	agaaccaat
	aaagcacaaa	agccaactga	aggatgtgaa	ttgagacagt	gaatgggggt	atagctgatg
55	gaagaggggac	taaggggaaa	ggatcaatgg	tccagaggag	tcactagagg	aaaaaacagg
	tccaatagat	cagcaggatc	catgaagggtg	ggcctgtgtg	tgaaggggcca	ataagaaaagg
	tgaaccattg	gatgaagggc	cagtgggaag	gcagagacaa	tgggggagga	tgccggcaagt
	tagaaaagga	ccaatgaggg	aggtggacca	ttggatgaag	ggctaatagg	aaggggagagc
	cagtggggga	tggtagggcc	agttagaaaa	ggaccaagga	gggaagcaga	ccaataggaa

gagagagcca atgagggagg gcagggccag ttaggaaagg accaatgagg aaggtagacc
 attggaggaa gggccaatag aaagggagga tccatgagg aggggtggga cagttagaaa
 aggaccaatg atggagggtg accattggat gaagaaccaa tagaaaaggaa gaaccaatgg
 gagagggcat ggccagttag gaaaagacca atggtcacag agtgaccaat caagatgaat
 5 caatgggcag gaagtgtcca atgaagaatg gactactgat caggaggggt acagtagagg
 agggcgtaac agaggaagag tcctccaggt caactgaaac tactgaagaa ggtgggacca
 gtggaagaga gaaaagtgga ggagggacct aagagaaaaag gaaaaccaat aggaaatgag
 gactcctgga gaagagacta ttaatgagga agacagccaa tgggggggaa gaatgataga
 aagagggacc aattaggagg cagggacgat ggtaatgaga tgtaagaatg agagacaaac
 10 aggaagagggt gtgccaatag aaaagaggga ccaatagagg atggaggact tataggggtt
 ggggggtgac tggggaggat gaggggagtg caaggcctgg gctgagtctg gcccatctct
 cccctaacag gtgatttccc tgacaccatc cagtgtgcat acatccacct ggtgtcccgt
 gagaggtgtg agcatgccta ccctggccag atcaccagga acatgttgtg tgctggggat
 gagaagtacg ggaaggattc ctgccaggtg aggtgaccog gatctgccac ttacacagcc
 15 agggacagga cgaagtcaca aaaacatggc cagacacagg aagagagaga cacaggccaa
 aagagagctt tacagagaca gatagagaca ggctgaggga gaaccaagc ctgaaaaga
 agagacttag ttcaacacac agagacacag tcagggatat gcagagatat aaagacacag
 ccagcagaga caggaagtgc agagacaagg atggaggccg cgggatcaag aaccagagag
 gccaggagca gcggtcatg cctgtaatcc cggcactttg ggaggccgaa gcaggaggat
 20 cacctagggt caggagtctg agaccagcct gatcaacatg gtgaaacctt atctctacta
 aaaatacaaa aattaggatg ggcacagtgg ctcatgcctg taatcccagc accttgggag
 gccgaagcag gaggatcacc tggggtcagg agttcgagac cagcctgatc aacatggtga
 aacctatct ctactaaaaa taaaaaatt aggatgggca cagtggctca tgccgtgaat
 cccagcacct tgggaggccg aagcaggagg atcacctggg gtcaagagat tgagaccagc
 25 ctggccgata tggtgaaacc ctatctctac taaaaataca aaaattagct gggcctggtg
 caggcgccctg tagtccagc tactcaggag gctgtggcag gagaatcact tgaacctgga
 ggcggagggt gttgcagtga gtcgagatca tgctactgca ctccagcctg gcaacagagc
 aagattccgt ctcaaaaaaa aacaaaaaa caaaaattac gcaagcatgg tgggacacac
 ctgtagtccc agctactcgg gaggttgagg ctggagaatt gcttaaacc aggaggcaga
 30 ggctgcagtg agctgagatc acgccactgc actccagcct ggggacagag ccagactctg
 tctaaaaaca aaaagaacca aagagaagta gtaaggagc agatgggtgtg aggggactgt
 ccttcctcaa acagagcccc cagcagtcct gctcagaaac gaccaggctc tggaggaggg
 agacactagc tggggaaaag ggactccctc ccgaatactt taacttgggt ttccctcatt
 gtcattccatc caggctctcc tctttatgcc agaatgacta atgcactgag ggaatgtcag
 35 agaccaacca agggggagac acaggcagaa acggagacac aggcagaaac agggacagag
 acagggaaag cgatacatag caagtggac gcaaagaaag ggcaggtggg cgagactgtc
 ctcaagacac gaggtggaga ggtgtccctg gacagaatag tgccaggcat atctctccct
 gggccctccc tacctctccc acctgggtct tatcgtctcc tccctccccct cctccctctc
 ctctctctcc tctctctctc cctccctcat catcttcttc ttttctctct ctctccatcg
 40 gtctctacac ctctgcctct ctccacacct ctcaagtctcc attctttaat tgtttctctt
 tctgtctctc tatgttctct tgcatcttgg cattcctatc tctgtgtctt tgagtctcct
 ttattctctc tctaccattc tctctctgtg cctttgtgtg tcttactgtc tctctctctg
 tctctctgtc cctgagtcct tctctccatc tttcagtaag tacctctgtc cctttctacc
 tctctctctg tcacacacac acacacacac acacacacac acacacagtc acacacagtc
 45 tctgggtttc tatctgtatc tgactttctc cctctttcct gcagggtgat tctgggggtc
 cgctgggtatg tggagaccac ctccgaggcc ttgtgtcatg gggtaacatc ccctgtggat
 caaaggagaa gccaggagtc tacaccaacg tctgcagata caggaactgg atccaaaaaa
 ccattcaggc caagtgacct tgacatgtga catctacctc ccgacctacc accccactgg
 ctggttccag aacgtctctc acctagacct tgcctccctc cctctctgc ccagctctga
 50 ccctgatgct taataaacgc agcgacgtga gggctcctgat tctccctggg tttaaccag
 ctccatcctt gcactactgg ggaggacgtg atgagtgagg acttgggtcc tcggctcttac
 cccaccact aagagaatac aggaaaatcc cttctaggca tctctctcc ccaaccttc
 cacacgtttg atttcttctc gcagaggccc agccacgtgt ctggaatccc agctccgtg
 ctactgtcg gtgtcccctt gggatgtacc tttcttcaact gcagatttct cacctgtaag
 55 atgaagataa ggatgataca gtctccataa ggcagtggct gttggaaaga ttaaggttt
 cacacctatg acatacatgg aatagcacct gggccaccat gcactcaata aagaatgaat
 ttt

SEQ ID NO. 9

KLK6 nucleic acid

5 CDS 246..980

```
aggcggacaa agcccgattg ttcctgggccc ctttcccat ogcgccctggg cctgctcccc
agccccggggc agggcgggg gccagtgtgg tgacacacgc tgtagctgtc tccccggctg
gctggctcgc tctctcctgg ggacacagag gtcggcaggc agcacacaga gggacctacg
10 ggcagctgtt ccttccccg actcaagaat ccccgaggc ccggaggcct gcagcaggag
cggccatgaa gaagctgatg gtggtgctga gtctgattgc tgcagcctgg gcagaggagc
agaataagtt ggtgcatggc ggaccctgcg acaagacatc tcacccttac caagctgccc
tctacacctc gggccacttg ctctgtggtg gggtccttat ccatccactg tgggtcctca
cagctgcccc ctgcaaaaaa ccgaatcttc aggtcttctt ggggaagcat aaccttcggc
15 aaagggagag ttcccaggag cagagtcttg ttgtccgggc tgtgatccac cctgactatg
atgccgccag ccatgaccag gacatcatgc tgttgcgcct ggcacgcccc gccaaactct
ctgaactcat ccagcccctt cccctggaga gggactgtc agccaacacc accagctgcc
acatcctggg ctggggcaag acagcagatg gtgatttccc tgacaccatc cagtgtgcat
acatccacct ggtgtcccggt gaggagtgtg agcatgccta ccctggccag atcaccacaga
20 acatgttgtg tgctggggat gagaagtacg ggaaggattc ctgccagggt gattctgggg
gtccgctggt atgtggagac cacctccgag gccttgtgtc atggggtaac atccccctgtg
gatcaaagga gaagccagga gtctacacca acgtctgcag atacacgaac tggatccaaa
aaaccattca ggccaagtga ccctgacatg tgacatctac ctcccgacct accacccac
tggctggttc cagaacgtct ctcacctaga ccttgccctc cctcctctcc tggccagctc
25 tgaccctgat gcttaataaa cgcagcgacg tgagggtcct gattctccct gggtttaccc
cagctccatc cttgcatcac tggggaggac gtgatgagtg aggacttggg tcctcggtct
tacccccacc actaagagaa tacaggaaaa tcccttctag gcatctctc tccccaaccc
ttccacacgt ttgatttctt cctgcagagg cccagccacg tgtctggaat cccagctccg
ctgcttactg tcggtgtccc cttgggatgt acctttcttc actgcagatt tctcacctgt
30 aagatgaaga taaggatgat acagtctcca tcaggcagtg gctgttgga agatttaaga
tttcacacct atgacataca tgggtagca cctgggccc catgcaactca ataaagaatg
tatttt
```

35

SEQ ID NO. 10

hk7 amino acid

```
MARSLLLPLQILLLSLALETAGEEAAQGDKIIDGAPCARGSHPWQ
40 VALLSGNQLHCGGLVNERWVLTAAHCKMNEYTVHLGSDTLGDRRAQRIKASKSFRHP
GYSTQTHVNDLMLVKLNSQARLSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFF
SDLMCVDVKLISPQDCTKVYKDLENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGL
VSWGTFPCGQPNDFGVYTQVCKFTKWINDTMKKHR
```

45

SEQ ID NO. 11

KLK7 nucleic acid

CDS 16..777

```
ggatttccgg gctccatggc aagatccctt ctctgcccc tgcagatcct actgctatcc
50 ttagccttgg aaactgcagg agaagaagcc cagggtgaca agattattga tggcgcccca
tgtgcaagag gctcccaccc atggcagggt gccctgtcga gtggcaatca gctccactgc
ggaggcgtcc tggtaaatga gcgctgggtg ctactgccg cccactgcaa gatgaatgag
tacaccgtgc acctgggcag tgatacgtg ggcgacagga gagctcagag gatcaaggcc
55 tcgaagtcat tccgccaccc cggctactcc acacagaccc atgttaatga cctcatgtc
```

```

gtgaagctca atagccaggc caggctgtca tccatggtga agaaagtcag gctgccctcc
cgctgcgaac cccctggaac cacctgtact gtctccggct ggggcactac cagcagccca
gatgtgacct ttccctctga cctcatgtgc gtggatgtca agctcatotc ccccaggac
tgcacgaagg ttacaagga cttactggaa aattccatgc tgtgcgctgg catccccgac
5 tccaagaaaa acgcctgcaa tggtgactca gggggaccgt tgggtgtcag aggtaccctg
caaggtctgg tgcctgggg aactttccct tgcggccaac ccaatgaccc aggagtctac
actcaagtgt gcaagttcac caagtggata aatgacacca tgaaaaagca tcgctaacgc
cacactgagt taattaactg tgtgcttcca acagaaaatg cacaggagtg aggacgccga
tgacctatga agtcaaattt gactttacct ttccctaaaag atatatattaa acctcatgcc
10 ctgttgataa accaatcaaa ttggtaaaga cctaaaacca aaacaataa agaaacacaa
aacctcaa

```

SEQ ID NO. 12

KLK7 nucleic acid

15

mRNA

```

join(1756..1785,3179..3309,3722..3869,4566..4813,5129..5265,7362..8265)
/product="stratum corneum chymotryptic enzyme" /note="alternatively
spliced"

```

20

```

mRNA join(1756..1785,3179..3309,3722..3869,4566..4813,
5129..5265,7362..7991) /note="alternatively spliced"

```

mRNA

```

25 join(1821..1864,3179..3309,3722..3869,4566..4813,5129..5265,7362..8265)
/product="stratum corneum chymotryptic enzyme" /note="alternatively
spliced"

```

mRNA

```

30 join(1821..1864,3179..3309,3722..3869,4566..4813,5129..5265,7362..7991)
/note="alternatively spliced"

```

```

CDS join(3237..3309,3722..3869,4566..4813,5129..5265, 7362..7517)

```

35

```

ggcatggtgg tgcacgcctg taatccagct actcaggact ctgaggcagg agaatcactt
gaacacgggg gagtggaggt tgcagtgagc cgagatcgtg ccattgcact ccagcctggg
tgacagagcc agagtccatc aaaaaaaaaa aaaaaataaga aagattcttc tctcctctat
gtgtccatgc agtctcatca tttagctacc acttgtaagt aggaacatgc catatctggt
40 tttctgttcc tgccttagtt tgtaagggtg atggcctcca gctccattca cgtccctaca
aaggacatga tcgtgttctt ttttatggct acgtagtatt caattgtgta tacgtaccac
atcttcttaa tccagtctat cactgatgga catttaggtt gattccctgt gtttgcgtgt
gtcaatagtt ctacaatgaa cgtacgtgtc catgtgtctt taaacagaat gatttatatt
cctttgggta cacacactgg ggcttatgag aggggtggaga gtgggaggaa ggagaggatc
45 agaaaaaaat aactaatggg tactaggcct aatacctggg tgattaaata atctgtataa
caaaccocca tggcgcacgt tcacctacgc aacaaacctg cacatcctgc acatgtaccc
ccgaactgaa aagttaaaaa aagaaaaata aatatttgct tataaattaa taaatgaagc
cctcaaaaaa gttctattag ataattgtta gtacagacat ttttgttata aatacataat
atacaaagaa atctatgtat aacatgatta aaatgaccat aagaacatag atcctaaaca
50 tggcaaatat tagtgggggt gggttaggga aagcgttgtt ttttaacttac acctctctgt
tagagtggg aatgggttca ggcgtaatta caggcacgac tgggatcagc ttggacaagt
tccccaggc gggccagaat taggatgtag ggtctaggcc acccctgaga gggggtgagg
gcaagaaaaa gggcccagaa gccgggcgca gtggctcagc cctgtaatcc cagcactttg
cggggcccag gcgggcacat catgaggtca ggagatcgag accattctgg ccaacatagt
55 gaaacccggt ctctactaaa aatacaaaaa ttagctggga gtggtgggtg gtgacctgta
tcccaggtag tcgggaggct gaggcaggag aatcacttga acctgggagg cggagctggc
agtgaagcga gatcgcgcca ccgcactcca gcctggcgat agagagagac tccatccaaa
aaaaagaaag gaaggaggagg agggaggagg gaagaaagaa agaaaaccgc ccagagagaag

```

gaccccgagcc agagccctatt ctctgagctc agcgactgct tgaatcccgc tcctgcccct
cagacccagc gcacccgggtc cctccccga gagcagccag gagggactgt gggaccagaa
tgtgcggggg cgcaggagct gggcaccgcc cgtccttcgg agggagggtg gagagagagt
gcagtggtgc caattgtctc cgctgcgtca gggttccaga taaccagaac cgcaaatgca
5 ggcgggggtg tcccagagtc ggctccgcct gcacccaggg gcgctggggc cgggcatggg
gcggggggtg atataagagg acggcccagc agagggatga agattttgga gccagctgt
gtgccagccc aagtcggaac ttggatcaca tcagatcctc tcgaggtgag aagaggcttc
atcaagggtg cacctgtagg ggagagggtg atgctggctc caagcctgac tctgctctcg
agaggtaggg gctgcagcct agactcccg tcctgagcag tgagggcctg gaagtctgca
10 atttggggccc ttttagggaa aaacgaacta cagagtcaga agtttggtt ccacagggaa
gggcaagatc ggagcctaga ttctgggtc tctagggatc tgaagaacag gaattttggg
tctgagggag gaggggctgg ggttctggac tcctgggtct gagggaggag ggcctggggg
cctggactcc tgggtctgag ggaggagggg ctgggggtct cgactcctgg gtctgaggga
ggaggggctg gggcctgga ctccctgggtc tgagggagga ggggctggga cctggactcc
15 taggtctgag ggaggaggag ctggggcctg gactcctggg tctgagggag gaggggctgg
ggcctggact cctgggtctg agggaggagg ggctggggcc tggactcctg ggtctgaggg
aggaggggct ggggcctgga ctccctgggtc tgagggagga ggggctgggg cctggactcc
tgggtctgag ggaggagggg ctggggcctg gactcctggg cctgagggag gagggactga
gacctggact cctaggctcg agggaggagg gactgggacc tggactcctg ggtctgaggg
20 aggaggagct gggggcctgg actcctgggt ctgagggagg aggggctggg gcctggactc
ctgggtctga gggaggaggg gttggggcct ggactcctga gcctgaggga ggagggactt
ggacctggac tcttaggtct gagggaggag gactcctgg gtctgaggga ggagggggtg
ggaggcgggg ctgggggctt ggacttggac ctggactcct aggtctgagg gaggaggagc
25 tgggggctg gactcctagg tctgagggag gaggggctgg gggcctggac tctgggtct
gagggaggaa ggtgctaggg tctggactct tgggtatgag ggaggaggag gttagggggtc
tggacttctg agtgaagga aggagaggcc agagaaagga atttctgggt ctgagggagg
aggggctggg gttctggacc cctaggctct agggaggagg ggctggggcc tggacccctg
ggctgagggg aggaggggct ggggcccgtg ctccctgggtc tgtgggggga ggggctgggg
30 cctggacccc tgggtctgag tggggagggg ctgggcctga atgctttctc cttctcagct
ccagcaggag aggcccttcc tgcctggga gccctgagc ggctcagcag ggcaccatgg
caagatccct tctcctgccc ctgcagatct tactgctatc cttagccttg gaaactgcag
gagaagaagg tgaaagctgg actgggaagt ctgacctcac ctcaggggccc ccaactgaccc
35 tctccaagga gtccctgagt cagaaccctt cctcctcaa acagcttcca tctggggagg
accagactgt cggctgaagc ccccgctctt cctgcttctg ctgactcagg gggctctctg
ccctccagg ccctgcctcc tgtgctcagg gtctctctgt ggttccccag atgagatgcg
cctcctgggt ttctgagtg gctcctctct tctgtctcta tccctatctc ttgctttctc
tgtatttctc cacacatttt catctgtctc tgtccatctc tgactctggg aatccctgag
40 gtgcagcctc agccttcccc taatgctagc tacccactg ctccctccatg tctccatcca
gcccagggtg acaagattat tgatggcgcc ccatgtgcaa gaggctccca ccatggcag
gtggccctgc tcagtggcaa tcagctccac tgccggaggcg tcctgggtcaa tgagcgctgg
gtgctcactg ccgcccactg caagatgaag taggtgccgc ccaagtctct gctggagggtg
caccagcgct tccagctcgc tatgggggtg gaagggcagt ctttctgtgc ctacggctct
attctcctct ctctgggtct ctgtcctcct ctctctgggc ctctgtaccc cctctccctg
45 gggctctgtc cccctctctc cctggctctc tgtctccctc tctctgggtc tctgtccccc
tctctctgga tctctgttcc cctctctctg tgtctctgtt ccccatctc tctaggtctc
tgttccccct cctctctctc tgggtctctg tccctctctc tctggatctc tgtccccc
tctctctggg tctctgttcc cctctctctg ggtctctgtc cctctcctc tctctgtgtc
tctctcccc ctccctctct tgtgtctctg tccccctcc tatctctgtg tctctctccc
50 cctcctctc tctgggtctc tgtccccccc tctctgggtc tctgtctccc tctctctggg
gctctgtccc cctctctctc tggatctctg ttccccctc tctgggtctc tgtctcccc
cctctctctg tgtctctgtc cccctcctc tctctgggtc tctgtcccca ccccgcccc
caggtctttg cacacccctc ctgtcacagt gtctcttctg aatctgtgaa tgtcactcct
cgcagtgagt acacccgtga cctgggcagt gatacgctgg gcgacaggag agctcagagg
55 atcaaggcct cgaagtcatt ccgccacccc ggctactcca cacagacca tgtaaatgac
ctcatgctcg tgaagctcaa tagccaggcc aggcgtgtcat ccatgggtgaa gaaagtcagg
ctgccctccc gctgcgaacc cctggaacc acctgtactg tctccggctg gggcactacc
acgagcccag atggtaggtg gcctcagtga cccaggagtg caggcccccag cctcctccc
tcagaccag gagtccaggc cccagcccc tcctccctca gaccaggag tccaggcctc

	agccccctct	ccctcagacc	caggagtcca	ggccccagc	ccctcctccc	tcagaccchg
	gagtcagac	cccagcccct	cctccctcag	accagcagct	cctggggccc	agaccctcct
	ccctcggaac	caggagcctg	aacaacagcc	cttctgggtcc	tggcccccat	cctctctgac
	tgacagctct	ccctgctcct	ccctgcagtg	acctttccct	ctgacctcat	gtgcgtggat
5	gtcaagctca	tctcccccca	ggactgcacg	aagggtttaca	aggacttact	ggaaaattcc
	atgctgtgcg	ctggcatccc	cgactccaag	aaaaacgcct	gcaatgtgag	accctccccc
	ccaattcctc	cccagtcctg	ggtaccctgt	ctgcatgccc	cagggacaga	gcttgaccgg
	agtgaactgg	taccaagccc	ggccttgccc	tccccccagg	cctggcctcc	tcagcttttt
	ccacctcatt	ctctgcctag	gtcaggggtg	ggagtttact	taggggcca	tgtggccctg
10	gggatgagac	agagagttaa	ataggggtga	gaaagtgggg	gtgggaccag	ggaaggagac
	tgagggtgctg	gcctcaggcc	caaaccctaa	gggggcacca	aaaacctoag	tgattgagat
	aaatcataat	gcaatattta	aaaataaaaa	taaaaactca	tcagaaagtc	catgatggac
	aaaatgtcac	attttaaata	aagagcaggt	ggatcttact	gaattttccc	ttgcccgaag
	tactagcgtg	gtcagcaca	gcgctgtact	ggcactgtct	tcatttaaaa	tgtggatacc
15	atgcccataca	tgagttttta	tgtattacat	ttgatttcgt	taagtactgc	attgaagtat
	tgtgtattgc	agtactgag	atgtttgtcc	tgaagctgat	gactcactca	cctgaccctg
	gccctgggtcc	cggggaaaac	actctttctc	tccaactcct	ctctgttccc	tctttctggc
	cttttgcctc	ccctctgtt	tctgaacagt	cttccacat	ctctctttgt	gacataattt
	catcttcatc	ttttcctctt	tgttttttct	ctgtgttgag	ctagcttgct	ctccctccct
20	tgttctctct	ccatgccctc	ctctctgtct	tctgtcttct	ccctctttct	cttgtctctc
	tctctctcct	ccctccctc	tctctctctc	ctgccccctc	gctctctctt	ttttcctctc
	tctctgtctc	ctctctggcc	ctctctctct	tctctctctc	ccccacttct	ctgtctctct
	tcactctctc	ccctcatctc	tccttgcccc	ctccttttta	ctgtctctct	ctttctcttt
	cttctatctc	tctctctctc	ctgcccctcc	cccatctctg	tctttctttc	tctctcttta
25	ttctctctct	ctcttccagt	ctctctctct	tctccccacc	cccaccccat	ctctctcccc
	acaccttccc	cccttttctc	tttgtctctc	tcttctccct	ctttcttctc	cacccccatc
	tctctctctc	ttctcttccc	acaccttccc	catctccctc	atctctttgt	ctgtctctct
	tctccctcct	tcttttccac	ccccatctct	ctgtctctct	ctctcccat	accctttccc
	tottctcat	ctctctttgt	ctctctctct	ttccctctct	tcttctccac	ctccaactct
30	ctctgtctct	ccacacccat	cctccttgct	cacatctgca	ccttcagctg	tcaggggatg
	tgggatgggtg	agtgttaggg	atagaggaga	tgggagagag	atgactgtcc	tagagaatag
	ggtgttcccc	ttctcccctg	gtgagggcca	gtttcatgaa	tgtgcaagct	ctgcacggac
	acagagcccc	acactcagaa	gggtctcaaa	cttagtctaa	tgcattcctg	ctgttgtctt
35	gaaattctca	ataatttttg	aacaaaaggc	cctgcatttt	cgttttgca	caagctcctg
	aaattatgta	actggtcttc	accctggtct	ccgagaccat	cgtgtcccc	tttctgccc
	cacagggcac	gcattccacc	cttgagatg	atgttctctc	tccactagc	ttggagcagg
	gtccttaaca	ttggaaaata	aagagtgtct	tgaactctga	agccccacc	cttctctgca
	attggtctca	ttggccaagg	gtcaaacacc	tgtcttcaaa	ggacctagtg	tgtccctagc
	actagctctc	ccattagctc	ccagagacaa	tgaactctct	ctcattggct	atggtggaag
40	tccataatct	gcaagacaaa	gaccgataac	tgaggaatgt	atgagaatga	gttgggcttt
	gatctgaagc	caaagttaat	ctccggctct	attccctcta	gggtgactca	gggggaccgt
	tgggtgtgag	aggtaaccctg	caaggtctgg	tgtcctgggg	aactttccct	tgcggccaac
	ccaatgacc	aggagtctac	actcaagtgt	gcaagttcac	caagtggata	aatgacacca
	tgaaaaagca	tcgctaaccg	cacactgagt	taattaactg	tgtgcttcca	acagaaaatg
45	cacaggagtg	aggacgcga	tgacctatga	agtcaaat	gactttacct	ttcctcaaa
	atatatttaa	accaacctca	tgcctgttg	ataaaccaat	caaatttgga	aagacctaaa
	acaaaaacaa	ataaagaac	acaaaaccct	cagtgtctga	gaagagtcag	tgagaccagc
	actctcaaac	actggaactg	gacgttcgta	cagtctttac	ggaagacact	tgttcaacgt
	acaccgagac	ccttattcac	cacctttgac	ccagtaactc	taacttagg	aagaacctac
50	tgaacaaaaa	aaaatccaaa	atgtagaaca	agacttgaat	ttacctgat	attatttatc
	acagaaatga	agtgaacca	tcaaacatgt	tccaaaagta	ccagatggct	taaataatag
	tctggcttgg	cacaacgatg	ttttttttct	ttgagacaga	gtctctgttg	cttgggctgc
	aatgcagtga	tgcaatcttg	gtcactgca	acctccgcct	cctgggttca	agtgtattct
	gtgcttcagc	ctcccaagta	cctgggacta	caggtgtgca	ccaccacacc	aggctaattt
55	tttgtgtatt	tttactagag	acagggttct	accatgttgg	ccagcatggg	cttgaacgcc
	tgacctcaga	tgatccaccc	accttggcct	cccaaagtgc	tgggattaca	ggcatgagcc
	accacggcca	gcccacaatg	atattacaaa	cctattaaaa	atgatactta	gacagaattg
	tcagtattat	tcaagaacat	ttaggctata	ggatgttaaa	tgacaaaagg	aaggacaaaa
	atatatatgt	atgtgaccct	accataaaaa	aatgaaatat	tcacagaatc	agatctgaaa

```

acacatgtcc cagactgcat actggggtcg tcatgaggtg tctccttcc tctgtgtact
tttccttgaa tgtgcacttt tataacatga aaaataaagg tggggaaaaa agtctgaaga
tctaagattg gagagaggtg acctttcagg aaggagagact agaaagaaat atgtgcttg
ttttgagccc tggctcctgcc ggccctgttc cagggcatat ttccatttcc cagatctcag
5 tttttcctgt ctgtaaaatg ggagagagag gaaaggatgg agagaggaag aaggaaggga
ggagggagga gagaacaggc caacttcata agcgtgggaa ggggtgtgaa agtgtttctg
agcatctcac gagtgacaag tgaggaggga ggctggcggg tttcagaggg attgggatga
cagtagacag gacacagggg tcccacgggg gtctgccaga agtaagcaaa cagtgccgga
ggaagatggt ggcacctgct cccaagaag ggagggaaaag gaacctcggg aagcgggtag
10 gatgaggag gagtcctctg tgactcagag cctggccaca gcccagcca tctaacaatca
aagatcctct gtgtggtcac acctcagacg ctgctgaccg aggagccact ccagcccagg
acacgccctc ctacctgttc ttctgtttt tctcccagaa ttccctcccc accaagatcc
tccagatcct tccctcctt atctcatctc cctctgagtc tctcctaacc caggcaccac
agccctgtca tattgcagaa attctgcagc cgctaattct gattctccca tataggaggc
15 taacacagaa aacgcaggag tccaggcccc cagcccctcc ttcctcagac ccaggagtcc
agaccccccg cccaacccc tctcctcca gaccaggag ccaggtccc cagccccttc
tgtttctggg cctgtcaagt ttaagaatgt caaacatttt cgaccagtca ttcccttgaa
gttttagcaa cattttctct ctcttctgca aggcactcca acattcaatc tggattttta
aaaagtaaca aaacattgca tttgactaa gtacgcctgg agatccctgg ccctggccct
20 ctgctctcct atacgcaagc tacaggtaga ttggtttgca atgactgaga tggactaat
gttgattttt ttaagtaat tcattttct ttgggtaagc agtatagtgt ygtagttaag
ggactagctc tggatcttgg ctctctgggt tcaaatccca gttctagtcc ctacaagcta
ttttccttta agctcattac ttccctgtc cctgttctt catccttgaa atgggagaaa
aagcacctac tttctagggt tattacagag attcaataag ttaatatata gaaagtgtc
25 aaacattgt

```

SEQ ID NO. 13

Hk8 amino acid

```

30 MGRPRPRAAKTWMFLLLLGGAWAGHSRAQEDKVLGGHECQPHSQ
PWQAALFQGQQLLCGGVLVGGNWLTAACHCKPKYTVRLGDHSLQNKDGPQEIPVVQ
SIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSVKPISLADHCTQPGQKCTVSGWGTV
TSPRENFDTLNCAEVKIFPQKKCEDAYPGQITDGMVCAAGSSKGADTCQGDSSGGPLVC
35 DGLAQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSKG

```

SEQ ID NO. 14

KLK8 nucleic acid

40 CDS 35..817

```

gtgaccccgcc cctggattc tggagacct caccatggga cggcccgac ctctgctggc
caagacgtgg atgttctctg tcttgctggg gggagcctgg gcaggacact ccagggcaca
ggaggacaag gtgctggggg gtcatgagtg ccaaccccat tgcagcctt ggcaggcggc
45 cttgttccag gccagcaac tactctgtgg cgggtgcctt gtaggtggca actgggtcct
tacagctgcc cactgtaaaa aaccgaaata cacagtacgc ctgggagacc acagcctaca
gaataaagat gggccagagc aagaaatacc tgtggttcag tccatccac acccctgcta
caacagcagc gatgtggagg accacaacca tgatctgatg cttcttcaac tgcgtgacca
ggcatccctg ggttccaaag tgaagcccat cagcctggca gatcattgca ccagcctgg
50 ccagaagtgc accgtctcag gctggggcac tgtcaccagt ccccgagaga atttctctga
cactctcaac tgtgcagaag taaaaatctt tcccagaag aagtgtgagg atgcttacc
ggggcagatc acagatggca tgggtctgtg aggcagcagc aaaggggctg acacgtgcca
gggcgattct ggaggcccc tgggtgtgtg tgggtgcactc cagggcatca catcctgggg
ctcagacccc tgtgggagggt ccgacaaacc tggcgtctat accaactctt gccgtacct
55 ggactggatc aagaagatca taggcagcaa gggctgattc taggataagc actagatctc
ccttaataaaa ctcacaactc tctggttc

```

SEQ ID NO. 15

KLK8 nucleic acid

5 CDS join (<1..39, 418..712, 878..>946)

Exon <1..39

Exon 418..712

Exon 878..946

```
10 tcttcggttc ccggttactg gcagcagccc cctcctccca caaaagatca ggttccaagc
   ttctcctttt aaaagtactt agaattcagc ccccagctct ctctcctc acacccagga
   atccaggccc ctagcccctc ctccctcaga cccaggagtc ctggccccta gcagcccctt
   cctccctcag acccaggagt ctgggccccc agcccctcct cggtcagacc taaatcccag
   gtcccagttc ctctcctctt agatttagga gtccaggccc ccagcctctc ctccctcaga
15 cccagggaatc caggccccca gcctcctccc ctctcagaac taaaatcttg gccccagcc
   ctttatgttt cagatcgtag agtctcagca ccgagtcctt cctctcccta gcctcaggag
   tctgagattc cagcccctcc tccctcaaga ttccacgttc aatcccctcc gcccttctc
   actcacacc cagtgttcag ttcccagaag ctcccaggc tctagtgcag gaggagaagg
   aggaggagca ggaggtggag attcccagtt aaaaggctcc agaatcgtgt accaggcaga
20 gaactgaagt actggggcct cctccactgg gtccgaatca gtaggtgacc ccgcccctgg
   attctggaag gtgaggtgca gaggtactca gatacagaca tcaggccccg gacctcctt
   ctccagattc caggacccca gcctcagatg cccttctctg tcgagatoca gcagtctgga
   ccccggttcc ctctcctccc taatttagga gtcccagctc ccagctccct gtcccctcag
   acccagacat cgaggactcc cccctccctt ggaatgtagg aatccagtc cccagcctcc
25 tccttctccc agagaagccc agaacagccc cagatactct cggctgcctc cccagtgcc
   aaatccagaa ctgggagctc aggtcctccc ttctgttta ccggccccgc cctctccatt
   tcccagacct caccatggga cgccccgac ctctgtcggc caagacgtgg atgttctctg
   tcttgctggg gggagcctgg gcaggtgagg aggggttgcg aggcctccgg aggggagga
   tctgaaggca gcagtggcgc tggggagtct gtgggaatgc cgcgggggtt atgtgggtgc
30 gtgtgcacgg atgtgaagag tgcgatacgg tgcaggagcc tctgtgggtt ttctcaggg
   tggacagagg caagaaacag gtagcagcag gtaggagtag gttccgtgat gctgtaaatt
   gtctgaatag ctacagcctt tgggggctgc ttgcttgggg gcatagattc acctgggagt
   actcggggcc tgtagactca tgtggaagca tgtgggggca ttcttgggtg tgtgactctt
   gtatgatgac acatggactg aaatgagtgt cccgtgtgtg cagcgtgtgg aagcctggac
35 ctctcacta agttgtatgc ggagaacttg ccgtgtgtcc atttgaacc acagtggcct
   tcccagccct cgcactgccc cagagggtgg cgatccaacc ctctccctcc tctgtcagga
   cactccaggg cacaggagga caaggtgctg gggggtcatg agtggcaacc ccattcgag
   ccttggcagg cgcccttgtt ccagggccag caactactct gtggcggtgt cctgttaggt
   ggcaactggg tccttacagc tgcccactgt aaaaaaccgt gagtggatga tgggggcaga
40 ggtcagctgg ggcttaagga aagagggggc tgggggttct actcaggaag gagagagctg
   aggactggac tcctgggtct gaaggaggag ggggctgggg gcaatacccc tgccctgggtc
   ccaaactatc cccaccatta caggaaatac acagtacgcc tgggagacca cagcctacag
   aataaagatg gccagagca agaaatacct gtggttcagt ccatcccaca cccctgctac
   aacagcagcg atgtggagga ccacaacat gatctgatgc ttcttcaact gcgtgaccag
45 gcatccctgg ggtccaaagt gaagcccatc agcctggcag atcattgcac ccagcctggc
   cagaagtgca ccgtctcagg ctggggcact gtcaccagtc cccgaggtag tgggttctc
   cactaatggg agggagagga ggagctggtt ggcccagtg aaccaagct attggcaag
   cttggtcccc cagagggaga caaagaagg aaagtgatca tgatgttgag attcacaagc
   aggagtcata tgagaagcct cgaagatctg actactaaca agagtgggtg agaaagaac
50 caactagcag attgttaagc agggccagaa aagcccatcc tgtatggcgg agagcactac
   octatgggac ctttggttgt ataggatttt atataatctt aacacacttg ggatattttg
   gacttctcag agggccagga aaacaggctc ctaagcacct tctccccac ctccctcctt
   tttttttttt tttttttttt ttttgcagg ggacacagtt tcaactcaat gcccaggctg
   gagtgcagtg gcacaatctc agctcactac aatctctgcc tcctgggttt aagcgattct
55 cgaacctcag cctcccgagt agctgggatt acaggcacc gccaccacgc gagctaattt
   ttgtatttgt ttagagaca gggtttcgcc atgttgacca ggctggtct gaactcctga
   cctcaagtga tctgcccgc tcggcctacc aaagtgtctg gattacaagc atgagccacc
   gccctggcc tttttctcct tcttgaacct aggaaacctg ggccctgggt acctcttccc
```

	tcagacccgg	gagtcctaggg	ccttcttctc	ccaggaccca	gcagtcctag	ctccctcttg
	actctggacc	ccaaaatctg	gacctccaat	gaagctgtcc	ctttgggact	ccagaatcca
	gagagccct	cgccttccct	cacagtgaat	acattgggac	tcacctaa	gagtcaggga
	gcttctccag	gaagtggcaa	agtcagcatt	caggctccctg	cctgcctcac	tcctgtctctg
5	aatgctttgg	atgagacagt	ttgcccgtgt	ggaaacacac	gtgctcgcaa	atcaagtaga
	tcagttcaaa	ctatggctct	gccctttctc	cctgggcaaa	ttcctttcca	tctctgagcc
	tcactttcct	tatctgcaaa	atgggaatca	ttaccaata	gatttttttag	ctacgtgagg
	gttcagggtta	catcagtttt	cttcattgtg	ttctcctagt	gtcagaatg	gtgcctgcta
	catggtagat	gctcaataaa	tatttgttga	atggatgacc	tgatgaataa	ataatgaaat
10	gaatgaatgc	atctctcctt	caaagcgtg	ttgtgaggat	ttaatgagat	tatgagcata
	ttgcttttgg	cacgtagaga	tgccagatgg	aagtttttcc	ccctcaaaga	ggctttggag
	aagtctattc	ctcaaaagag	gttaataaaa	aagatcaatt	ccaccttcaa	tcattaatte
	aactcttatt	tactgagcac	ctagtatgcc	tgaggtgctg	ttgcaggcgc	tggatataca
	gccatgagca	aactgtacaa	agtccttgtc	gttatggagt	tgcaagctag	gtgggagaaa
15	tagacaataa	acaaatacac	ataaaaataa	acattaggca	aagtgctgta	aggaaatatt
	gtggagcgta	aaaggatagg	gagtaatgga	gggatgggat	tttttaattc	gagtggtcag
	ggaaggcttc	caggaggagg	tgacacttgg	aaggagcagg	atttagcaca	gattgaggac
	ccggttgtct	gagggcagga	agactggaaa	gagagggtca	gaggtatcat	aaaggggcac
	ctccaagtaa	ccccagccc	cttgatttga	aaatggctca	gggtaagaaa	aaacacgtga
20	gatccaaggg	ccccctctct	gatggagaaa	gccaatagc	aacaagtaca	gcttcgttta
	atgtggtgag	aagtgtgtgc	ccctgtgcac	agtgtcagaa	aattccccc	tgagctgga
	aaactccccc	attacatcct	ggaaagaaag	gggttagat	ccagacaggg	atggaggcaa
	agggtgtctc	tctcagggaa	ccttacaacc	tcttccccct	cagagaattt	tcctgacact
	ctcaactgtg	cagaagtaaa	aatctttccc	cagaagaagt	gtgaggatgc	ttaccggggg
25	cagatcacag	atggcatggg	ctgtgcaggc	agcagcaaa	gggctgacac	gtgccagggtg
	agcaatttct	gaaatccttc	tcctcacaca	tcctcattg	ccctctcgag	gttcaaggct
	tggatggggg	tgggggtggg	aagggagtga	cccaaagac	ttggcaccog	gagtgttcac
	ccctatctct	acggattggg	agccaggttc	agagaagcca	aactctctct	ctgaaagtca
	cactgcatag	ggattaggag	cattgaattg	ctgctgctgt	tttctttcca	acgcttaact
30	acaggatggg	atgcagagtt	gggggctata	gaggggtggg	tagatgtcca	gcaaggagag
	agtctgaggg	tagagtttag	acgagttgcc	tgctctctgg	ttccagcat	tacatcgtgg
	aatttgtgcc	gactttacca	ccggcccggt	ggtcagccac	ttttctttga	gaccgggcta
	gaatcccaag	gctggttccc	ttctcctgtg	attggttcct	tgggagacaa	tgggtgtctc
	ccagttgggt	ggagtaaatg	gtgccattga	cttcagtgtc	tcctcaatga	gctccaatcc
35	ctttctcttg	ggatttgtca	tagatataac	tctctcttct	aactgcaact	tcgttgttcc
	tagcaactttc	ccctggcctt	gtccacttcc	tggaaagccc	accacctttg	ccaatgactg
	gtccctaata	acaatgcttt	cttccccatt	ggccaaaaat	ggagtctgtt	ccatcagcga
	tactgccatg	aaagccagtc	tctggattgt	tctgtagaga	tagtggtctc	ttccacaaat
	atttcagcca	tggctctctg	gggatattgg	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt
40	gtgtgtgtgt	gtgtccataa	gaatcttgat	cctttctcct	atgttttgca	actgcaatca
	atgatgcctt	cactattggc	caggaacaga	ggaaacttca	gtcagtcct	ctccaagtaa
	tocctactgt	cttctccctg	gattggaccc	tcgagaactc	tttttttttt	ttttttgaga
	cagggtctcg	ctctgtcccc	caagctggaa	tgagtgga	caatcttggc	tcactgcagc
	ctctgctccc	cagttcaagc	aattctccca	cctcagcctc	ccgagtagct	gtgattacag
45	gtgtgcacca	ccacaccag	ctagtttttg	tatttttagt	agagacaggg	attcaccatg
	ttggccaggc	tggctctgaa	cgcctgactt	caagtgatct	accgcctcgg	cctcccaaag
	tgccgggatt	gcaggtgtga	gccaccaagc	ctgtctggga	tttcattctt	ttccctcttc
	tgtagtggtt	ttgaccacta	cccttagaca	ccatgtctgt	ctgtacatgg	aagccccaa
	ccctgtcctg	actggtctca	ggggacaatg	cttttaccct	cattggctac	aggggaccaa
50	tcattgcaaa	gaactggtaa	aacgtggga	cagcaggaaa	agggacgttg	tggacatctc
	agatgcaagg	ctgttctcat	tctccctgtc	tagggcgatt	ctggaggccc	cctggtgtgt
	gatggtgcac	tccagggcac	cacatcctgg	ggctcagacc	cctgtgggag	gtccgacaaa
	cctggcgtct	ataccaacat	ctgccgctac	ctggactgga	tcaagaagat	cataggcagc
	aagggctgat	tctaggataa	gcactagatc	tccttaata	aactcacaac	tctctggttc
55	cttgccctgtc	tctgttttgg	ccctgtgggg	agggctggat	ggggatccgg	gattgttcc
	gctggcagac	taggtgggga	tgtgcagaaa	ccaagttctc	atggtcactt	tggccatcac
	cactgcctaa	agtgtacct	cgttttctgg	aagaacttgg	gtaagagctt	tatttcaggg
	gagaaaatac	atacaaaggt	cttcaaacat	tcagtggtgt	ggtatgtgaa	agacagtttt
	gaaagagtgt	gtgttttagt	ttcctgagca	aagcattttac	aagcttttga	gataaaattt

tcccccttta aaaaaataatt

SEQ ID NO. 16

5 Hk10 amino acid

MRAPHLHLASAASGARALAKLLPLLMAQLWAAEAALLPQNDTRL
PEAYGAPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDHLL
LLQGEQLRRTRTSVVHPKYHQSGPILPRRTDEHDLMLLKLARPVVPGRVRALQLPY
10 RCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVTTNNMICAGL
DRGQDPCQSDSGPLVCDLTLQGILSWGVIYPCGSAQHPAVYTQICKYMSWINKVIRSN

SEQ ID NO. 17

15 KLK10 nucleic acid

Gene 1...1580
CDS 220...1050

20 catcctgccca cccctagcct tgctggggac gtgaaccctc tccccgcgcc tgggaagcct
tcttggcacc gggaccggga gaatccccac ggaagccagt tccaaaaggg atgaaaaggg
ggcgtttcgg gcaactgggag aagcctgtat tccagggccc ctcccagagc aggaatctgg
gaccaggag tgccagcctc acccacgcag atcctggcca tgagagctcc gcacctccac
ctctccgccg cctctggcgc ccgggtcttg gcgaagctgc tgccgctgct gatggcgcaa
25 ctctggggccg cagaggcggc gctgctcccc caaaacgaca cgcgcttggg ccccgaggcc
tatggctccc cgtgcgcgcg cggctcgcag ccctggcagg tctcgtctt caacggcctc
tcgttccact gcgcgggtgt cctggtggac cagagttggg tgctgacggc cgcgcactgc
ggaaacaagc cactgtgggg tcgagtaggg gatgaccacc tgctgcttct tcagggagag
cagctccgcc ggaccactcg ctctgttgtc catcccaagt accaccaggg ctcaggcccc
30 atcctgcca ggcgaacgga tgagcacgat ctcatgttg tgaagctggc caggcccgtg
gtgctggggc cccgcgtccg ggcctgcag ctccctacc gctgtgctca gcccgagac
cagtgcagg ttgctggctg gggcaccacg gccgcccggg gactgaagta caacaagggc
ctgacctgct ccagcatcac tatcctgagc cctaaagagt gtgaggtctt ctacctggc
gtggtcacca acaacatgat atgtgctgga ctggaccggg gccaggacc ttgccagagt
35 gactctggag gcccctggt ctgtgacgag accctccaag gcatcctctc gtgggtgtt
tacctctgtg gctctgcccc gcatccagct gtctacacc agatctgcaa atacatgtcc
tggatcaata aagtcatacg ctccaactga tccagatgct acgctccagc tgatccagat
gttatgctcc tgctgatcca gatgccaga ggctccatcg tccatcctct tcctcccag
tcggctgaac tctccccttg tctgactgt tcaaacctct gccgccctcc acacctctaa
40 acatctcccc tctcacctca ttccccacc tatccccatt ctctgctgt actgaagctg
aatgcagga agtggtggca aaggtttatt ccagagaagc caggagccg gtcatoaccc
agcctctgag agcagttact ggggtcacc aaactgactt cctctgccac tccctgctgt
gtgactttgg gcaagccaag tgccctctct gaacctcagt ttctcatct gcaaaatggg
aacaatgacg tgctacctc ttagacatgt tgtgaggaga ctatgatata acatgtgtat
45 gtaaactctt atggtgattg tcatgtaagg cttaacacag tgggtggtga gttctgacta
aaggttacct gttgtcgtga

SEQ ID NO. 18

KLK10 nucleic acid

50

Gene 1..5574
mRNA join(48..120,605..701,2455..2635,3589..3863,4195..4328, 4793..5474)
CDS join(614..701,2455..2635,3589..3863,4195..4328,4793..4945)
Promoter 1...47
55 5'UTR join(48..120,605..613)
exon 48...120

exon 605...701

	ttgggggtcaa	aaggggaaggt	cccgccaggg	gtccctgggc	agaggatacc	agcggcagac
	cacaggcagg	gcagaggcac	gtctgggtcc	cctccctcct	tcctatcggc	gactcccagg
5	tgaagctacc	tgacccccac	ccgggttggg	gtggattgcg	agaggatggg	tgggaacccc
	cgggccacag	gcaggagccg	gcttagagcc	tcggtttctc	cactgcggga	cgcggaagtc
	ccccgcgtgt	gaggttgaga	aagaggctcc	cactggctcc	gagcctcggg	tccccacccc
	gcgcgtgaag	gagggggaaa	cctcgggcgc	ggcgtggctg	cagccagggg	agctggggcg
	cggagagcgc	tccactcggg	cacagggagg	acgggaagat	gccgcgaggg	gcgtcattag
10	ggtaattgtg	cccattaccg	tggtccagcc	cgaatctccc	gtctgccagc	ccctgggggtt
	atcggtcgca	ggtcaaaagg	gtgcttgccg	gctgggggtg	cccaggctgg	gcggatgagc
	gcggcgagggt	gggggtctct	aacggagcat	ctgttttaac	ccgccccctg	acacacccca
	gcagatcctg	gccaatgagag	ctccgcacct	ccacctctcc	gccgcctctg	gcgcccgggc
	tctggcgaaag	ctgctgccgc	tgctgatggc	gcaactctgg	ggtaaggtag	gggacagggg
15	gcggggagag	gcgccggtgg	gaggcacggg	cgggagggca	atgtgttccc	gtcaccaagc
	cccgcgcacc	tctcctcccc	cgagacccca	gcacccaccc	agcgtctcgg	agcacggccc
	gcccccaagt	cagctggggc	cttctctctg	ctcgccccct	gggtgaccgc	ccccactcag
	gcocctgtccg	atttctgcca	cccgatccct	cgctcttccg	tggactcttc	ggcgtgttct
	ttctcctcct	cttacgcgcg	cccatcccg	cccgcctcca	ttttacacta	ccgtgttttg
20	ttttgtttgt	ttgtttgttt	gagacggagt	ctcgtctctg	cgcccaggct	ggagtgcagt
	ggcgcgatct	cggctcactg	caagctccgc	ctcccgggtt	cacaccattc	tcctgcctca
	gcctcccagag	tagctggggac	tacaggcgcc	cgccaccaag	cccgctagt	tttttgtatt
	tttagtagag	atgggatttc	accgtggtct	cgatctcctg	gcctcgtgat	ccgcctgcct
	cggcctccca	aagtgcctgg	attacaagcg	tgagccaacc	ctcccggcca	caccacagt
25	ttttatcctg	agtcttgctt	taaccgtttt	tgccctctcc	cctcactttt	tttcttctc
	tttccctttc	tctctctttt	ttctttttct	ttctttcttt	tctttctttc	gttcttcttt
	tccttccttc	ctttccttcc	ttcctttcgt	ttgtttcttc	tttcttgttt	tactttctct
	cttatttttt	cttcttttct	tottgttttt	ttcttttctc	tctctttttc	tttcttcttt
	tttttttttt	tttttttgag	acagggcagt	gctctgtctc	cgtggctgga	gtacagtggc
30	ccaatcagag	ctcactgcag	cctcgacctc	ctgggctcaa	gcgatactca	gcctccagag
	tagctgggtac	cacaggcatg	caccaccaca	tccggctttt	tttttttttt	tttttttttt
	tttttttgag	acagggtctc	actctgtcgc	ccagactgga	gtgcagtggc	ccaatctcgg
	ctcattgcaa	cctccacctc	ctgggctcaa	gcgatcctcc	cacctcagcc	tcccaggtag
	ctgtgactac	aggcgcagtc	ctccgcgact	acttttttgt	tggtgtgtgt	gttgtttgt
35	ttttgtagag	actgggtcct	gctgtgttgc	ccgggctggt	cttgaattcc	cgagctcaag
	cggctccaacc	gcctcggctt	cccaaagtgc	tgggattaca	ggcgtaaacc	actgcgcccc
	acccctctcc	tggttttcaa	tcccgttttg	ttattcacac	cccttcctct	ccccgatccc
	cgagttctat	ccccgcaccc	ttacctcccc	gccgcgttca	atccccgccc	ctctatcgac
	cagcgacgtt	ctagccagct	ctccaggcgc	gctgcgttca	gtccctgccc	tccagaccca
40	ccctattctg	tctcattact	ccacgctacc	ctatcccagc	ttccttcac	tttcacgcgc
	ttcttctcct	cccattcctt	cgggtgcacgc	gaaacccccca	atatttccct	accaccctcg
	cgttctggct	gcgtcccccg	tcccgaacg	cagtccagtg	ccacagccca	gtcccaaccc
	caaaccocaga	ccctgcccctc	cgtgctttga	ttccgtcccc	tttctttctc	ccagccgcag
	aggcggcgct	gctcccccaa	aacgacacgc	gcttggaacc	cgaagcctat	ggcggcccgt
45	gcgcgcgcgg	ctcgcagccc	tggcaggtct	cgctcttcaa	cggcctctcg	ttccactgcg
	cgggtgtcct	ggtggaccag	agttgggtgc	tgacggccgc	gcactgcgga	aacaagttag
	aggagatcca	tccccgagga	cgccacgggg	ggctgtggag	gcggcctcca	gggaggagcg
	ggcagggcgg	ggtctctcgg	aactcccaca	gctggagggtg	cggctccccg	tgtccttcca
	gcaggaggag	agaccgggct	tgcgctgtgg	ccgccagggg	acgggtgtgt	ccttttccgc
50	atttctgggc	ccgtcaactcc	tctccgctg	attctccttg	agctctagga	ggaggtgggt
	gcctgcaacg	gatagaagcc	agggtccggt	gtggtcagga	atttagaact	aaaggaaaag
	gttcaacttcg	tgagtccccg	ttgaaggagg	aagggttggg	tattaccaca	gagaaaatgt
	ggagttgggc	tgggctcggg	ggctcacgcc	tgtaatccca	gcactttggg	aggccaaggc
	gggtggatca	cctgaggtca	ggagttcaag	accagcctgg	ccaacatggg	gaaaccactt
55	ctcaactaaa	aataaaataa	aataaaaaat	aaaaaatttt	aaaaaaatta	aaaaaaaaaa
	aaggctgggt	gtggtggcgg	gtgcctgtaa	tcccagctac	tcaggaaagg	ggctgaggca
	ggagaactgc	ttgaacctgg	gaggtggagg	ttgcagttag	ccgagattgc	gccattgcat
	tctagcctgg	gtgacaagag	cgaaactctg	tttcaacaaa	gaaaagaaaa	agagaaaaga
	aatgtggaa	ggcttaccta	ggtgtccagg	ccccagccc	tcctcaattc	ctgcagatcc

tcagagctca aacaactgat tctcctccc catgtccact gaggtccct tctcccacaa
 ggccctcttc cctcagactc ttcctatctc caggccctgc ttcactgccc acctgctttc
 ccagtccttg tgaagggttt gccttcacat gcctcttcc tccccaggc cactgtgggc
 tcgagtaggg gatgaccacc tgctgtctct tcagggcgag cagctccgc ggacgactcg
 5 ctctgttgtc catcccaagt accaccagg ctcaggcccc atcctgcca ggcgaacgga
 tgagcacgat ctcatgttg taaagctggc caggcccgta gtgcccgggc cccgcgtccg
 ggccctgcag cttccctacc gctgtgctca gcccgagac cagtgcagg ttgctggctg
 gggcaccacg gccgcccgga gaggcaagag ctggggctct gaggccagaa cctcaggagg
 agggggctga gggcctgaac cctgggtct gaggaaggat gggctggga ctggattcct
 10 ggatctgagg gaggacgggc tggggtccta gatgcctgg tctgtgagtc tgaggggagg
 aggggctggg ggctggact cctgggtcta agtggggagg ggctggggc aggattcttg
 agtctgaagg aggaggggct ggggcttagg atagaaacg tctgtatct ggaactcctg
 ctccccagg attgggggct ggaccaggg attactggca tattctccct tcagtgaagt
 acaacaagg cctgacctgc tccagcatca ctatcctgag ccctaaagag tgtgaggtct
 15 tctaccctgg cgtggtcacc aacaacatga tatgtgctgg actggaccgg gccagggacc
 cttgccaggt aggtctgaa caggagagt ctctgactcc tgggaggag gacagggagg
 ttatgggaaa agagcagacc ctgtgccga tcccaaactc cattcccaa cccatccttg
 accccaactc ttaccagac ctaacccct cctcatccct atcctcaatc ccatctccat
 cctaacccca cccattccc atctccaagc ccattttcat cccctcacct tccatgaact
 20 acaatcccaa cccaagtctc actgtgcctt cattctcatc cccagccca acctccata
 acctgaagtc cacctccatt cctaccttc agtccatcc taattccaac cccatcccat
 cctcgtcttt atcccaaccc aaccccttc tccccacca ctgcccaga tccaaagtg
 acagctctca cgttggcaca tttattgat ctctccttc tggcaccgcc agagtactc
 tggaggcccc ctggtctgtg acgagacct ccaaggcatc ctctcgtgg gtgtttacc
 25 ctgtggctct gccagcatc cagctgtcta caccagatc tgcaaatata tgcctggat
 caataaagtc atacgctcca actgatccag atgctacgct ccagctgatc cagatgttat
 gctcctgctg atccagatgc ccagaggctc catcgtccat cctcttctc cccagtcggc
 tgaactctcc ccttgtctgc actgttcaaa cctctgccgc cctccacacc tctaaacatc
 tcccctctca cctcattccc ccacstatcc ccattctctg cctgtactga agtgaaatg
 30 caggaaagtg tggcaaaggt ttattccaga gaagccagga agccggtcat caccagcct
 ctgagagcag ttactgggtt caccacacct gacttctct gccactcccc gctgtgtgac
 tttgggcaag ccaagtgcct tctctgaacc tcagtttct catctgcaa atgggaacaa
 tgacgtgctt acctcttaga catgttgtga ggagactatg atataacatg tgtatgtaaa
 tcttcatgtg attgtcatgt aaggcttaac acagtgggtg gtgagttctg actaaagggt
 35 acctgtgtc gtgatctgac cagtcctcg tgaaagcgtg tgtccaggga agaagtgac
 agggtagccc ccaatcccaa ccttccatcc ccaaccctta gggatgatgg aaga

SEQ ID NO. 19

40 Hk11 amino acid

MQRRLRWLRDWKSSGRGLTAAKEPGARSSPLQAMRILQLILLALA
 TGLVGGETRIKGFCKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIV
 HLGQHNLOKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRP
 45 LTLSSRCVTAGTSCGISGWGSTSSPQLRLPHTLRCANITIIHQKCNAYPGNITDTM
 VCASVQEGGKDSQGDSSGGLVNCQSLQGIISWGQDPCAITRKPVGVTYKVCKYVDWIQ ETMKNN

SEQ ID NO. 20

50 Hk11 amino acid

MRILQLILLALATGLVGGETRIKGFCKPHSQPWQAALFEKTR
 LLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLOKEEGCEQTRTATESFPHPGFNNSL
 PNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTSCGISGWGSTSSPQLRLPHT
 LRCANITIIHQKCNAYPGNITDTMVCASVQEGGKDSQGDSSGGLVNCQSLQGIIS
 55 WGQDPCAITRKPVGVTYKVCKYVDWIQETMKNN

SEQ ID NO. 21

KLK11 nucleic acid

```

5  aggaatctgc gctcgggttc cgcagatgca gaggttgagg tggctgcggg actggaagtc 61
   atcgggcaga ggtctcacag cagccaagga acctggggcc cgctcctccc cctccaggc 121
   catgaggatt ctgcagttaa toctgcttgc tctggcaaca gggcttgtag ggggagagac 181
   caggatcatc aaggggttcg agtgcaagcc tcactcccag ccctggcagg cagccctgtt 241
   cgagaagacg cggctactct gtggggcgac gctcatcgcc ccagatggc tcctgacagc 301
   agcccactgc ctcaagcccc gctacatagt tcacctgggg cagcacaacc tcagaagga 361
   ggagggctgt gagcagaccc ggacagccac tgagtccttc cccacccccg gcttcaacaa 421
10  cagcctcccc aacaaagacc accgcaatga catcatgctg gtgaagatgg catcgccagt 481
   ctccatcacc tgggtgtgtc gacccctcac cctctcctca cgctgtgtca ctgctggcac 541
   cagctgcctc atttccggct ggggcagcac gtccagcccc cagttacgcc tgcctcacac 601
   cttgcgatgc gccaacatca ccatcattga gcaccagaag tgtgagaacg cctaccccgg 661
   caacatcaca gacaccatgg tgtgtgccag cgtgcaggaa gggggcaagg actcctgcca 721
15  ggggtgactcc gggggccctc tggctctgtaa ccagtctctt caaggcatta tctcctgggg 781
   ccaggatccg tgtgcgatca cccgaaagcc tgggtgtctac acgaaagtct gcaaatatgt 841
   ggactggatc caggagacga tgaagaacaa ttagactgga cccaccacc acagcccatc 901
   accctccatt tccacttggc gtttggttcc tgttcaactc gttaataaga aaccctaagc 961
   caagaccctc tgcgaacatt ctttgggcct cctggactac aggagatgct gtcacttaat 1021
20  aatcaacctg gggttcgaaa tcagttagac ctggattcaa attctgcctt gaaatatgtt 1081
   gactctggga atgacaacac ctggtttgtt ctcgtttgta tccccagccc caaagacagc 1141
   tcctggccat atatcaaggt ttcaataaat atttgctaaa tgagtg

```

SEQ ID NO. 22

25 KLK11 nucleic acid

gene 2313..7622

30 mRNA join(2313..2398,4189..4263,5061..5217,5545..5810,
6627..6763,7158..7622)

CDS join(4224..4263,5061..5217,5545..5810,6627..6763, 7158..7310)

```

35  tgataatagt gttctctctc ctcatgtgtc agggccccag ccattgtcct tgagagaatg 61
   ctgcactctt tatgttgtct tgacagcctc ccttgagatt ggtcattaat gactgtgtc 121
   tctctcctca ttggtcaggg ccccagccat tgccttgag agaacctctg tcctttatgg 181
   agttccaccc ttcttcctcg ggattggccc cttagagacag tggttcttct cttttggtta 241
   gccattgcca ttgtcctccg ggaaagtgat tatactcttt tgtctaataga ccagacttgg 301
40  agccctcccc aaggcccagg actgggttga agggttgggg aggaaaaacag aaataagatg 361
   tctcccttgt tcagacagta cttctcttcc cttccagggt gattctgggg gccccctggt 421
   gtgtggggga gtccttcaag gtctgtgtgc ctgggggtct gtggggccct gtggacaaga 481
   tggcatccct ggagtctaca cctatatatt caagtatgtg gactggatoc gvatgatcat 541
   gaggaacaac tgacctgttt cctccacctc cacccccacc ccttaacttg ggtaccctc 601
45  tggccctcag agcaccaata tctcctccat cacttcccct agctccactc ttgttggcct 661
   gggaaactct tggaaacttta actcctgcc a gcccttctaa gaccacagag cggggtgaga 721
   gaagtgtgca atagtctgga ataaatataa atgaaggagg ggccatgtct gtccatttga 781
   agtctctcatg ctggttgaga ctggaagaag gactcagcag tttccctatc tcataggagt 841
   agaaacagag ctcaaataag gccaggcaca gtggctcaca cctgtaatcc catcactttg 901
50  ggaagctgag gcaggtggat cacctgaggt caggaaactc ggaccagcct ggtcaacata 961
   gtgaaacccc aactctacta aaaatgcaaa aattagccag gcatggtggc gcatgcctgt 1021
   aatcccagct actcaggagg ctgagacagg agaatagcag gaaccctgta ggcagaggct 1081
   gcagcgagcc gagattgaac cattacactc cagcctgggc gacagagcga gactccatct 1141
   caaaaacaaa caaacaaaaa acccagtgtc caaataggat gagggctctc cctgagtagt 1201
55  tactcagaaa tggagtagaa aaagttactt ttaataatat aggccgggtg cagtggccca 1261
   cgcctgtaac cccagcactt tgggaggccg aggtgggagg atggcttgag ctcaagattc 1321
   gagatcagcc tggcaacaca gtgaaatctt gtactacaaa aaacacaaaa aattagctgy 1381

```

	gtgtgggtgt	gcggtgcctgt	agtccagct	acttgggaag	ctgaggtggg	aggatcacc	1441
	gagccgggga	ggtggaggct	gcaaagagcc	gagatcatgc	cactgcactc	cagcctgggc	1501
	aataaagtga	gacctgtgtc	caaaaacaaa	aaccagcaa	tataaataag	acacatgttt	1561
	cttcatctgg	cataatagaa	atagtgccca	gagcttataa	gcttttcaag	agtcacaaaa	1621
5	agacccgaaa	aagaaaaaga	aaattgttag	ctccaaaata	ccagatgaaa	gctgcaaagt	1681
	caacattttat	gaccatttta	tcacatgtcc	ataaaacgta	gcattctttc	cactagccaa	1741
	ctgcagttta	ctttcttgta	atgaagcata	cattgtatct	ttaatgtggg	acgtggcttt	1801
	gttctaataa	gacgaagggt	ggagtgcagg	cttggaaagc	aggagagctc	agcctacgtc	1861
	tttaatcctc	ctgcccaccc	cttggattct	gtctccactg	ggactcaaga	ggtgaggaga	1921
10	gaccatctcc	ccaaatgcac	tgaagggaaa	ctggaggagg	gagggagtga	ggggtgatca	1981
	taccagcgga	ggcacatttg	ctgagccccc	ccgcagtctg	ctctttccaa	gtggaccctc	2041
	ctggaagcct	gatcccaacc	tcccctgcaa	gcaggtctgt	cacccccatc	tctcagatga	2101
	agaaactgag	ccttgcaggg	gtggagtccc	ttgtccccc	gtcataaggg	tagtcatagt	2161
	agtaggaaga	ggaagcacct	aggtttgagg	ccagggtggt	ctgctgtcag	aacctaggcc	2221
15	ctcccctgcc	ttgtctccca	cctgggtcagg	ggagagaggg	gaggaaagcc	aagggaaggg	2281
	acctaactga	aaacaacaa	gctgggagaa	gcaggaatct	gcgctcgggt	tccgcagatg	2341
	cagaggttga	ggtggctgcg	ggactggaa	tcatcgggca	gaggtctcac	agcagccagt	2401
	aagtgaacag	ctggactcgg	gctgcctggg	cggcaggagg	aagcgggcag	gggaagggtc	2461
	agcagaggag	cgaggcccca	gaggagccct	ggggtggagc	acagccaagg	gctctgtttc	2521
20	ctttcctgga	ctcggcttcc	acaggccctg	acctgcctcc	cccaccctcc	ggctctgccc	2581
	ctgtgcctgg	cagcagcccc	acctgtgtga	catcccagca	cacccccctc	ctccttgcaa	2641
	aggagaaggg	agcggcctag	gggaggccag	gggcccacct	gggctggggc	tgtggagagg	2701
	gagtggtctg	gacgggagga	aaaagagaga	cggagattag	atggaagaag	agggatttca	2761
	agacaaattg	ccagagatgc	agtcagagag	actgactgag	agacacaaa	atagaaggaa	2821
25	ttagagaaag	ggccacacag	agccagacag	agagagaaga	gtggagatgg	agacagggac	2881
	gaggacagag	aaaggcagac	agacacatag	ggacagaaag	agaaaaatca	cacaaagtca	2941
	gaattactga	atgacaggga	atgacacata	gaacgagaca	cagattcaga	gactcagggc	3001
	agggaaagga	aggctgcaga	cagacagaca	gacagaggga	ggctgagaca	cagggagaag	3061
	aggggcttgg	agagtgggca	caggcaggca	gccagtgcct	cagaggcctc	cggggaggggc	3121
30	cctcacacac	accccgcccc	ggggcattaa	ggcagggtct	ggaggccaag	catcctgggc	3181
	ccgcccaggg	ccgccccctc	gccagcccgc	ctgcctggtg	cctggcacct	ggcgctccaa	3241
	cccagcctac	ctgctgtagc	tgccgccact	gccgtctccg	ccgccactgg	gccccagag	3301
	ccccagcccc	agagcctgtg	agtcacagg	gaaagggaa	ctgccccctc	ccgtccagg	3361
	gtcagccctc	cccaaggaca	cctgtcccac	tcgggcaccc	atttctccct	ctgctctgtc	3421
35	cttctctgct	tgggtggggg	ttcctggcct	ctctctacac	ctctcacctc	cgatggctgt	3481
	ccgcagcctc	agttacctct	aatctccatg	gcttcagctg	ctgagctggc	cctctgtctc	3541
	cacccccgct	ggccagggca	gcggagggca	ctggccctcc	cctcgaccag	ccccgccag	3601
	ctttgcttgg	ctgtccttca	aaagggcagg	ggtttggcgg	acagggcttc	agcaagccgg	3661
	gtgatggggg	tcccagacat	tgtctggggc	tgagccccct	actccccctc	agcagacctc	3721
40	aaaggctcca	tatcgctctg	ctgcgaagac	aatgaaaaag	gggtgggtac	ggaacggtgt	3781
	ctggttcccc	ttgtccttcc	accccaagct	gctggggcct	ggccagctct	caaggcaaga	3841
	aggaaaacat	cctctgacat	gtgcccggga	ggtcccatgg	ctgacttgaa	caggggccga	3901
	ccatggcttg	acagctcaaa	gccccctcca	acgacttcca	catggttctt	ggtatctcgg	3961
	aagcttctag	ctgtgaccag	gccctctcca	aggccaccct	agacacctaa	gatataat	4021
45	aagtgttttg	agatctgagt	gctgtgagaa	acaggggatt	tcccaacct	tgtttctccc	4081
	aagtggggag	cgggagcagg	tgagggagag	aggagagggc	atgagccagc	ccccccctcc	4141
	cgatttcccc	gtaaagtgat	gcggccccc	gtccctcctt	gttcccagag	gaacctgggg	4201
	cccgtctctc	ccccctccag	gccatgagga	ttctgcagtt	aatcctgctt	gctctggcaa	4261
	caggtagcga	ggggatgggg	gcagggcagg	atcctccctc	ttgaatctct	gggatccctc	4321
50	aacctctgtg	gtctggacag	tgacagggtc	gattccaaat	tacagaacaa	cccataaggc	4381
	acctgaactg	gagcagtggt	catgagggcc	tggatgcctt	tctagataat	ccctttaa	4441
	gccaaggag	gagaggtcaa	gggggtcgta	aagggtcccg	tggaggggct	gaggaagctg	4501
	gagttggggg	agcagtcact	caaagcgccc	aggacagggg	ctactgacca	accagtatgg	4561
	aagtatttcc	tttttttttt	ttcccagaga	caaagtcttg	ctctattgtc	caggctggag	4621
55	tgccgtggtg	ccaacacggc	tcactgcagt	cttgacttcc	cgggcttaag	tgatccttaa	4681
	gccatctcag	cttcccgggt	agctgggacc	acaggcacct	gccaccaagc	caggctaatt	4741
	gtttaattgt	ttgtagagat	gggggaggag	gtctcactat	gtttgcctag	gctgatctag	4801
	aactcctggg	ctcaagtaat	cctccacct	tagcctctca	aagtgtggg	attacaggca	4861
	tgagccactg	catttgacct	tatggaagta	ttttcatcct	ttaatacccg	acccagcat	4921

	ccagggcaac	ccagagggac	accagaccag	ggcccagacc	accactctc	tttctctcct	4981
	ccccacccc	atttctggga	gtcctcctgg	tctaccacct	ctccttctcg	agcccttct	5041
	tttgctctca	ccccctccag	ggcttgtagg	gggagagacc	aggatcatca	aggggttcga	5101
	gtgcaagcct	cactcccagc	cctggcaggc	agccctgttc	gagaagacgc	ggctactctg	5161
5	tggggcgacg	ctcatcgccc	ccagatggct	cctgacagca	gcccactgcc	tcaagccgtg	5221
	gggtgcgggg	ctggggcggt	gcgggggtgg	ggggctggga	atggggagat	ggatggagag	5281
	aagctcaggg	ataggggtgc	tggttaaggg	attagagatg	gggatgggta	gtgtcagcaa	5341
	ggttgatggg	ctcgagttgg	tattgaaggt	gggggatga	atggggttgg	gatggggcta	5401
	tggctgggaa	gggggcttcg	tggggagacc	tggaagaggt	tggaagcaga	gcatgttttc	5461
10	ttcatcctca	aaggtgtcac	tcacctctcc	cacccatgtc	tccccgacc	tttctcctc	5521
	caactactgt	ctctcccacc	tcagccgcta	catagttcac	ctggggcagc	acaacctcca	5581
	gaaggaggag	ggctgtgagc	agacccggac	agccactgag	tccttcccc	accccggtt	5641
	caacaacagc	ctcccaaca	aagaccaccg	caatgacatc	atgctgtgtga	agatggcact	5701
	gccagtctcc	atcacctggg	ctgtgcgacc	cctcacccctc	tcctcacgct	gtgtcactgc	5761
15	tggcaccagc	tgccctcattt	ccggctgggg	cagcacgtcc	agcccccagt	gtaggagcac	5821
	cagaggggaa	cctggcaggg	gggtgtgagg	agggagtggg	caggattgtg	gaagggttca	5881
	gggcatcaga	gatcgcggttc	acagtgacga	tgtgggataa	gttgagagga	tgtgtggaaa	5941
	acgtcaggat	aggggggtgg	ggacaaaagt	tggggccttg	gagtcagacg	gacgggatat	6001
	gcaatcatat	atccataacc	tcctggttgt	aagacottag	gcaagcagct	tcacctctct	6061
20	gaatcttgat	tttcttctct	ataaaatgag	aatgattata	cccacctgtc	aggattggat	6121
	tagagataat	gtatatcaag	caactgacat	aaatcattta	ttggatagca	ggctgggcac	6181
	cgtggctcac	gcctgtaatc	ccagcacttt	gggaggccga	ggtgggaaga	tcacctgagg	6241
	tcaggacttt	gataccagcc	tggccaaagt	ggtgaaatcc	catctctact	aaaaatgtga	6301
	aaattagttg	ggcgtgggtt	tgtgcgcctg	taatccagc	tactcgggag	ggttaggcag	6361
25	gagaatcgct	taaaacttggg	agacggaggt	tgcatgtagc	caagatcacg	ccactgcact	6421
	ccagcctggg	caacagagca	agactctgtc	tcgaaaaaaa	aaaaaaaaaa	gctggatagc	6481
	attgctgttg	ctattgtttac	aagaagagag	gtgaattggc	tgctgtctaa	gacagggatt	6541
	ccccagggg	cgggatcaca	gcaagcactg	cattagggga	ggtggcaggg	ggctcattcc	6601
	cacagcccct	cacgctgttt	ccacagtacg	cctgcctcac	accttgcgat	gcgccaacct	6661
30	caccatcatt	gagcaccaga	agtgtgagaa	cgcctacccc	ggcaacatca	cagacaccat	6721
	gggtgtgtgc	agcgtgcagg	aagggggcaa	ggactcctgc	caggtcagtg	tggtctccaa	6781
	ccacagcccc	atccccatcc	ccagcttcaa	tgacatcttt	accgacatcc	acaatttcat	6841
	ccccaacctc	aacccgcgca	cccctgcaac	tcccaatcca	tctcttcccc	tgttcccggt	6901
	tctgactcoa	gcacaaactt	cagctccatc	ccggtttcca	caccatttcc	agctccaacc	6961
35	atccccaaac	tcgtttttga	gcctaaccoc	atcctttatc	ccacccataa	tcccagcttt	7021
	atcgctaaac	ctatcacctt	tcccagtgcc	tacccatcct	gtctcggccc	cactcctaag	7081
	caccgtcccc	acctcctccc	tggctaacac	catgctcaac	gctttctctg	accgacattc	7141
	tctctccccg	tgcccagggt	gactccgggg	gcctctgggt	ctgtaaccag	tctcttcaag	7201
	gcattatctc	ctggggccag	gatccgtgtg	cgatcaccoc	aaagcctggg	gtctacacga	7261
40	aagtcctgcaa	atatgtggac	tggatccagg	agacgatgaa	gaacaattag	actggaccca	7321
	cccaccacag	cccatacccc	tccatttcca	cttggtgttt	ggttcctgtt	cactctgtta	7381
	ataagaaacc	ctaagccaag	accctctacg	aacattcttt	gggcctcctg	gactacagga	7441
	gatgtctgca	cttaataaat	aacctggggg	tcgaaatcag	tgagacctgg	attcaaatcc	7501
	tgccctgaaa	tattgtgact	ctgggaatga	caacacctgg	tttgttctct	gttgtatccc	7561
45	cagccccaaa	gacagctcct	ggccatatat	caagggtttca	ataaatattt	gctaaatgag	7621
	tgaatctact	gagtgtttac	tatgtgtctg	accctgatcc	aatggctttt	attttatttt	7681
	attttttgac	agagtctcgc	tctgtcaccc	aggctggagt	acagtgggtg	tatctctgct	7741
	cactgcaacc	tccacctcct	gggttcaagc	aattctcctg	cctcagcctc	ctgaatagct	7801
	gggattacag	gtgcctacca	ccacatccgg	ctaatttttg	tattttttag	tagagatggg	7861
50	gcttcaccat	gttgcccagg	ctgggtctcg	actcctgacc	tcagatgac	tgccctcctt	7921
	ggcctcccaa	actcctggga	ttacagacgt	gagccaccgc	gcccggccgg	cttctattta	7981
	ttaattaaaa	gaaattaaat	taattaatct	atttaggaga	cagtcttgct	ctgttgccca	8041
	ggctggagtg	cagtaacaat	cacagctcac	ggcaatctca	atttctctgg	gtcaagtgat	8101
	tgtctccctt	cagcctccag	agtagctggg	actacaggca	catgccacga	agcccagcta	8161
55	atttttgtat	ttttogtaga	gacagaggtc	tcagtatgtt	gccccggcta	gtctcaaatc	8221
	cctgggctca	agcagtctgt	cctcctcagc	ctccaaaagt	ggtagagatta	caggcatgag	8281
	tcgctgtgcc	tggcctccaa	gcactttcaa	atgtatcaac	ttaatcctca	caaaacctg	8341
	tgaggtcggg	actgttttca	tacctatttt	atagttgaag	aaacagacac	agagaagcaa	8401
	agtcacttgc	tcacagtcac	gtggctagga	gagcaaggat	ctgaagcaag	gcgatctctt	8461

```

aattaccaag tgatgttcct ggagtaaggo tctgtttggt tcctttcctg taaaatgctg 8521
catgcaaaag tataacacag taagtaaaga agtcagttag cctgcacata ctaagaccta 8581
accaaaggag cttattgttt ttctccaact tccatgatag gtaattagat agtggagacc 8641
tctgctggcc aatatggtag ccactaaccg cagctggctc ttccaattaa aattacataa 8701
5 agccagaaat gtaactcctc tgtctcactt gttatatctc caaggctgga tagccacatg 8761
tgactggtgg tggctggatt agctagtgcata taaaaacat cactgcagaa agttcagctg 8821
agcagcactg agttagatgg cctctgaaga ggatgtccca cggagagaat ccagaactca 8881
ggatcctttt tttttttttt ctttgcgaca gagtcttgct ctgtcaccca ggctggagtg 8941
cagtggcgtg atctcggctc actgcaactt ctgcctccca ggttcaagca attctcctgc 9001
10 ctcagcctcc ctagtagctg ggactacagg cctgtgcca catcccagc taatttttgt 9061
gtcttttttag tagagatggg gtttcactat gttggccagg ctggtctcga actcctgacc
```